



Russian
Society
of Cardiology

RUSSIAN NATIONAL CONGRESS OF CARDIOLOGY


RUSSIAN SOCIETY OF CARDIOLOGY 2024 –
FOR IMPLEMENTATION OF NATIONAL GOALS AND PRIORITIES

SEPTEMBER 26–28, 2024 | SAINT-PETERSBURG

EXPOFORUM CONVENTION AND EXHIBITION CENTER
(196140, SAINT-PETERSBURG, 64 PETERBURGSKOE HIGHWAY)

SCIENTIFIC PROGRAM

THE CONGRESS IS HELD IN THE YEAR
OF THE 150TH ANNIVERSARY OF N.S. KOROTKOV





**DEAR COLLEAGUES,
DEAR FRIENDS!**

It is a great honor and pleasure for me to welcome the participants of the Russian National Congress of Cardiology, which this year is taking place in the year of the 150th anniversary of the birth of N.S. Korotkov! This anniversary date once again reminds us that the Russian scientific and clinical school has always been at the forefront of progress, and the names of our outstanding compatriots — doctors and scientists — are forever inscribed in gold letters in the history of world medicine.

Highly effective healthcare is one of the priority goals of the country's development today, and the role of science in its implementation cannot be overestimated. The main paths of cardiology development include the widespread introduction of the concepts of translational, patient-oriented and personalized medicine, the development of new models of care using digital technologies, telemedicine and artificial intelligence.

The congress program has been prepared in those trends, that are characterized by an interdisciplinary approach to a comprehensive solution of scientific, practical and educational problems in response to current challenges of our time in the field of combating cardiovascular diseases.

The scale and novelty of the tasks that healthcare is facing dictate the need for a broad collegial discussion of current plans for their implementation, and that is the context that the Russian National Congress of Cardiology should be regarded — a unique platform for the exchange of experience and professional communication in terms of scale, representation and coverage of issues.

The congress program traditionally includes plenary and sectional sessions devoted to the practical aspects of the application of new medical technologies and achievements of fundamental medicine; results of original research; clinical reviews and debates based on cases from real clinical practice.

The Russian Society of Cardiology makes a great contribution to the expansion of scientific and educational contacts with foreign colleagues. Within the Congress we will continue to search for the ways to expand cooperation and strengthen professional and human contacts that can ensure further development of our countries' healthcare.

I am confident that the congress will be successful and will once again become a landmark event in the life of the scientific and medical community. I wish you fruitful and interesting work!

President
Russian Society of Cardiology
Evgeny Shlyakhto

A handwritten signature in blue ink, appearing to read 'Evgeny Shlyakhto', written in a cursive style.

The Congress is held in accordance with the Order No. 726 of the Ministry of Health of the Russian Federation on December 29, 2023 “On approval of the Plan of scientific and practical meetings of the Ministry of Health of the Russian Federation for 2024”, as amended by the Order No. 321 of the Ministry of Health of the Russian Federation on June 24, 2024.

PROGRAMME COMMITTEE OF THE RUSSIAN NATIONAL CONGRESS OF CARDIOLOGY

Chairperson of the Programme Committee – President of the Russian Society of Cardiology, RAS Academician, Prof. **E.V. Shlyakhto** (Saint-Petersburg)

Congress Executive Secretaries –

Vice-President of the RSC, corresponding members of the RAS, Prof. **G.P. Arutyunov** (Moscow);
Vice-President of the RSC, RAS Academician, Prof. **A.O. Konradi** (Saint-Petersburg);
Vice-President of the RSC, Prof. **S.V. Nedogoda** (Volgograd)

Programme Committee:

Averkov O.V. (Moscow)	Grinshtein Yu.I. (Krasnoyarsk)
Ageev F.T. (Moscow)	Gubareva I.V. (Samara)
Alekhin M.N. (Moscow)	Demin A.A. (Novosibirsk)
Arutyunov G.P. (Moscow)	Ezhov M.V. (Moscow)
Baranova E.I. (Saint-Petersburg)	Zhernakova Yu.V. (Moscow)
Barbarash O.L. (Kemerovo)	Zhirov I.V. (Moscow)
Blagova O.V. (Moscow)	Zavadovsky K.V. (Tomsk)
Boytsov S.A. (Moscow)	Zateyschikov D.A. (Moscow)
Boldueva S.A. (Saint-Petersburg)	Zvartau N.E. (Saint-Petersburg)
Borovkova N.Yu. (Nizhny Novgorod)	Karamnova N.S. (Moscow)
Bubnova M.G. (Moscow)	Karpov Yu.A. (Moscow)
Vasichkina E.S. (Saint-Petersburg)	Kashtalap V.V. (Kemerovo)
Vasyuk Yu.A. (Moscow)	Kim A.I. (Moscow)
Vezikova N.N. (Petrozavodsk)	Koziolova N.A. (Perm)
Veselova T.N. (Moscow)	Kozlov B.N. (Tomsk)
Villevalde S.V. (Saint-Petersburg)	Konradi A.O. (Saint-Petersburg)
Gapon L.I. (Tyumen)	Kontsevaya A.V. (Moscow)
Garanin A.A. (Samara)	Korneva V.A. (Petrozavodsk)
Golitsyn S.P. (Moscow)	Kosmacheva E.D. (Krasnodar)
Golukhova E.Z. (Moscow)	Kostareva A.A. (Saint-Petersburg)
Gordeev M.L. (Saint-Petersburg)	Kotovskaya Yu.V. (Moscow)
Grigorieva N.Yu. (Nizhny Novgorod)	Kuznetsova T.Yu. (Petrozavodsk)

Kukharchuk V.V. (Moscow)	Rotar O.P. (Saint-Petersburg)
Lebedev D.S. (Saint-Petersburg)	Ryabov V.V. (Tomsk)
Lifshits G.I. (Novosibirsk)	Simonova G.I. (Novosibirsk)
Lomakin N.V. (Moscow)	Skibitsky V.V. (Krasnodar)
Lopatin Yu.M. (Volgograd)	Smolensky A.V. (Moscow)
Malchikova S.V. (Kirov)	Sychev D.A. (Moscow)
Matskeplishvili S.T. (Moscow)	Tarlovskaya E.I. (Nizhny Novgorod)
Menzorov M.V. (Ulyanovsk)	Tereshchenko S.N. (Moscow)
Mikhailov E.N. (Saint-Petersburg)	Ternovoy S.K. (Moscow)
Moiseeva O.M. (Saint-Petersburg)	Trufanov G.E. (Saint-Petersburg)
Nazarenko M.V. (Tomsk)	Filippov E.V. (Ryazan)
Nebieridze D.V. (Moscow)	Khaisheva L.A. (Rostov-on-Don)
Nedogoda S.V. (Volgograd)	Khubulava G.G. (Moscow)
Nikulina S.Yu. (Krasnoyarsk)	Tsaregorodtsev D.A. (Moscow)
Novikova N.A. (Tomsk)	Chazova I.E. (Moscow)
Oleynikov V.E. (Penza)	Chernyavsky A.M. (Novosibirsk)
Orlova Y.A. (Moscow)	Chesnikova A.I. (Rostov-on-Don)
Pavlyukova E.N. (Tomsk)	Chumakova G.A. (Barnaul)
Paleev F.N. (Moscow)	Shaposhnik I.I. (Chelyabinsk)
Panov A.V. (Saint-Petersburg)	Shakhnovich R.M. (Moscow)
Pevzner A.V. (Moscow)	Shneider Yu.A. (Kaliningrad)
Petrova M.M. (Krasnoyarsk)	Shubik Yu.V. (Saint-Petersburg)
Podzolkov V.I. (Moscow)	Shumakov D.V. (Moscow)
Popov S.V. (Tomsk)	Yavelov I.S. (Moscow)
Posnenkova O.M. (Saratov)	Yakovlev A.N. (Saint-Petersburg)
Protasov K.V. (Irkutsk)	Yakushin S.S. (Ryazan)
Rebrov A.P. (Saratov)	Yakhontov D.V. (Novosibirsk)
Revishvili A.Sh. (Moscow)	

RUSSIAN SOCIETY OF CARDIOLOGY AWARD 2024 COMMITTEE

Shlyakhto E.V. (Saint-Petersburg) — chairperson

Boytsov S.A. (Moscow), Galyavich A.S. (Kazan), Duplyakov D.V. (Samara), Karpov R.S. (Tomsk), Koziolova N.A. (Perm), Konradi A.O. (Saint-Petersburg)

YOUNG SCIENTISTS AWARD COMMITTEE

Shlyakhto E.V. (Saint-Petersburg) — chairperson

Abdullaev A.A. (Makhachkala), Borovkova N.Yu. (Nizhny Novgorod), Villevalde S.V. (Saint-Petersburg), Grinstein Yu.I. (Krasnoyarsk), Duplyakov D.V. (Samara), Zateishchikov D.A. (Moscow), Kontsevaya A.V. (Moscow), Kosmacheva E.D. (Krasnodar), Mikhailov E.N. (Saint-Petersburg), Nikulina S.Yu. (Krasnoyarsk), Chumakova G.A. (Barnaul), Khaisheva L.A. (Rostov-on-Don).

SECRETARIAT OF THE CONGRESS PROGRAMME COMMITTEE

Nedoshivin A.O. (Saint-Petersburg) — chairperson

Ratova L.G. (Saint-Petersburg), Tanicheva A.A. (Saint-Petersburg),

Chumak I.B. (Saint-Petersburg)

GENERAL INFORMATION

The Organizing Committee invites you to take part in the work of the Russian National Congress of Cardiology, which will be held in Saint-Petersburg on September 26-28, 2024.

CONGRESS VENUE OFFLINE

EXPOFORUM Convention and Exhibition Center
(196140, Saint-Petersburg, 64 Peterburgskoe highway).

CONGRESS VENUE ONLINE – www.scardio.ru

HOW TO GET THERE

By car

5 min from the Pulkovo Airport

5 min from the ring road

15 min from the Moskovskaya Metro station

Points: turn from Pulkovskoe highway to the left into the tunnel to the town of Pushkin further riding according to the map



By the hotel transfer

Check the bus schedule with the official accommodation partner of the Congress participants

MIR INTERNATIONAL Travel Company — congress@mirint.ru

Tel. +7 (812) 315 56 92, +7(812) 312 06 40

Registration on the website www.scardio.ru

REGISTRATION of the Congress participants is carried out online on the website of the Russian Society of Cardiology www.scardio.ru until September 17, 2024. After September 17th registration is only possible at the Congress venue.

Electronic registration for participation in the congress in person is carried out on the website www.scardio.ru until September 17, 2024 (inclusive). After September 17, 2024, registration is only possible on site.

Electronic registration for participation in the Congress in online format is carried out on the website www.scardio.ru without restrictions.

Those registered on the website of the Society www.scardio.ru will be able to receive a badge in the registration area.

Those participants who registered on the website of the Society www.scardio.ru and paid for the materials of the Congress will be able to receive the participant's bag and badge in the registration area at a separate counter.

Admission to all meetings and the exhibition is free; it is carried out by badges, which are issued (free of charge) to registered participants!

Congress registration

September, 26 — 07:30-17:30

September, 27 — 08.00-15:30

September, 28 — 08.00-13:30

Entrance to the Congress Center (Passage).

OFFICIAL EVENTS OF THE CONGRESS

September 26st — 11:00-12:30 | Plenary Hall

Opening Ceremony of the Congress.

Awarding of the winners of the awards of the Russian Society of Cardiology

September 27st — 17:15-19:00 | Plenary Hall

Assembly of the Russian Society of Cardiology

September 28st — 15:30-17:00 | Plenary Hall

Closing Plenary Session.

Awarding of the winners of the competition for young scientists and laureates

Scientific Sessions will be held

September, 26 from 09:00 to 19:00

September, 27–28 from 09:00 to 17:00

All lecture halls are located on the 1st, 2nd and 3rd floors of the Congress Center:

E-POSTERS are placed at the exhibition area (1st floor).

AN EXHIBITION of medicines, diagnostic and therapeutic equipment, modern information technologies, medical specialized publications will be presented daily on the 1st floor of the Congress Center (Passage and zone E).

Exhibition opening hours

September, 26 — 08:00-18:30

September, 27 — 08:00-17:00

September, 28 — 08:00-15:30

SIMULTANEOUS TRANSLATION

The official language of the Congress is Russian. Simultaneous translation will be organized during all plenary sessions, as well as international sessions and symposia with the participation of foreign lecturers.

It is prohibited to use mobile phones during sessions!

ORGANIZING COMMITTEE ROOM

The organizing committee room is located in the exhibition area (1st floor, zone E).

ONLINE SPEAKING ROOMS

The online speaking rooms (E25 and E26) is located on the 2nd floor of the Congress Center (entrance from the Passage side).

SMOKING


The Russian Society of Cardiology actively promotes a healthy lifestyle and smoking cessation as a serious risk factor for cardiovascular diseases. The organizing committee strongly recommends that all participants withhold smoking during the Congress.

WI-FI

You can use free Wi-Fi at the Congress Center: Expoforum-Free.


FLOOR 1

Halls №1 (E7), №2 (E8-E9),
№3 (D1), №4 (D2), №5 (D3), №6 (D4)
and Plenary Hall.




FLOOR 2

Halls №7 (B1), №8 (B2), №9 (B3-B5), №10 (B6-B8), №11 (F200)



FLOOR 3

Halls №12 (A1-A3), №13 (A4-A5), №14 (A8-A9).



09:00–10:30

PLENARY HALL

«NEW NATIONAL PROJECT “LONG ACTIVE LIFE”: TASKS AND PROSPECTS FOR THE CARDIOLOGY COMMUNITY»

Simultaneous translation

- **Chairpersons: Kamkin E.G.** (Moscow), **Shlyakhto E.** (Saint-Petersburg), **Boytsov S.** (Moscow)
-
- **Kamkin E.G.** (Moscow). Main tasks and structure of the National project «Long active life». Importance for achieving national goals.
- **Shlyakhto E.** (Saint-Petersburg). The role of RSC in the realization of national projects.
- **Boytsov S.** (Moscow). What has been achieved within the framework of the realization of the federal project «Fight against cardiovascular diseases».
- **Drapkina O.** (Moscow). The role of the therapeutic care in the realization of national projects.
- **Tkacheva O.** (Moscow). Geriatric care in prolonging the life of patients with cardiovascular diseases.

09:00–10:30

HALL №1 (E7)

SATELLITE SYMPOSIUM

«RARE AND COMMON CONDITIONS IN CARDIOLOGY»

(supported by «Pfizer», CME points are not accrued)

Simultaneous translation

Chairperson: Vezikova N.N. (Petrozavodsk)

- **Vezikova N.N.** (Petrozavodsk). Introduction.
- **Vezikova N.N.** (Petrozavodsk). Changes in the Programm of Cardiovascular diseases: new opportunities.
- **Novikova T.N.** (Saint-Petersburg). Comorbid patient with non-valvular atrial fibrillation: determining criteria for choosing anticoagulant therapy.
- **Kucherenko S.S.** (Saint-Petersburg). Stroke prevention and more. An expert view from a neurologist on anticoagulant therapy for non-valvular atrial fibrillation.
- **Perlini S.** (Italy). The evolution of ATTR-CM diagnosis and treatment from the last decade until today

- **Moiseeva O.M.** (Saint-Petersburg). Cardiac amyloidosis as not obvious but common cause of HFpEFy.
- **Veziikova N.N.** (Petrozavodsk). Discussion.
- **Veziikova N.N.** (Petrozavodsk). Closing.

09:00–10:30

HALL №2 (E8-E9)

SATELLITE SYMPOSIUM

«HYPERTRIGLYCERIDEMIA: A JOURNEY IN SOLVING THE PROBLEM OF RISK OF CVD AND PANCREATITIS»

(supported by «Abbott Laboratories», CME points are not accrued)

Chairpersons: **Ezhov M.** (Moscow), **Arutyunov G.** (Moscow)

- **Sergienko I.** (Moscow). Pathological pathways of triglyceride-rich particles.
- **Alieva A.** (Saint-Petersburg). Severe turns in hypertriglyceridemia phenotypes.
- **Arutyunov G.** (Moscow). Forks in clinical decision making in patients with hypertriglyceridemia.
- **Ezhov M.** (Moscow). Hypertriglyceridemia: steps to solve the problem.
-

09:00–10:30

HALL №3 (D1)

SATELLITE SYMPOSIUM

«CHRONICLES OF TIME 10 YEARS OF OPPORTUNITIES»

(supported by «AstraZeneca», CME points are not accrued)

Chairperson: **Tereschenko S.** (Moscow)

- **Tereschenko S.** (Moscow). DAPA-HF: on the way to quadruple therapy for HFrEF.
- **Ageev F.** (Moscow). Heart failure with preserved ejection fraction: what we know and don't know yet.
- **Zhirov I.** (Moscow). Cardiac amyloidosis: a modern view of the problem.
- **Lopatin Yu.** (Volgograd). Features of HF management at the inpatient and outpatient department.
- **Nedogoda S.** (Volgograd). Cardio-renal-metabolic syndrome: a cardiologist's view.

09:00–10:30

HALL №4 (D2)

SATELLITE SYMPOSIUM

«ACUTE CORONARY SYNDROME 2024: WHAT SHOULD EVERYONE KNOW?»

(supported by «Sanofi», CME points are not accrued)

Chairpersons: Barbarash O. (Kemerovo), **Paleev F.** (Moscow)

- **Paleev F.** (Moscow). Atherosclerotic CVD: key tasks and priorities.
- **Shakhnovich R.** (Moscow). Antithrombotic therapy: what do the clinical recommendations say?
- **Barbarash O.** (Kemerovo). LDL cholesterol control in patients after myocardial infarction at the hospital stage: evidence base and real practice.
- **Sergienko I.** (Moscow). Intensification of lipid-lowering therapy in patients after ACS.

09:00–10:30

HALL №5 (D3)

SATELLITE SYMPOSIUM

«AH AND HD: PATIENTS AND DOCTOR'S VIEW. MINISERIES ABOUT THE PATIENT'S LIFE»

(supported by «Merck», CME points are not accrued)

Chairpersons: Konradi A. (Saint-Petersburg), **Kobalava Zh.** (Moscow)

- **Nedogoda S.** (Volgograd). What are you complaining about? About imbalance in sympathetic nervous system and RAAS.
- **Matskeplishvili S.** (Moscow). Objective study data, make it in 24 minutes.
- **Konradi A.** (Saint-Petersburg). Medical reflections and patient's thoughts. How to avoid polygramasy.
- **Kobalava Zh.** (Moscow). Choice of therapy in a comorbid patient, from recommendations to practice.

09:00–10:30

HALL №6 (D4)

SYMPOSIUM

«HEART FAILURE, WHERE THERE IS AGREEMENT, THERE IS VICTORY – A CONSULTATION WITH EXPERTS»

Chairpersons: **Kosmacheva E.** (Krasnodar), **Villevalde S.** (Saint-Petersburg)

- **Kruchinova S.** (Krasnodar), **Baglikov A.** (Kaluga). Heart failure or Terra incognita.
- **Soloveva A.** (Saint-Petersburg), **Novitskii N.** (Kaluga). Elderly patient with heart failure or Dum spiro, spero.
- **Kuzheleva E.** (Tomsk), **Dolgushin G.** (Moscow). Coronary heart disease and heart failure or Tempus consilium dabet.
- **Safronenko V.** (Rostov-on-Don), **Baymukanov A.** (Moscow). Obesity, apnea, conduction disorders, heart failure – a dangerous quartet or Carpe diem!

09:00–10:30

HALL №7 (B1)

SATELLITE SYMPOSIUM

«THE HEART CAN ONLY BE TREATED WITH THE HEART: FROM CLINICAL RECOMMENDATIONS TO REAL PRACTICE»

(supported by «Viatrix», CME points are not accrued)

Chairperson: **Rotar O.** (Saint-Petersburg)

- **Rotar O.** (Saint-Petersburg). The evolution of dyslipidemia treatment: from total cholesterol to HCV and inflammasoma.
- **Arutyunov A.** (Armenia). An interdisciplinary approach to patients with CVD and obesity.
- **Vasuk Yu.** (Moscow). From risk factors to additional years of life.

09:00–10:30

HALL №8 (B2)

SYMPOSIUM

«MANAGEMENT OF OBESITY IN PATIENTS WITH CARDIOVASCULAR PATHOLOGY»

Chairperson: Drapkina O. (Moscow)

- **Eliashevich S.** (Moscow). Therapeutic nutrition or how to catch three birds with one stone.
- **Rudenko E.** (Moscow). The hidden dangers of a fatty heart.
- **Misharova A.** (Moscow). Cardiometabolic concerns of an endocrinologist: do not waste time.
- **Stankevich V.** (Moscow). Bariatric surgery: cure or cripple — that is the question.
-

09:00–10:30

HALL №9 (B3-B5)

SYMPOSIUM

«HIGH-RISK PCI IN PATIENTS WITH ACS»

Chairperson: Ganykov V. (Kemerovo), **Larionov A.** (Astrakhan)

- **Ganyukov V.** (Kemerovo). Justification of the widespread use of mechanical circulatory support in PCI.
- **Gubarenko E.** (Barnaul). High-risk PCI, definition, criteria for selecting patients for endovascular treatment.
- **Tarasov R.** (Kemerovo). The concept of revascularization accessibility for patients with NSTEMI-ACS: from standard PCI to emergency coronary bypass surgery and PCI ECMO.
- **Larionov A.** (Astrakhan). Modern X-ray endovascular techniques for the treatment of complex lesions of the coronary bed.
- **Sukmanova I.** (Barnaul). Experience in performing high-risk PCI in patients with ACS in the Altai Regional Cardiology dispensary. Clinical cases.

09:00–10:30

HALL №10 (B6-B8)

SYMPOSIUM

«CARDIOVASCULAR PATHOLOGY IN AUTOIMMUNE DISEASES: IMAGING INFLAMMATION – A WAY OUT?»

Chairperson: Karpov Yu. (Moscow)

- **Popkova T.** (Moscow). The significance of inflammation in the development of cardiovascular pathology in rheumatic diseases: an update.
- **Gerasimova E.** (Moscow). Subclinical carotid atherosclerosis in patients with rheumatoid arthritis: association with traditional, disease-specific risk factors and cellular biomarkers.
- **Balakhonova T., Pogorelova O., Tripoten M.** (Moscow). Modern possibilities of peripheral arterial ultrasound in the diagnosis of atherosclerosis in autoimmune diseases.
- **Fomicheva O., Ansheles A., Gaman S., Shingareeva F.** (Moscow). The new diagnostic options for cardiovascular disease associated with atherosclerosis in autoimmune inflammation: focus on rheumatoid arthritis.
-

09:00–10:30

HALL №11 (F200)

SATELLITE SYMPOSIUM

«CONTROL OF RISK FACTORS OF THE CARDIOVASCULAR CONTINUUM: CURRENT ISSUES OF THE PRACTICING PHYSICIANS»

(supported by «Teva LLC», CME points are not accrued)

Chairperson: Belenkov Yu. (Moscow)

- **Glezer M.** (Moscow). Recommendations in practice: which treatment of arterial hypertension is preferable, taking into account compliance, clinical effectiveness and tolerability during long-term use.
- **Ostroumova O.** (Moscow). Therapy depending on the phenotype of patients: what should the practitioner consider.
- **Arutyunov A.** (Armenia). Young, active patient with arterial hypertension: strategy for managing prognosis.

09:00–10:30

HALL №12 (A1-A3)

SYMPOSIUM

«JOINT SESSION RUSSIAN ANTITHROMBOTIC FORUM AND ASIAN HEART SOCIETY. AVANT-GARDE APPROACHES IN COMPLEX CLINICAL CIRCUMSTANCES»

Simultaneous translation

Chairpersons: Lomakin N. (Moscow), Jiang Ch. (China)

- **Jiang Ch.** (China). The emerging role of SGLT2 inhibitors in the management of atrial fibrillation.
- **Lomakin N.** (Moscow). Thromboembolism prevention in complex clinical circumstances.
- **Chapurnykh A.** (Moscow). How to improve patient care in patients with long-standing atrial fibrillation and low ejection fraction?
- **Buryachkovskaya L.** (Moscow). Platelet-related effects of direct oral anticoagulants.

09:00–10:30

HALL №13 (A4-A5)

SYMPOSIUM

«ANEMIA IN THE PRACTICE OF A CARDIOLOGIST»

Chairperson: Arutyunov G. (Moscow)

- **Grigorieva N.** (Nizhny Novgorod). Iron deficiency conditions in cardiac patients.
- **Koziołova N.** (Perm). Differential diagnosis of normochromic anemia in cardiovascular disease.
- **Shaposhnik I.** (Chelyabinsk). Methods for the correction of preoperative anemia in patients with diseases of the cardiovascular system.
- **Kuznetsova T.** (Petrozavodsk). B12 deficient conditions in patients with sercovascular disease.

09:00–10:30

HALL №14 (A8-A9)

SCIENTIFIC SESSION «CARDIOVASCULAR SURGERY AND INTERVENTIONAL CARDIOLOGY»

Chairpersons: **Karpenko M.A.** (Saint-Petersburg), **Urvantseva I.A.** (Surgut)

- **Shneider Yu.A., Tsoi V.G., Fomenko M.S., Shilenko P.A., Pavlov A.A.** (Kaliningrad). Coronary bypass as one of the methods of surgical treatment of patients with acute coronary syndrome.
- **Maznev D.S., Sergeev A.S., Shloido E.A., Nozdryakova M.S., Zalyubovsky D.A.** (Saint-Petersburg). Short-term prognosis in patients with hypertrophic cardiomyopathy with left ventricular outflow tract obstruction after septal alcohol ablation.
- **Boyko A.M., Kamenshchikov N.O., Podoksenov Yu.K., Dyakova M.L., Panfilov D.S., Kozlov B.N.** (Tomsk). Nitric oxide in hemiarch aortic arch surgeries under hypothermic circulatory arrest.
- **Shadrina U.M., Korzhova M.A., Litskevich N.O., Tagirbegova Z.T., Babakehyan M.V., Sefieva G.G., Irtyuga O.B.** (Saint-Petersburg). Features of the course of primary and secondary infective endocarditis of aortic valve.
- **Prokhorikhin A.A., Zubarev D.D., Gorbatykh A.V.** (Saint-Petersburg). Pilot prospective randomized study of early withdrawal of antiaggregant therapy in patients with diabetes mellitus and high risk of bleeding after amphiliimus-eluting stent implantation.
- **Kudaev Yu.A., Vorobyeva A.V., Lokhovinina N.L., Abesadze I.T., Titenkov I.V., Alugishvili M.Z., Kozulin V.Y., Panov A.V.** (Saint-Petersburg). Risk factors of myocardial damage during planned percutaneous coronary interventions.

09:00–10:30

ONLINE-HALL №1

MEETING

09:00–10:30

ONLINE-HALL №2

SCIENTIFIC SESSION

«ADVANCING THE CARDIOTOXICITY DIAGNOSTICS
IN CANCER PATIENTS»

Chairperson: **Menkov I.** (Saint-Petersburg)

- **Schekochikhin D.** (Moscow). Current diagnostic strategies of cardiotoxicity in the light of actual clinical recommendations.
- **Pershina E.** (Moscow). Multimodality cardiovascular imaging of cardiotoxicity: the role of computed tomography and magnetic resonance imaging.
- **Bogdanova A.** (Moscow). Echocardiographic strategy for early detection of cardiotoxicity.
- **Chanakhchian F.** (Moscow). Features of myocardial perfusion scintigraphy in predicting perioperative risk in cancer patients.
- **Gulyaev N.** (Moscow). Novel strategies for early detection of cardiotoxicity.

11:00–12:30

PLENARY HALL

PLENARY SESSION «GRAND OPENING OF THE CONGRESS»

Simultaneous translation

Chairpersons: **Shlyakhto E.** (Saint-Petersburg),
Nedoshivin A. (Saint-Petersburg)

- **Official greetings**
- **Shlyakhto E.V.** (Saint-Petersburg). Personalized medicine for cardiology.
- **Shevchenko Yu.L.** (Moscow). Phenomenon of alternate contraction of cardiomyocytes and their associations. A new look at the physiology of the heart.
- **Pinto F.** (World heart federation). The impact of air pollution in cardiovascular health.
- **Award Ceremony of RSC – 2024**

13:30–15:00

PLENARY HALL

SATELLITE SYMPOSIUM «FAMILY HEALTH CARD: DIAGNOSIS AND TREATMENT OF CVD. HOW TO PROLONG LIFE»

(supported by «KRKA PHARMA», CME points are not accrued)

Chairperson: **Shlyakhto E.** (Saint-Petersburg)

- **Shlyakhto E.** (Saint-Petersburg). Introduction.
- **Villevalde S.** (Saint-Petersburg). The many faces of hypertension: how not to make a mistake with the choice of treatmentnsion.
- **Susekov A.** (Moscow). Recommendations for the treatment of dyslipidemia as the key to active longevity.
- **Panchenko E.** (Moscow). Very heartfelt stories: the life of patients with AF and the prevention of possible complications.

13:30–15:00

HALL №1 (E7)

SATELLITE SYMPOSIUM

«UPDATES OF THE GUIDELINES FOR HTN-TREATMENT 2023-2024: ESC, ESH AND RUSSIAN. WHAT ARE THE SIMILARITIES AND WHAT ARE THE DIFFERENCES? HOW TO USE IT MOST EFFECTIVELY IN CLINICAL PRACTICE»

Chairperson: Konradi A. (Saint-Petersburg)

- **Kobalava Zh.** (Moscow), **Nedogoda S.** (Volgograd), **Konradi A.** (Saint-Petersburg). interactive symposium without reports.

13:30–15:00

HALL №2 (E8-E9)

SATELLITE SYMPOSIUM

«COMORBID PATIENT AT THE INTERSECTION OF ENDOCRINOLOGY AND CARDIOLOGY»

(supported by «Gedeon Richter Pharma», CME points are not accrued)

Chairperson: Nedoshivin A. (Saint-Petersburg)

- **Shestakova M.** (Moscow). Cardiovascular risk management in patients with type 2 diabetes: an endocrinologist's view.
- **Nedoshivin A.** (Saint-Petersburg). The art of managing cardiometabolic risks: a cardiologist's perspective.

13:30–15:00

HALL №3 (D1)

SATELLITE SYMPOSIUM

«DIAMOND APPROACHES IN THE TREATMENT OF PATIENTS WITH ACS – ANALYSIS OF CLINICAL CASES AND CHOOSE DAPT»

(supported by «AstraZeneca», CME points are not accrued)

Chairperson: **Boytsov S.** (Moscow)

- **Koziolova N.** (Perm). Wont let heart to die. We save the patient using conservative medical management.
- **Duplyakov D.** (Samara). Fell. Woke up. Stent. Focus on the 1st year DAPT after ACS.
- **Glezer M.** (Moscow). Arguments for the doctor – prolong DAPT for the patients over 1st year after ACS.
- **Kalashnikov V.** (Saint-Petersburg). Who will write a pack of prescriptions... and what kind of antiplatelet agent will they contain?
-

13:30–15:00

HALL №4 (D2)

SATELLITE SYMPOSIUM

«FEATURES OF HYPERTENSION THERAPY IN PATIENTS OF DIFFERENT AGE GROUPS»

(supported by «Sanofi», CME points are not accrued)

Chairperson: **Arutyunov G.** (Moscow)

- **Arutyunov G.** (Moscow). Trends in hypertension therapy in 2024.
- **Karpov Yu.** (Moscow). Features of therapy in young patients with hypertension.
- **Orlova Ya.** (Moscow). Therapy in patients with hypertension and diseases associated with atherosclerosis.
- **Gilyarevsky S.** (Moscow). Features of therapy in patients with hypertension and metabolic disorders.
- **Tkacheva O.** (Moscow). Features of therapy in elderly patients with hypertension.

13:30–15:00

HALL №5 (D3)

SATELLITE SYMPOSIUM

«MODERN STRATEGIES FOR MANAGING PATIENTS WITH CORONARY ARTERY DISEASE IN 2024»

(supported by «Nizhpharm», CME points are not accrued)

Chairpersons: Barbarash O. (Kemerovo), **Drapkina O.** (Moscow)

- **Lomakin N.** (Moscow). Effective tools in the hands of the clinician in the treatment of coronary artery disease: focus on antiplatelet therapy.
- **Drapkina O.** (Moscow). Epidemiology of cardiovascular diseases in the Russian Federation.
- **Barbarash O.** (Kemerovo). How we diagnose and treat IHD in 2024.

13:30–15:00

HALL №6 (D4)

SATELLITE SYMPOSIUM

«CARDIAC PUZZLE: ARE ALL PATIENTS THE SAME?»

(supported by «Abbott Laboratories», CME points are not accrued)

Chairperson: Gurevich V. (Saint-Petersburg)

- **Panov A.** (Moscow). IHD and metabolic syndrome: the role of hypertriglyceridemia.
- **Obrezan A.** (Saint-Petersburg). Complex issues in lipidology: correction of triglycerides in patients with CKD.
- **Baranova E.** (Saint-Petersburg). Arterial hypertension in peri- and postmenopausal women — how to treat?

13:30–15:00

HALL №7 (B1)

SYMPOSIUM «PARADIGM SHIFT IN DIGITAL MEDICINE»

Chairpersons: **Kontsevaya A.** (Moscow), **Lopatin Yu.** (Volgograd)

- **Garanin A.** (Samara). Experience in implementing telemonitoring in patients with cardiovascular diseases.
- **Gridnev V., Posnenkova O.** (Saratov). Monitoring the effectiveness of treatment using telemetry data: expectations and reality.
- **Kontsevaya A.** (Moscow). Information systems and digital solutions for primary health care: review of international experience 2024.
- **Kozhevnikova V.** (Moscow). The problem of the Last Mile in remote monitoring of patients: the possibilities of personal messengers.
- **Laskova A.** (Volgograd). Mobile technologies in monitoring patients with stable coronary artery disease.

13:30–15:00

HALL №8 (B2)

SATELLITE SYMPOSIUM «ACT AS EARLY AS POSSIBLE AND PRESCRIBE FOR AS LONG AS POSSIBLE! INDIVIDUAL APPROACH TO STATIN THERAPY»

(supported by «Recordati», CME points are not accrued)

Chairpersons: **Ezhov M.** (Moscow), **Bubnova M.** (Moscow)

- **Bubnova M.** (Moscow). A look at statins from a biochemical point of view. Let's dot the i's.
- **Ezhov M.** (Moscow). What will we get later if we prescribe statins earlier?
- **Rotar O.** (Saint-Petersburg). Treatment history of one family who received a statin.
- **Koziolova N.** (Perm). Which statin should we choose to prevent DM?

13:30–15:00

HALL №9 (B3–B5)

SATELLITE SYMPOSIUM

«ATRIAL FIBRILLATION PATIENT: JOURNEY FROM THE DOCTOR'S OFFICE TO LIFE WITHOUT ATRIAL FIBRILLATION»

(supported by «Johnson & Johnson», CME points are not accrued)

Symposium is going on without broadcasting

Chairperson: Golukhova E. (Moscow)

- **Golukhova E.** (Moscow). Atrial fibrillation is the underrated epidemic of our time.
- **Serova M.** (Moscow). Patient with atrial fibrillation, who is he and how can we help him?
- **Rzaev F.** (Moscow). Myths and reality of interventional treatment of atrial fibrillation.

13:30–15:00

HALL №10 (B6–B8)

SATELLITE SYMPOSIUM

«ENDOVASCULAR TREATMENT OF PULMONARY EMBOLISM»

(supported by Cardiomedics, CME points are not accrued)

Symposium is going on without broadcasting

Chairpersons: Skrypnik D. (Moscow), **Pevzner D.** (Moscow), **Merkulov E.V.** (Moscow), **Krestyaninov O.V.** (Novosibirsk)

- **Komarov A.** (Moscow). Modern concept of pulmonary embolism: etiopathogenic factors, prevalence and clinical classification. What are the main clinical criteria and scales to assess the severity and course of pulmonary embolism?
- **Zyuryaev I.** (Moscow). Clinical Guidelines on the management of venous thromboembolic complications: a strategy of antithrombotic therapy. What is the role of interventional technologies for the treatment of pulmonary embolism?

- **Skrypnik D.** (Moscow). Ultrasound-assisted catheter-directed thrombolysis: a novel treatment approach for patients with moderate and high risk PE. The role of a multidisciplinary approach to developing a reperfusion strategy.

Ultrasound-assisted catheter-directed thrombolysis: real clinical practice.

- **Skrypnik D.** (Moscow). Clinical case presentation from Davydovsky Moscow city clinical hospital.
- **Merkulov E.** (Moscow). Clinical case presentation from Chazov National Medical Research Center of Cardiology.
- **Litvinyuk N.** (Krasnoyarsk). Clinical case presentation from Krasnoyarsk regional clinical hospital.
- **Zubarev D.** (Saint-Petersburg). Clinical case presentation from Almazov National Medical Research Center.
- **Krestiyandinov O.** (Novosibirsk). Clinical case presentation from Meshalkin National Medical Research Center.
- **Kan P.** (Surgut). Clinical case presentation from Surgut district clinical hospital.

13:30–15:00

HALL №11 (F200)

SYMPOSIUM

«TRANSTHYRETIN AMYLOID CARDIOMYOPATHY: ACHIEVEMENTS AND PROSPECTS»

Chairpersons: Galyavich A. (Kazan), **Tereshchenko S.** (Moscow)

- **Zhirov I., Nasonova S.** (Moscow). Two years of expert centre for amyloidosis center's activity: does it need to invent the bicycle?
- **Moiseeva O.** (Saint-Petersburg). Hyperdyagnosis of transthyretin amyloid cardiomyopathy: paradox or reality?
- **Galyavich A.** (Kazan). Practical aspects of the diagnosis of the amyloid cardiomyopathy.
- **Amelin A.** (Saint-Petersburg). Neurologic aspects of transthyretin amyloidosis.

13:30–15:00

HALL №12 (A1–A3)

**SYMPOSIUM HEALTH CARE WORKING GROUP
OF THE SAINT-PETERSBURG DIALOGUE FORUM
«DISEASES OF THE CIRCULATORY SYSTEM: CHALLENGES
AND SOLUTIONS. PART 1»**

**RUSSIAN-INDIAN SYMPOSIUM
«NEW TECHNOLOGIES OF DIAGNOSTICS AND TREATMENT
OF AORTA AND AORTIC VALVE PATHOLOGY»**

Simultaneous translation

Chairpersons: **Shlyakhto E.V.** (Saint-Petersburg), **Rath P.Ch.** (India),
Gordeev M.L. (Saint-Petersburg)

- **Rath P.C.** (India). TAVR in complex anatomy and challenging clinical scenario.
- **Irtuga O.B.** (Saint-Petersburg). Bicuspid aortic valve — pathogenesis and relationship with aortic stenosis and aortic aneurysm.
- **Bali H.K.** (India). TAVR in bicuspid aortic valve stenosis..
- **Uspensky V.E** (Saint-Petersburg). Surgery of the aortic valve.

13:30–15:00

HALL №13 (A4–A5)

**SYMPOSIUM
«DIGITAL CARDIOLOGY»**

Chairpersons: **Kopylov P.** (Moscow), **Matskeplishvili S.** (Moscow)

- **Kurapeev D.** (Saint-Petersburg). Artificial intelligence as a tool for searching for nonspecific diagnostic signs in patients with cardiovascular diseases.
- **Matskeplishvili S., Dyachuk L., Usherzon M., Gurfinkel Yu.** (Moscow). Digital technologies and artificial intelligence in cardiology.
- **Kopylov F.** (Moscow), **Bessonova M., Shestova I.** (Tula), **Gapon L., Todosiychuk V., Samoiloa E.** (Tyumen), **Chomakhidze P.** (Moscow). Practical application of artificial intelligence algorithms in Russian regions.
- **Shutov D.** (Moscow). Clinical trials of artificial intelligence systems in physiology: stages and scenarios.

13:30–15:00

HALL №14 (A8-A9)

**SCIENTIFIC SESSION
«MANAGING PATIENTS WITH NON-CORONARY
PATHOLOGIES»**

Chairpersons: Kosmacheva E.D. (Krasnodar), **Nechaeva G.I.** (Omsk).

- **Maslova M.Y., Krylova N.S., Poteshkina N.G., Kovalevskaya E.A.** (Moscow). Analysis of genetic factors in patients with hypertrophic cardiomyopathy phenotype.
- **Simakova M.A., Zhilenkova Yu.I., Goncharova N.S., Karelkina E.V., Malikov K.N., Vavilova T.V., Moiseeva O.M.** (Saint-Petersburg). Study of iron metabolism in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
- **Legkonogov A.V., Sokolovskaya E.A., Legkonogova L.G.** (Simferopol). Clinical and echocardiographic features of congenital heart defects in mature and elderly age.
- **Danilchenkova N.A., Golovina G.A., Tatarintseva Z.G., Kosmacheva E.D.** (Krasnodar). Clinical characteristics of patients with non-familial form of hypertrophic cardiomyopathy.
- **Goncharova N.S., Lapshin K.B., Matakaeva J.A., Andreeva E.M., Moiseeva O.M.** (Saint-Petersburg). Prevalence and reasons for failure of acute vasoreactive test in patients with idiopathic pulmonary arterial hypertension.
- **Parkhomenko S.I., Lapshin K.B., Simakova M.A., Moiseeva O.M.** (Saint-Petersburg). High and intermediate mortality risk pulmonary embolism: long-term follow-up data.

13:30–15:00

ONLINE-HALL №1

SATELLITE SYMPOSIUM

**«NEWS OF ANTIARRHYTHMIC THERAPY. THE NEW PLAYER
IN OUR TEAM – FLECAINIDE»**

(supported by «Mir-Pharm», CME points are not accrued)

Chairpersons: **Mikhailov E.** (Saint-Petersburg), **Tarasov A.** (Moscow)

- **Mikhailov E.** (Saint-Petersburg). Drug and hybrid therapy for paroxysmal atrial fibrillation.
- **Tarasov A.** (Moscow). Ectopic mechanism in atrial tachyarrhythmias, choice of effective therapy.
- **Tsaregorodtsev D.** (Moscow). Ventricular arrhythmias in patients without structural heart pathology: modern therapy.
-

13:30–15:00

ONLINE-HALL №2

SYMPOSIUM

**«MINIMALLY INVASIVE AORTIC SURGERY
OF THE XXI CENTURY A VECTOR IN ENDOVASCULAR
TECHNOLOGIES»**

Chairpersons: **Chang S.** (China), **Chernyavskiy M.** (Saint-Petersburg)

- **Chang S.** (China). Endovascular interventions for aortic arch pathology.
- **Chernyavskiy M.** (Saint-Petersburg). Minimally invasive treatment of complex aortic pathology — innovative solutions of the XXI century.
- **Imaev T.** (Moscow). Endovascular treatment of aortic arch pathology: experience of one center.
- **Polyakov R.** (Moscow). Branched stent grafts in the treatment of diseases of the thoracoabdominal aorta.
- **Khafizov T.** (Ufa). Application of fenestrated stent grafts for juxtarenal aneurysms.

15:30–17:00

PLENARY HALL

PLENARY SESSION «CARDIOLOGY NEWS 2024. PART 1»

Simultaneous translation

Chairpersons: Lopatin Yu. (Volgograd), **Chesnikova A.** (Rostov-on-Don)

- **Belenkov Yu.** (Moscow). What omics technologies say about heart failure classification.
- **Shlyakhto E.** (Saint-Petersburg). New classification of chronic heart failure.
- **Golukhova E.** (Moscow). Arrhythmology 2024.
- **Villevalde S.** (Saint-Petersburg). Heart Failure 2024.
- **Kostareva A.** (Saint-Petersburg). Cardiomyopathy 2024.

15:30–17:00

HALL №1 (E7)

SATELLITE SYMPOSIUM «WHEN BLOOD PRESSURE TAKES OVER: IDENTIFY AND CONTROL THE ARTERIAL HYPERTENSION!» (supported by «Nizhpharm», CME points are not accrued)

Chairperson: Konradi A. (Saint-Petersburg)

- **Arutyunov G.** (Moscow). Heavy burden: struggle for normal blood pressure of an obese patient.
- **Konradi A.** (Saint-Petersburg). Fresh look at an old enemy: modern approaches to blood pressure control.
- **Kozilova N.** (Perm). Monotherapy of arterial hypertension: who, when and how?
- **Fomin I.** (Nizhny Novgorod). Searching the balance: treatment of arterial hypertension with CKD.

15:30–17:00

HALL №2 (E8-E9)

SATELLITE SYMPOSIUM

«TO MEET THE LIFE: REAL CLINICAL PRACTICE DATA OF USING INCLISIRAN IN THE RUSSIAN FEDERATION»

(supported by «Novartis Pharma», CME points are not accrued)

Chairpersons: Vasilieva E. (Moscow), **Boytsov S.** (Moscow)

- **Boytsov S., Vasilieva E.** (Moscow). Introductory remarks.
- **Ezhov M.** (Moscow). Inclisiran: what do we see in real practice of its prescribing?
- **Shakhnovich R.** (Moscow). Innovative lipid-lowering therapy in patients with extreme and very high risk for the prevention of cardiovascular diseases.
- **Sapina A.** (Moscow). Regional initiatives to improve access to medicines. Moscow experience.

15:30–17:00

HALL №3 (D1)

SATELLITE SYMPOSIUM

«HOW TO LIVE TO 90: STATINS, BETA BLOCKERS AND OTHER FACTORS»

(supported by «AstraZeneca», CME points are not accrued)

Chairperson: Susekov A. (Moscow)

- **Susekov A.** (Moscow). Statins and prevention CVD: congress results, questions answers, clinical practice.
- **Napalkov D.** (Moscow). Beta-blockers: therapy for everyone or to each their own?
- **Gurevich V.** (Saint-Petersburg). Synergism of hypertension and dyslipidemia. Focus on length and quality of life.

15:30–17:00

HALL №4 (D2)

SATELLITE SYMPOSIUM

«KEY STEPS TOWARDS CONTROLLING CVD RISK FACTORS»

(supported by «Sanofi», CME points are not accrued)

Chairperson: Nedogoda S. (Volgograd)

- **Nedogoda S.** (Volgograd). CV-continuum: how to keep risks under control?
- **Kobalava Zh.** (Moscow). What should modern hypertension therapy be like?
- **Lebedeva A.** (Moscow). Dyslipidemia as a risk factor for atherosclerotic CVD.
- **Yezhov M.** (Moscow). Secondary prevention of CVD: focus on LDL-C control.

15:30–17:00

HALL №5 (D3)

SATELLITE SYMPOSIUM

«EXIT FROM THE HYPERTENSIVE LABYRINTH: FROM RECOMMENDATIONS TO REAL CLINICAL PRACTICE»

(supported by «Gedeon Richter Pharma», CME points are not accrued)

Chairperson: Drapkina O. (Moscow)

- **Drapkina O.** (Moscow). How to manage cardiovascular morbidity and mortality at the therapeutic site?
- **Nedoshivin A.** (Saint-Petersburg). Masterful balance in blood pressure control: from the start of therapy to uncontrolled hypertension.
- **Arutynov G.** (Moscow). Polypill: from science to real clinical practice.

15:30–17:00

HALL №6 (D4)

SATELLITE SYMPOSIUM

«INTERACTIVE DISCUSSION: SHOULD THE PREMATURE VENTRICULAR CONTRACTIONS BE TREATED?»

(supported by «TELERA-Pharma», CME points are not accrued)

Chairperson: Lebedev D. (Saint-Petersburg)

- **Ionin V., Tatarsky R., Garkina S.** (Saint-Petersburg). Interactive discussion: should the premature ventricular contractions be treated?

15:30–17:00

HALL №7 (B1)

SATELLITE SYMPOSIUM

«INTERVENTIONAL TECHNOLOGIES IN CARDIOLOGICAL PATIENTS. HOW, WHEN AND WHERE TO SEND A PATIENT?»

(supported by «Cardiomedics», CME points are not accrued)

Chairpersons: Imaev T. (Moscow), **Sapelnikov O.** (Moscow)

- **Serova M.** (Moscow). The current guidelines for ICD implantations: what they tell us.
- **Sergeeva O.** (Moscow). Interventional treatment of atrial fibrillation-1st line therapy.
- **Sapelnikov O., Uscach T.** (Moscow). Patient selection for cardiac contractility modulation.
- **Imaev T.** (Moscow). Endovascular treatment of critical aortic stenosis: affordable than it looks.

15:30–17:00

HALL №8 (B2)

ROUND TABLE

«WHAT THE CORONARY PLAQUE HIDES IN NON-ST-ELEVATION ACUTE CORONARY SYNDROME: FIND AND NEUTRALIZE»

Chairperson: Barbarash O. (Kemerovo), **Ganyukov V.** (Kemerovo)

- **Kashtalap V.** (Kemerovo). Clinical case of management of a patient with non-ST-elevation acute coronary syndrome and low risk: how it happens in real practice.
- **Boschenko A.** (Tomsk). The place imaging stress tests and coronary CT angiography in assessing the prognosis and determining indications for revascularization in a patient with non-ST-elevation ACS and low risk.
- **Kochanov I.** (Saint-Petersburg). Intravascular methods (IVUS, OCT) for detecting unstable coronary plaques in a patient with non-ST-elevation ACS and low risk.
- **Arutyunyan G.** (Moscow). Evaluation of FFR/iFR on coronary artery stenosis in determining indications for revascularization in a patient with non-ST-elevation ACS and low risk.
- **Kochergin N.** (Kemerovo). Promising approaches to defining indications for preventive coronary stenting in a patient with non-ST-elevation ACS?
- Discussion.

15:30–17:00

HALL №9 (B3-B5)

MASTER CLASS

«FAST TRACK — INNOVATIVE APPROACHES TO DISPENSARY FOLLOW-UP, BEST PRACTICES, EXPERIENCE EXCHANGE»

Chairpersons: Paleev P. (Moscow), **Kurapeev D.** (Saint-Petersburg)

- **Meshkova M.** (Lipetsk), **Benimetskaya K.** (Novosibirsk). Low-density lipoproteins in patients in the first year after events — automation for effective goals achievement.
- **Kozhokar K.** (Novy Urengoy). The use of specialized information systems for remote monitoring in CVD patients.
- **Strokolskaia I.** (Kemerovo). Proactive monitoring of patients with chronic heart failure. A new generation of interactive nosological register.
- **Shestova I.** (Tula). Dispensary follow-up of patients with coronary heart disease and myocardial infarction suffered more than a year ago. A digital approach to achieving health targets using the example of low-density lipoproteins and blood pressure.
- **Shebonkina D.** (Samara). Medical decision support in patients with arterial hypertension and atrial fibrillation. Adherence to recommendations — the way to control risk factors.
- **Kuzub A.** (Pskov). Automatic quality control of therapy for patients with cardiovascular diseases — the basis for achieving health targets.

15:30–17:00

HALL №10 (B6-B8)

SYMPOSIUM

«NUTRITIONAL CARE FOR PATIENTS WITH CARDIOVASCULAR DISEASES»

Chairpersons: Starodubova A. (Moscow), **Kislyak O.** (Moscow)

- **Starodubova A.** (Moscow). Introduction.
- **Khlynova O.** (Perm). Dietary patterns and cardiometabolic health.
- **Bakulin I., Zhuravleva M.** (Saint-Petersburg). Diet therapy for NAFLD from the perspective of evidence-based medicine.
- **Liskova Yu.** (Moscow). Possibilities of cardionutrition in the management of arterial hypertension: achievements and problems.
- **Leiderman I.** (Saint-Petersburg). Metabolic control and nutritional support in patients with CHF.

- **Shulkina S.** (Perm). Therapeutic nutrition for comorbid pathologies: chronic kidney disease and cardiovascular diseases.

15:30–17:00

HALL №11 (F200)

SYMPOSIUM

«THE PROBLEM OF METABOLIC HEALTH OF THE POPULATION IN CARDIOLOGICAL PRACTICE»

Chairperson: Baranova E. (Saint-Petersburg)

- **Kuznetsova T.** (Petrozavodsk). History and modernity of the problem of metabolic health of the population.
- **Chumakova G., Gritsenko O.** (Barnaul). Possibilities for prevention and treatment prospects for metabolic diseases in cardiology.
- **Nikulina S.** (Krasnoyarsk). Genetic aspects of obesity.

15:30–17:00

HALL №12 (A1–A3)

SYMPOSIUM OF THE HEALTH CARE WORKING GROUP OF THE SAINT-PETERSBURG DIALOGUE FORUM «DISEASES OF THE CIRCULATORY SYSTEM: CHALLENGES AND SOLUTIONS. PART 2»

RUSSIAN-TURKISH SYMPOSIUM

«NEW TECHNOLOGIES IN INTERVENTIONAL CARDIOLOGY. CHOICE OF TECHNOLOGY AND TARGET GROUP OF PATIENTS FOR PCI»

Simultaneous translation

Chairpersons: Danilov I. (Saint-Petersburg), **Degertekin M.** (Turkey), **Gorbatykh A.** (Saint-Petersburg).

- **Aktyurk F.** (Turkey). Complex 3-vessel disease interventions, which patient and how.
- **Vasiliev D.** (Moscow). CTO, which patient and how.
- **Degertekin M.** (Turkey). Left main procedures, which patient and how.
- **Prokhorikhin A.** (Saint-Petersburg). Calcified complex coronary lesion intervention, which patient and how.

15:30–17:00

HALL №13 (A4-A5)

SYMPOSIUM

«PERIOPERATIVE ASPECTS OF MANAGING A COMORBID PATIENT IN A CARDIAC SURGERY CLINIC»

Chairpersons: Lyapina I. (Kemerovo), Efremova E. (Ulyanovsk)

- **Bezdenezhnykh N.** (Kemerovo). Perioperative management for patients with carbohydrate metabolism disorders during cardiac surgery.
- **Smolyakova E.** (Moscow). Cardiac surgery in comorbid patients with cardiorespiratory pathology.
- **Efremova E.** (Ulyanovsk). Patient with chronic kidney disease: what should a cardiologist pay attention to in the perioperative period.
- **Magamadov I.** (Saint-Petersburg). Complications in the postoperative period of coronary artery bypass grafting in the practice of a cardiologist: methods of prevention and treatment.
- **Lyapina I.** (Kemerovo). Physical rehabilitation in patients after heart surgery: new methods.

15:30–17:00

HALL №14 (A8-A9)

SCIENTIFIC SESSION

«IMAGING IN CARDIOLOGY, ULTRASOUND AND TOMOGRAPHY»

Chairpersons: Kanysheva S. (Yoshkar-Ola), Khludeeva E. (Vladivostok).

- **Usov V., Kobelev E., Fridman A., Krestyaninov O., Bobrikova E.** (Novosibirsk), **Shelkovnikova T., Alekseeva Yu.** (Tomsk), **Chernyavsky A.** (Novosibirsk). Visualization of activated atherosclerotic coronary plaques with increased risk of myocardial infarction according to MRI of coronary arteries with paramagnetic contrast enhancement.
- **Boschenko A., Zhuravleva O., Ryabova T., Svyazova N., Vrublevsky A.** (Tomsk). Global longitudinal deformation of the left ventricle at stress-echocardiography as a prognostic factor for stable coronary artery disease.
- **Shirokov N., Yaroslavskeya E., Krinochkin D., Enina T., Musikhina N., Kosterin M.** (Tyumen). Left atrial stiffness index in determination of heart failure with preserved ejection fraction.

- **Resnyanskaya E., Evdokimov D., Boldueva S.** (Saint-Petersburg). Morphological changes of coronary arteries in different forms of acute coronary syndrome and their relationship with in-hospital complications.
- **Maltseva A., Kopyeva K., Mochula A., Grakova E., Zavadovsky K.** (Tomsk). Assessment of myocardial blood flow and coronary flow reserve by dynamic single photon emission computed tomography in patients with non obstructive atherosclerotic lesion of coronary arteries.
- **Pivovarova A., Soboleva G., Stukalova O., Ternovoy S., Karpov Yu.** (Moscow). Relationship of clinical characteristics of patients with probable coronary artery disease with coronary flow reserve according to stress MRI with adenosine triphosphate.

15:30–17:00

ONLINE-HALL №1

SYMPOSIUM

«HEART DAMAGE IN FABRY DISEASE: NEW HORIZONS OF DIAGNOSIS AND THERAPY»

Chairperson: **Yankovskaya I.** (Moscow)

- **Matskeplishvili S.** (Moscow). Fabry's disease. Cardiovascular manifestations and "red flags" for a cardiologist.
- **Philippov E.** (Ryazan). Selective screening for Fabry's Disease in cardiology on the example of a practical case in the Ryazan regional university.
- **Vedernikov A.** (Tyumen). Experience of managing a patient with Fabry's disease in the practice of a cardiologist in the Tyumen region.
- **Yankovskaya I.** (Moscow). Algorithms for the diagnosis and management of patients with Fabry's disease. The program of observational research. The project helpfabry.ru

15:30–17:00

ONLINE-HALL №2

SATELLITE SYMPOSIUM

«HARD TREATMENT TO HANDLE: ACTUAL ISSUES OF COMPLIANCE IN ANTIHYPERTENSIVE THERAPY»

(supported by «Kanonpharma Production», CME points are not accrued)

Chairperson: Blinova N. (Moscow)

- **Blinova N.** (Moscow). Antihypertensive therapy in front-rant clinical practice: trend towards the fixed combinations usage.
- **Martynyuk T.** (Moscow). Challenges and opportunities of PAH-specific therapy: what does international and Russian up to date experience say?
- **Aksenova A.** (Moscow). The place of candesartan in real clinical practice in 2024.

17:30–19:00

PLENARY HALL

PLENARY SESSION

«REDUCING MORTALITY FROM CARDIOVASCULAR DISEASES. EXPERIENCE AND VISIONS OF DIFFERENT COUNTRIES»

Simultaneous translation

Chairpersons: Nedoshivin A. (Saint-Petersburg), **Galyavich A.** (Kazan).

- **Mitkovskaya N.** (Belarus). Reducing the burden of circulatory diseases: experience of the Belarus Republic.
- **Berkinbaev S.** (Kazakhstan). Achievements and prospects of cardiologic service in the Kazakhstan Republic.
- **Ayrapetyan G.** (Armenia). Heart failure and left ventricular ejection fraction: what we know and what awaits us.
- **Pineiro D.** (Argentina). Secondary prevention. The new WHF's roadmap.
- **Sooronbaev T.M.** (Kyrgyzstan). High-altitude pulmonary hypertension.

17:30–19:00

HALL №1 (E7)

SYMPOSIUM

«UNOBVIOUS ASPECTS OF THE TREATMENT OF CARDIOGENIC SHOCK»

Chairpersons: **Pevzner D.** (Moscow), **Zhbanov I.** (Moscow)

- **Sukhinina T., Komarov A.** (Moscow). Difficulties of antithrombotic therapy in cardiogenic shock.
- **Osiev A.** (Moscow). Endovascular treatment of post-infarction IVS rupture.
- **Zhbanov I.** (Moscow). Open heart surgery in the treatment of cardiogenic shock.
- **Merkulova I.** (Moscow). Mixed cardiogenic and septic shock.

17:30–19:00

HALL №2 (E8-E9)

SYMPOSIUM

«MODERN POSSIBILITIES FOR THE PREVENTION, DIAGNOSIS AND TREATMENT OF INFECTIVE ENDOCARDITIS»

Chairpersons: **Rebrov A.** (Saratov), **Kobalava Zh.** (Moscow)

- **Ponomareva E.** (Saratov). Prevention of infective endocarditis: is it easier to prevent than to treat?
- **Safarova A.** (Moscow). EchoCG is a key player in the diagnosis of infective endocarditis: what to look for?
- **Pursanova D.** (Moscow). Novel approaches for evaluation of prosthetic valve endocarditis using nuclear medicine imaging techniques: radio labeled leukocyte SPECT/CT and 18F-FDG PET/CT.
- **Domonova E.** (Moscow). Complex issues and ways to optimize the etiological diagnosis of infective endocarditis: focus on PCR studies.
- **Kotova E.** (Moscow). Modern strategies for antibacterial therapy of infective endocarditis.

17:30–19:00

HALL №3 (D1)

SYMPOSIUM

«SYMPOSIUM 3D: DETAILED, DYNAMIC, EVIDENCE-BASED. UNDESIRABLE EFFECTS OF DRUGS IN CARDIOVASCULAR DISEASE»

Chairperson: Arutyunov G. (Moscow)

- **Tarlovskaya E.** (Nizhny Novgorod). Chemotherapy drugs for cancer.
- **Grigorieva N.** (Nizhny Novgorod). Antibiotics.
- **Kozioлова N.** (Perm). glucose-lowering drugs.
- **Chesnikova A.** (Rostov-on-Don). Statins.
- **Rebrov A.** (Saratov). Nonsteroidal anti-inflammatory drugs and colchicine.
- **Shaposhnik I.** (Chelyabinsk). Antiarrhythmic drugs.
- **Orlova Ya.** (Moscow). Mineralcorticoid receptor antagonists.
- **Petrova M.** (Krasnoyarsk). Antidepressants.

17:30–19:00

HALL №4 (D2)

SYMPOSIUM

«CARDIOMYOPATHY – WHAT'S NEW?»

Chairpersons: Moiseeva O. (Saint-Petersburg), **Blagova O.** (Moscow)

- **Myasnikov R.** (Moscow). Modern trends in the classification of cardiomyopathy. Strengthening the position of genetics.
- **Kostareva A.** (Saint-Petersburg). Titinopathies: new molecular mechanisms and potential therapeutical targets.
- **Mayrina S.** (Saint-Petersburg). Is genetic testing justified for myocarditis?
- **Mershina E.** (Moscow). New capabilities of multiparametric cardiac MRI in diagnosis and prognosis assessment in patients with cardiomyopathy
- **Lutohina Yu., Zaklyazminskaya E.** (Moscow). Frequency and role of concomitant myocarditis in hypertrophic cardiomyopathy

17:30–19:00

HALL №5 (D3)

SYMPOSIUM

«A NEW ERA IN THE DIAGNOSIS AND TREATMENT OF AORTIC STENOSIS»

Chairpersons: **Irtyuga O.** (Saint-Petersburg), **Saidova M.** (Moscow)

- **Malev E.** (Saint-Petersburg). Bicuspid aortic valve: new nomenclature and clinical characteristics.
- **Saidova M.** (Moscow). Severe aortic stenosis: hemodynamic variants.
- **Irtyuga O.** (Saint-Petersburg). The place of drug therapy in the treatment of aortic stenosis.
- **Bogachev-Prokofiev A.** (Novosibirsk). Surgical and interventional treatment methods for aortic stenosis.

17:30–19:00

HALL №6 (D4)

EXPERT DISCUSSION CLUB

«DISCUSSION ISSUES IN THE TERMINOLOGY OF HEART FAILURE IN ACUTE MYOCARDIAL INFARCTION»

Chairpersons: **Boytsov S.** (Moscow), **Barbarash O.** (Kemerovo)

- **Ageev F.** (Moscow). Is heart failure a single disease with different trajectories of development, or are heart failures different phenotypes of one disease? The role of acute coronary syndrome.
- **Yakushin S.** (Ryazan), **Pereverzeva K.** (Ryazan). New heart failure in patients with acute coronary syndrome myocardial infarction: acute, subacute, or chronic?
- **Tereschenko S.** (Moscow). Russian Registry for the Study of Post-Myocardial Infarction Heart Failure — BRON-CHF.

17:30–19:00

HALL №7 (B1)

SYMPOSIUM

**«THE MANY FACES OF ATRIAL FIBRILLATION:
CASE STUDIES...»**

Chairperson: Popov S. (Tomsk)

- **Baranova E.** (Saint-Petersburg). Atrial fibrillation what's new in 2024?
- **Chernova A.** (Krasnoyarsk). Paroxysmal atrial fibrillation: how to prevent relapse?
- **Ionin V.** (Saint-Petersburg). Persistent atrial fibrillation: how to restore rhythm?
- **Batalov R.** (Tomsk). Persistent atrial fibrillation: how to control it?

17:30–19:00

HALL №8 (B2)

SYMPOSIUM

«RENAL DENERVATION: THERE IS A FUTURE!»

Chairpersons: Konradi A. (Saint-Petersburg), **Falkovskaya A.** (Tomsk)

- **Gapon L., Mikova E.** (Tyumen). Interventional treatment of arterial hypertension: time of new questions and their solutions.
- **Pekarsky S.** (Tomsk). The moderate effectiveness of renal denervation in clinical studies has led to its immaturity and does not reflect the true potential of this method.
- **Shugushev Z.** (Moscow). Pathophysiological approaches to improving the technique of renal denervation.
- **Emelyanov I., Ionov M., Yudina J., Avdonina N., Panarina S., Vakhrushev A., Zverev D., Mikhailov E., Lebedev D., Konradi A.** (Saint-Petersburg). Results of long-term follow-up of patients with resistant arterial hypertension after renal sympathetic denervation.
- **Feshchenko D.** (Moscow). Interdisciplinary approach to the study of renal denervation: promising areas of application.
- **Falkovskaya A., Lichikaki V., Zyubanova I., Manukyan M., Solonskaya E., Khunikhinova S., Popova A., Skomkina I., Soltanakhmetova A., Mordovin V.** (Tomsk). Renal denervation: from blood pressure control to organ protection.

17:30–19:00

HALL №9 (B3-B5)

SYMPOSIUM

**«CARDIAC REHABILITATION SYSTEM IN RUSSIA:
SUCCESSSES AND DIFFICULTIES OF THE CURRENT STAGE»**

Chairpersons: Aronov D. (Moscow), Bubnova M. (Moscow)

- **Demchenko E., Pomeshkina S.** (Saint-Petersburg). Russian and international recommendations for cardiac rehabilitation versus the Procedure for organizing medical rehabilitation for the adult population: two approaches to the solution. Real practice of organizing the inpatient stage of cardiac rehabilitation.
- **Korenova O., Druk I., Yukhina Yu., Savchenko M., Prikhodko E., Podolnaya S.** (Omsk). How to organize cardiac rehabilitation of the third outpatient stage? Omsk experience.
- **Ostroushko N.** (Voronezh). Cardiac rehabilitation in the Voronezh region: regional experience of the organization
- **Svetlova N.** (Cheboksary). Organization of cardiac rehabilitation in the Chuvash Republic within the framework of the Order for Medical Rehabilitation: achievements and problems.
- **Golovenkin S., Nikulina S., Ustyugov S.** (Krasnoyarsk). Rehabilitation of patients with acute coronary syndrome in the Krasnoyarsk Territory: region: present and future.
- **Bubnova M., Aronov D.** (Moscow). Improving the current Procedure for organizing medical rehabilitation in the field of cardiac rehabilitation: proposals.

17:30–19:00

HALL №10 (B6-B8)

SYMPOSIUM

«CARDIOVASCULAR PATHOPHYSIOLOGY»

Chairpersons: Malashicheva A. (Kemerovo), **Kutikhin A.** (Kemerovo)

- **Kutikhin A., Sinitsky M., Markova V., Markova Yu., Sinitskaya A.** (Kemerovo). Pro-inflammatory activation of endothelial cells and monocytes upon the internalisation of albumin- and fetuin-centric calciprotein particles.
- **Shishkova D., Kanonykina A., Lazebnaya A., Tyurina A., Poddubnyak A.** (Kemerovo). Therapeutic regulation of mineral homeostasis: prospects for anti-atherosclerotic treatment.
- **Malashicheva A.** (Saint-Petersburg). Search for efficient anti-calcification treatments: from basic studies to drug development.
- **Docshin P.** (Saint-Petersburg). Molecular and cellular mechanisms of aortic stenosis.
- **Kercheva M., Panteleev O., Ryabov V.** (Tomsk). Apheresis in patients with cardiogenic shock.
- **Ivanova A.** (Saint-Petersburg). Modified low-density lipoprotein cholesterol, anti-lipoprotein antibodies, and immune complexes in atherogenesis.

17:30–19:00

HALL №11 (F200)

SYMPOSIUM

«PRACTICAL ISSUES OF DIAGNOSTICS, TREATMENT AND PREVENTION IN AHF PATIENTS 2024»

Chairpersons: Dzhioeva O. (Moscow), **Kashtalap V.** (Kemerovo)

- **Kuzub A.** (Pskov). AHF hospitalised Patient's profile in region of RF.
- **Dzhioeva O.** (Moscow). Signs, symptoms, ultrasound and biomarkers, or something else in congestion diagnosis.
- **Vedenikin T.** (Moscow). Experience of russian center in STRONG-HF trial.
- **Kashtalap V.** (Kemerovo). Compliance in therapy after AHF.

17:30–19:00

HALL №12 (A1-A3)

SYMPOSIUM

«PATIENT HISTORY: HEART FAILURE AND ATRIAL FIBRILLATION»

Chairpersons: **Garkina S.** (Saint-Petersburg), **Simonenko M.** (Saint-Petersburg)

- **Garkina S.** (Saint-Petersburg). The first stage of chronic heart failure in a patient with atrial fibrillation - what should a cardiologist do?
- **Gromyko G.** (Moscow). Catheter ablation of atrial fibrillation as a treatment strategy for a heart failure patient.
- **Latkina A.** (Yaroslavl). Pharmacologic treatment of advanced heart failure combined with atrial fibrillation.
- **Yambatov A.** (Kovrov). Interventional treatment of chronic heart failure in patients with atrial fibrillation: implantable electronic devices.
- **Galenko V.** (Saint-Petersburg). Heart transplantation in patients with atrial fibrillation and chronic heart failure — when to make a decision?

17:30–19:00

HALL №13 (A4-A5)

SYMPOSIUM

«HEALTHY AND THERAPEUTIC NUTRITION: NEWS AND TRENDS»

Chairpersons: **Kontsevaya A.** (Moscow), **Starodubova A.** (Moscow)

- **Kontsevaya A.** (Moscow). Availability and economics of healthy food.
- **Karamnova N.** (Moscow). Healthy nutrition: main trends.
- **Starodubova A.** (Moscow). Therapeutic nutrition: achievements and prospects.
- **Varaeva Yu.** (Moscow). Difficult aspects of prescribing vitamins and minerals as part of dietary therapy for cardiovascular diseases.
- **Kushnarenko N.** (Chita). The role of selenium in the treatment and prevention of cardiovascular diseases.

17:30–19:00

HALL №14 (A8-A9)

**SCIENTIFIC SESSION
«FUNDAMENTAL RESEARCH AND PERSONALIZED
CARDIOLOGY»**

Chairpersons: Nikulina S. (Krasnoyarsk), **Osipova O.A.** (Belgorod)

- **Zotova I., Kochkina M., Alkam D., Baklanova T., Minushkina L., Zateishchikov D.** (Moscow). Association of the level of inflammatory markers with the rate of dissolution of a blood clot in the auricle of the left atrium in patients with atrial fibrillation.
- **Kharitonov D., Kovalenko E., Kamelin A., Shakhin L., Rubinova V., Rakitko A.** (Moscow). Validation of polygenic risk scales for 42 blood biomarkers in the Russian population.
- **Ivanova A., Dmitrieva A., Denisenko A.** (Saint-Petersburg). Modified low-density lipoproteins, anti-lipoprotein antibodies and immune complexes in atherogenesis.
- **Hryachkova O., Khutornaya M., Sinitskaya A., Sinitsky M.** (Kemerovo). The relationship of single nucleotide variants of the LEP and LEPR genes with the concentration of leptin and its soluble receptor in the blood of patients with myocardial infarction.
- **Kercheva M., Stepanov I., Ryabov V.** (Tomsk). Systemic assessment of the content of m1 and m2 macrophages in patients with myocardial infarction complicated by the development of cardiogenic shock.
- **Sinitskaya A., Kostyunin A., Asanov M., Khutornaya M., Poddubnyak A.** (Kemerovo). Characteristics of native heart valves affected by infectious endocarditis: results of histological and proteomic analysis.

17:30–19:00

ONLINE-HALL №1

**SYMPOSIUM
«HEART FAILURE 2024: WHAT SHOULD DEFINITELY
DISCUSSED?»**

Chairpersons: Belenkov Yu. (Moscow), **Lopatin Yu.** (Volgograd)

- **Seferović P.** (Serbia). Recent advances in the treatment of heart failure with preserved ejection fraction: phenotype-based therapy.

- **Belenkov Yu.** (Moscow). Heart failure and comorbidity: what's new in diagnosis and treatment?
- **Abdelhamid M.** (Egypt). Prevention of sudden death in heart failure with a low ejection fraction.
- **Lopatin Yu.** (Volgograd). When to start iNGLT2 therapy after acute myocardial infarction?

17:30—19:00

ONLINE-HALL №2

SYMPOSIUM

«FIGHTING CARDIOVASCULAR DISEASES AND YOUTH HEALTH: EVA SYNDROME, RISK FACTORS, CONNECTIVE TISSUE DYSPLASIA AND PROBLEMATIC PREGNANCY»

Chairpersons: **Eliseeva L.** (Krasnodar), **Statsenko M.** (Volgograd)

- **Evseviev M., Sergeyeva O., Rusidi A.** (Stavropol). Angioscreening of early vascular aging in young people is a promising trend in preventive cardiology. The place of non-traditional risk factors and timely differential diagnosis.
- **Tolkunova C., Rotar O.** (Saint-Petersburg). Transgenerational effects of vascular aging on the example of two generations of residents of besieged Leningrad/
- **Osipova I., Shirokostup S., Pospelov S.** (Barnaul). Approbation of a regional model of digital medical screening of the leading risk factors for cardiovascular diseases in the youth of the Altai region.
- **Pirozhenko A., Drobotya N., Khaisheva L.** (Rostov-on-Don). Risk factors and features of their combinations in young people with EVA phenomenon.
- **Statsenko M., Fedotov V., Shaposhnikova M., Derevyanchenko M.** (Volgograd). Assessment of risk factors for chronic non-infectious diseases in young people of the Volgograd region.
- **Eliseeva L.** (Krasnodar). Features of renal venous blood flow disorders in young patients with arterial hypertension: new possibilities of nephroprotection taking into account connective tissue dysplasia.

09:00–10:30

PLENARY HALL

PLENARY SESSION

«GLOBAL TRENDS IN CARDIOLOGY «

Simultaneous translation

Chairpersons: **Matskeplishvili S.** (Moscow), **Kosmacheva E.** (Krasnodar)

- **Komajda M.** (France). Diabetes and cardiovascular disease: what do the new ESC guidelines change?
- **Boytsov S.A.** How can we influence the cardiovascular continuum today?
- **Seferović P.** (Serbia). Precision treatment and individualized approach in heart failure.
- **Gordeev M.L.** Surgery of chronic heart failure. With a shield or on a shield?

09:00–10:30

HALL №1 (E7)

SATELLITE SYMPOSIUM

«CLINICAL SEARCH AND SOLUTIONS FOR A COMORBID PATIENT WITH CHF: VENI, VIDI, VICI!»

(supported by «Novartis Pharma», CME points are not accrued)

Chairperson: **Belenkov Yu.** (Moscow)

- **Kobalava Zh.** (Moscow). Tell us, professor, how can a practitioner resolve problems that arise when managing a comorbid patient with HFpEF?
- **Ageev F.** (Moscow). Tell us, professor, what should be treated first in a patient with HFpEF: a comorbid condition or CHF?
- **Tyrenko V.** (Saint-Petersburg). Tell us, professor, what are the secrets of success in treating patients in the preferential category?
- **Villevalde S.** (Saint-Petersburg). Tell us, professor, what are the points of application of ARNI in patients with CHF and CKD?

09:00–10:30

HALL №2 (E8-E9)

SATELLITE SYMPOSIUM «BASIC AND ADDITIONAL MARKERS OF CARDIOVASCULAR RISK: HOW TO IMPLEMENT A PERSONALIZED APPROACH»

(supported by «Abbott Laboratories», CME points are not accrued)

Chairperson: Konradi A. (Saint-Petersburg)

- **Orlova Ya.** (Moscow). Atherosclerosis and inflammation: the role of triglycerides.
- **Kalashnikov V.** (Moscow). Triglycerides: marker or target.
- **Polyakova E.** (Saint-Petersburg). What's new in the light of clinical guidelines on arterial hypertension.

09:00–10:30

HALL №3 (D1)

SATELLITE SYMPOSIUM «RUSSIAN AND INTERNATIONAL EXPERIENCE IN USING OF ANTICOAGULANT THERAPY FOR NON-VALVULAR ATRIAL FIBRILLATION IN COMORBID PATIENTS»

(supported by «Pfizer», CME points are not accrued)

Simultaneous translation

Chairperson: Averkov O. (Moscow)

- **Averkov O.V.** (Moscow). Introduction.
- **Lopes R.** (USA). Impact of the AUGUSTUS study on international treatment guidelines and management of patients with atrial fibrillation and acute coronary syndrome.
- **Averkov O.** (Moscow). Modern approaches to the management of patients with non-valvular atrial fibrillation and acute coronary syndrome.
- **Dzhioeva O.** (Moscow). Approaches to the choice of antithrombotic therapy in patients with non-valvular atrial fibrillation and impaired renal function.
- **Komarov A.** (Moscow). How to reduce the risks of gastrointestinal bleeding in a comorbid patient with non-valvular atrial fibrillation
- **Averkov O.V.** (Moscow). Discussion.
- **Averkov O.V.** (Moscow). Closing.

09:00–10:30

HALL №4 (D2)

SATELLITE SYMPOSIUM

«THE PATIENT'S PATH AFTER ACS: THE RED THREAD OF THERAPY CONTINUITY»

(supported by «Sanofi», CME points are not accrued)

Chairperson: Shlyakhto E. (Saint-Petersburg)

- **Zvartau N.** (Saint-Petersburg). The patient's route after ACS: the main pain points and solutions.
- **Yakovlev A.** (Saint-Petersburg). Discharge epicrisis of the patient after MI: what should we pay attention to?
- **Timoshchenko E.** (Nizhny Novgorod). Early intensification of lipid-lowering therapy at the hospital stage.
- **Alieva A.** (Saint-Petersburg). Control of LDL cholesterol in patients after ACS at the outpatient stage.

09:00–10:30

HALL №5 (D3)

SATELLITE SYMPOSIUM

«PATIENT-CENTRIC APPROACH TO THE MANAGEMENT OF ACS SURVIVORS: LANDMARK — MODERN RECOMMENDATIONS»

(supported by «AstraZeneca», CME points are not accrued)

Simultaneous translation

Chairperson: Shakhnovich R. (Moscow)

- **Yavelov I.** (Moscow). Treatment pathways in ACS: considering the patients medical history.
- **Barbarasch O.** (Kemerovo). What should not be forgotten, when choosing P2Y12 inhibitor.
- **Ragy H.** (Egypt). How to adapt the treatment to patient's profiles after ACS.

09:00–10:30

HALL №6 (D4)

SATELLITE SYMPOSIUM

«THE HEART CODE OF MENOPAUSE: INSIGHTS FROM AN INTEGRATED APPROACH»

(supported by «Abbott Laboratories», CME points are not accrued)

Chairperson: Arutyunov G. (Moscow)

- **Villevalde S.** (Saint-Petersburg). Menopause: how to improve a woman's quality of life and reduce cardiovascular risks? A cardiologist's view.
- **Arutyunov G.** (Moscow). A woman over 45 years old visiting a therapist — what should you pay attention to?
- **Tapilskaya N.** (Saint-Petersburg). Interdisciplinary management of patients over 45 years of age: the view of a gynecologist.
- **Shestakova E.** (Moscow). Menopause — a kaleidoscope of metabolic risks.
- **Sergienko I.** (Moscow). Management of patients with dyslipidemia in menopause.

09:00–10:30

HALL №7 (B1)

SATELLITE SYMPOSIUM

«YIN AND YANG IN ARTERIAL HYPERTENSION»

(supported by «Vertex», CME points are not accrued)

Chairperson: Nedoshivin A. (Saint-Petersburg)

- **Nedoshivin A.** (Saint-Petersburg). Introduction.
- **Baranova E.** (Saint-Petersburg). Female hypertension: nuances and features.
- **Nedogoda S.** (Volgograd). All facets of male hypertension.

09:00–10:30

HALL №8 (B2)

SATELLITE SYMPOSIUM

«FROM RECOMMENDATIONS TO THE EXPERIENCE OF THE BEST CLINICAL PRACTICES IN THE STRUGGLE FOR THE SINUS RHYTHM AT THE FP: THE FUTURE BEGINS TODAY»

(supported by «R-Pharm», CME points are not accrued)

Chairperson: Lomakin N. (Moscow)

- **Yricheva Y.** (Moscow). Sinus rhythm control during atrial fibrillation: what did we see in real practice? Analysis of data of the Russian register application of the antiarrhythmic drug of the III class of Cavutilide for cardioversion.
- **Pyataeva O.** (Novosibirsk). Regional experience of cardioversii anti -arrithmik of grade III: new horizons and best practices.
- **Garkina S.** (Saint-Petersburg). Rhythm control in the practice of arrhythmologist surgeon: are we using all the possibilities?
- **Stepin A.** (Yekaterinburg). Choice for cardioversion in atrial fibrillation in the practice of a cardiac surgeon.
- **Ionin V.** (Saint-Petersburg). Cardioversion of AF:to beat or not to beat? Classic or modern readings?

09:00–10:30

HALL №9 (B3-B5)

SYMPOSIUM

«CVD IN THE REGIONS – HOW IS THE CARDIOLOGICAL LANDSCAPE CHANGING IN THE XXI CENTURY?»

Chairpersons: Filippov E. (Ryazan), **Balanova I.** (Moscow)

- **Filippov E.** (Ryazan). Cardiovascular diseases in the clinic are we already too late? The role of clinical observation.
- **Lukianov M.** (Moscow). Patients with CVD in clinical practice: general characteristics, treatment and outcomes according to medical registers.
- **Provatorov S.** (Moscow). How to escalate therapy in a clinic: research data and our capabilities.
- **Balanova Yu.** (Moscow). Screening of CVD and their risk factors in the population: what does the collected data give to the physician?

09:00–10:30

HALL №10 (B6-B8)

TRAINING WORKSHOP

«LIFESTYLE MODIFICATIONS IN PATIENTS WITH ARTERIAL HYPERTENSION. DEALING WITH THE DETAILS OF LIFESTYLE CHANGES»

Chairperson: Lopatin Yu. (Volgograd)

- **Nedogoda S.** (Volgograd). Physical activity.
- **Ratova L.** (Saint-Petersburg). Eat or not to eat, or what to eat.
- **Khaisheva L.** (Rostov-on-Don). Drink or not to drink, or what to drink.
- **Drobotya N.** (Rostov-on-Don). Stress and sleep.
- **Lopatin Yu.** (Volgograd). Digital health and wearables devices.

09:00–10:30

HALL №11 (F200)

SYMPOSIUM

«ISCHEMIC STROKES IN YOUNG ADULT IN THE PRACTICE OF A CARDIOLOGIST AND NEUROLOGIST»

Chairpersons: Nikiforov V. (Saint-Petersburg),
Goldobin V. (Saint-Petersburg)

- **Goldobin V.** (Saint-Petersburg). Ischemic strokes in young adult.
- **Nikiforov V.** (Saint-Petersburg). Diagnosis of intracardiac sources of embolism in the practice of a cardiologist.
- **Tregubov A.** (Saint-Petersburg). Atrial fibrillation in young people with ischemic stroke: actual diagnostic and treatment options.
- **Korneva V.** (Petrozavodsk). Lipid metabolism disorders as a cause of ischemic strokes in young people.

09:00–10:30

HALL №12 (A1-A3)

**RUSSIAN-UZBEK SYMPOSIUM
«ATRIAL FIBRILLATION: OPPORTUNITIES
AND PROSPECTS»**

Chairpersons: **Kurbanov R.** (Uzbekistan), **Popov S.** (Tomsk)

- **Batalov R.** (Tomsk). Atrial fibrillation from fundamental knowledge to clinical practice.
- **Kurbanov R.** (Uzbekistan). Prevention of thromboembolic complications in patients with atrial fibrillation.
- **Mikhailov E.** (Saint-Petersburg). Comorbidity and its correction in atrial fibrillation: effect on prognosis, drug and interventional treatment.
- **Zakirov N.** (Uzbekistan). Features of the spread and course of atrial fibrillation in Uzbekistan.
- **Fozilov H.** (Uzbekistan). Rhythm control in atrial fibrillation: the possibilities of high technology. The experience of the RSCSPMC.

09:00–10:30

HALL №13 (A4-A5)

**SCIENTIFIC SESSION
«STRUCTURAL AND ELECTROPHYSIOLOGICAL
MYOCARDIAL CHANGES IN CARDIAC RHYTHM
DISORDERS. NON-INVASIVE IMAGING TO ASSIST
THE ARRHYTHMOLOGIST»**

Chairpersons: **Golitsyn S.** (Moscow), **Kulikov A.** (Saint-Petersburg)

- **Stukalova O., Rimskaya E.** (Moscow). New technologies for simultaneous non-invasive visualization of structural and electrophysiological characteristics of the myocardium.
- **Novikov P., Aparina O., Maikov E.** (Moscow). Left atrial myocardial fibrosis as a factor in effective interventional treatment of atrial fibrillation.
- **Rud S.** (Saint-Petersburg). Noninvasive visualization of myocardial fibrosis in clinical practice.
- **Chmelevsky M.** (Saint-Petersburg). New technologies for non-invasive electroanatomic mapping of the myocardium in various intraventricular conduction disorders.

09:00–10:30

HALL №14 (A8–A9)

SCIENTIFIC SESSION «ARRHYTHMOLOGY, STIMULATION, RESYNCHRONIZATION»

Chairpersons: **Borovkova N.** (Nizhny Novgorod), **Batsigov H.** (Grozny)

- **Plinokosova L.A.** (Barnaul). The effect of hyperuricemia on cardiac remodeling in COPD patients.
- **Sitkova E., Usenkov S., Archakov E., Stepanov I., Batalov R., Afanasyev S.** (Tomsk). The importance of MRI with contrast in the diagnosis of myocarditis in atrial fibrillation of unknown origin: comparison with the results of endomyocardial biopsy.
- **Glumskov A., Durmanov S., Kozlov A., Makarova N., Ushakov R., Bazylev V.** (Penza). Non-paroxysmal atrial fibrillation as a leading factor in the progression of tricuspid regurgitation in patients with two endocardial right ventricular electrodes of a permanent pacemaker.
- **Afanasyev S., Kondratieva D., Muslimova E., Korepanov V., Andreev S., Akhmedov S.** (Tomsk). Correlation of cardiac echocardiography parameters in patients with chronic ischemic heart disease with the inotropic response of isolated fragments of their myocardium during stimulation of β 1- and β 2-adrenoreceptors.
- **Gizatulina T., Mamarina A., Belonogov D., Martianova L., Kolunin G., Khorkova N., Belokurova A., Petelina T.** (Tyumen). Circulating biomarkers as predictors of the effectiveness of catheter ablation in patients with non-valvular atrial fibrillation.
- **Ilov N., Palnikova O., Stoppel D.** (Astrakhan), **Boitsov S.** (Moscow), **Kulikova E., Terentyeva M., Klimchuk D., Abdulkadyrov A., Paskeev D., Romantsov E., Zorin D., Nechepurenko A.** (Astrakhan). The IDEAL scale is a new tool for selection for implantation of a cardioverter defibrillator for the primary prevention of sudden cardiac death.

09:00–10:30

ONLINE-HALL №1

SYMPOSIUM

«ROLE OF BIOMARKERS IN CARDIAC PRACTICE»

Chairperson: **Tarlovszkaya E.** (Nizhny Novgorod)

- **Motloch L.** (Austria). Biomarkers of sudden cardiac death.
- **Koziołova N.** (Perm). Diagnostic and prognostic biomarkers in CHF: a critical view of the problem.
- **Gareeva D., Zagidullin N.** (Ufa). Biomarkers of adverse cardiovascular events in COVID-19.
- **Murkamilov I.** (Kyrgyzstan). Serum biomarker — cystatin C: new horizons of cardiorenal syndrome.

09:00–10:30

ONLINE-HALL №2

SYMPOSIUM

«THE PICTURE OF ACUTE CORONARY SYNDROME 2024: LARGE SMEARS AND IMPORTANT DETAILS»

Chairpersons: **Kostenko V.** (Saint-Petersburg),
Skorodumova E. (Saint-Petersburg)

- **Skorodumova E.** (Saint-Petersburg). Reperfusion in acute coronary syndrome the specific weight and location of thrombolysis, percutaneous coronary intervention, thrombextraction and coronary artery bypass grafting.
- **Siverina A.** (Saint-Petersburg). Myocardial bridges of coronary arteries and ACS — accidental findings or responsible participants?
- **Serdukov D.** (Saint-Petersburg). Acute coronary syndrome in military realities.
- **Efremova E.** (Ulyanovsk). Acute kidney disease in patients after acute myocardial infarction.
- **Kokorin V.** (Moscow). Review and adaptation of the recommendations on acute heart failure of the European federation of internal medicine.

11:00–12:30

PLENARY HALL

PLENARY SESSION

«PATHOLOGY OF THE AORTA AND HEART VALVES. A TEAM APPROACH»

Simultaneous translation

Chairpersons: Golukhova E. (Moscow), Chernyavsky A. (Novosibirsk)

- **Bax J.** (Netherlands). Imaging to assess tricuspid regurgitation.
- **Petrosyan K., Golukhova E., Mironenko M., Slivneva I.** (Moscow) Transcatheter technologies: a step forward in the treatment of heart valve pathology.
- **Zamorano J.L.** (Spain). New insights into diagnosis and prognosis of TR. How to treat and how to follow.
- **Mironenko V., Golukhova E.** (Moscow). Traditions and innovations in the surgery of acquired heart defects.

11:00–12:30

HALL №1 (E7)

SATELLITE SYMPOSIUM

«DIAGNOSIS AND THERAPY OF IDIOPATHIC RECURRENT PERICARDITIS REVOLUTION OR EVOLUTION?»

(supported by «R-Pharm», CME points are not accrued)

Chairperson: Konradi O. (Saint-Petersburg)

- **Moiseeva O.** (Saint-Petersburg). The clinical problem of IRP. Unresolved issues.
- **Maslynsky A.** (Saint-Petersburg). The modern concept of the pathogenesis of IRP and the evolution of therapy.
- **Machikova V.** (Saint-Petersburg). The first Russian IL-1 blocker is Arcerix. From research to practice.

11:00–12:30

HALL №2 (E8-E9)

SATELLITE SYMPOSIUM

**«ANTIHYPERTENSIVE THERAPY WITHOUT HYPE.
POLYPILL IS A CONSCIOUS CHOICE OF THERAPY
FROM THE VERY BEGINNING»**

(supported by «Servier», CME points are not accrued)

Chairperson: Nedogoda S. (Volgograd)

- **Nedogoda S.** (Volgograd). Polypill is a conscious choice of therapy from the very beginning.
- **Ionin V., Rotar O.** (Saint-Petersburg). Cardio debates, clinical examples, controversial cases, search for solutions.

11:00–12:30

HALL №3 (D1)

SATELLITE SYMPOSIUM

**«BRIGHT COMBINATIONS IN THE MILKY WAY OF
HYPERTENSION THERAPY»**

(supported by «KRKA PHARMA», CME points are not accrued)

Chairpersons: Chazova I. (Moscow), **Boytsov S.** (Moscow)

- **Boytsov S.** (Moscow). Introduction
- **Chazova I.** (Moscow). Current trends in optimizing antihypertensive therapy into the future.
- **Mkrtumyan A.** (Moscow). Comorbid patient: the duet of hypertension and MS is in focus.
- **Ageev F.** (Moscow). Advantages of the drug Telinstar in the treatment of arterial hypertension in comorbid patients. Blood pressure control and pleiotropic effects.

11:00–12:30

HALL №4 (D2)

SATELLITE SYMPOSIUM

«HEALTHY MIACARDUM. WHAT DO YOU NEED TO KNOW ABOUT HAPPY LIFE?»

(supported by «Berlin-Chemie/A.Menarini», CME points are not accrued)

Chairpersons: Lopatin Yu. (Volgograd), Shevchenko A. (Moscow)

- **Villedalde S.** (Saint-Petersburg). Cardiovascular continuum risks factors control — from AH to CHF.
- **Shevchenko A.** (Moscow). Ischemic heart disease — live a life.
- **Lopatin Yu.** (Volgograd). How to improve the treatment and and prolong life to the patients with CHF.

11:00–12:30

HALL №5 (D3)

SATELLITE SYMPOSIUM

«CHRONIC HEART FAILURE IN ALL ITS DIVERSITY OF PHENOTYPES»

(supported by «AstraZeneca», CME points are not accrued)

Chairperson: Shlyakhto E. (Saint-Petersburg)

- **Galyavich A.** (Kazan). The art of diagnosis and differential diagnosis of HF.
- **Khasanov N.** (Kazan). Significance of the DELIVER study for routine medical practice.
- **Fomin I.** (Nizhny Novgorod). The art of HF management: what do clinical guidelines say?
- **Kobalava Zh.** (Moscow). CKD and HF: the tandem of comorbidity.
- **Zvartau N.** (Saint-Petersburg). Practical digital tools to improve the prognosis of patients with high cardiovascular risk.
- **Villevalde S.** (Saint-Petersburg). Patient with CKD and arterial hypertension: what to pay attention to?

11:00–12:30

HALL №6 (D4)

SATELLITE SYMPOSIUM

«THE CLUB OF EXPERTS. SEARCHING OPTIMAL APPROACH TO PAROXYSMAL ATRAL FIBRILLATION TREATMENT»

(supported by «TELERA-Pharma», CME points are not accrued)

Chairpersons: **Drapkina O.** (Moscow), **Lebedev D.** (Saint-Petersburg)

- **Tarasov A.** (Moscow), **Tatarsky R.** (Saint-Petersburg), **Chernova A.** (Krasnoyarsk), **Batalov R.** (Tomsk). Searching optimal approach to paroxysmal atral fibrillation treatment. Discussion.

11:00–12:30

HALL №7 (B1)

SATELLITE SYMPOSIUM

«SOLVING COMPLEX LIPIDOLOGY ISSUES: 2+3!»

(supported by «Egis», CME points are not accrued)

Chairpersons: **Arutyunov G.** (Moscow), **Ezhov M.** (Moscow),

- **Gurevich V.** (Saint-Petersburg). Dyslipidemia 2024: where are we?
- **Alieva A.** (Saint-Petersburg). Difficult Patients: who are they?
- **Akhmedzhanov N.** (Moscow). Regression of atherosclerosis is possible!
- **Arutyunov G.** (Moscow). We will protect the liver!
- **Ezhov M.** (Moscow). FRIENDSHIP wins!

11:00–12:30

HALL №8 (B2)

SATELLITE SYMPOSIUM

«HYPERSYMPATHETIC PATIENT, WHO IS HE?»

(supported by «Merck», CME points are not accrued)

Chairperson: Karpov Yu. (Moscow)

- **Gilyarevsky S.** (Moscow). RAAS and SNS are “connected by one chain”.
- **Koziołova N.** (Perm). Is it possible to consider the signs of hypersympathicotonia at the initial appointment? What does it threaten the patient?
- **Karpov Yu.** (Moscow). Are young patients with AH (+40) a special group?
- **Kashtalov V.** (Kemerovo). Treatment of a patient with AH and signs of hypersympathicotonia, what is in a doctor’s arsenal?

11:00–12:30

HALL №9 (B3-B5)

SYMPOSIUM

«VARIETY OF PHENO- AND GENOTYPIC MANIFESTATIONS OF DYSLIPIDEMIA»

Chairpersons: Kuznetsova T. (Petrozavodsk), **Zateyshchikov D.** (Moscow)

- **Konstsantinov V.** (Saint-Petersburg). Dyslipidemias and their role in atherogenesis, modern view.
- **Urazgildeeva S.** (Saint-Petersburg). Clinical masks of patients with dyslipidemia.
- **Nikulina S., Emelianchik V., Emelianchik E.** (Krasnoyarsk). Indications for performance and significance of genetic studies for dyslipidemia.
- **Korneva V.** (Petrozavodsk). Personalized management of patients with dyslipidemia.

11:00–12:30

HALL №10 (B6-B8)

**SYMPOSIUM
«PSYCHOCARDIOLOGY»**

Chairpersons: Kopylov F. (Moscow), **Volel B.** (Moscow)

- **Pogosova N.** (Moscow). Psychosocial factors determining prognosis in patients with cardiovascular diseases: latest data.
- **Samushia M.** (Moscow). Psychosomatic disorders in pulmonary hypertension: impact on treatment adherence.
- **Kopylov F.** (Moscow). Psychocardiology and evidence-based medicine.
- **Volel B.** (Moscow). Therapy of psychosomatic disorders in cardiological practice.

11:00–12:30

HALL №11 (F200)

**SYMPOSIUM
«EPIDEMIOLOGY 2024. ONLY FORWARD.
NO OTHER ALTERNATIVE»**

Chairpersons: Shalnova S. (Moscow), **Simonova G.** (Novosibirsk)

- **Balanova Yu., Shalnova S.** (Moscow). Why the Russian Federation is considered to be a country of very high cardiovascular risk.
- **Imaeva A., Svinin G., Kutsenko V.** (Moscow). SCORE2 for the Russian population. Is it all so clear?
- **Simonova G., Shcherbakova L., Malyutina S.** (Novosibirsk). Experience of establishing the Siberian SCORE risk meter. Why is it necessary for the Russian Federation to have its own SCORE2 scale?
- **Tsygankova D., Agienko A.** (Kemerovo). Lifestyle as a factor affecting cardiovascular risk of industrial region residents.

11:00–12:30

HALL №12 (A1-A3)

RUSSIAN-BELARUSIAN SYMPOSIUM «HEART FAILURE – NEW TECHNOLOGIES AND UNRESOLVED PROBLEMS»

Chairpersons: **Mitkovskaya N.** (Belarus), **Kosmacheva E.** (Krasnodar)

- **Chesnikova A.** (Rostov-on-Don). CHF in patients with dilated cardiomyopathy: features of management tactics.
- **Grigorenko E.** (Belarus). “Deadly duet”: CHF and liver cirrhosis.
- **Goncharik D.** (Belarus). CPT therapy in patients with CHF: is there an alternative?
- **Mikhailov E.N.** (Saint-Petersburg). Non-pharmacological neuromodulation in heart failure: hopes, reality, perspective.

11:00–12:30

HALL №13 (A4–A5)

SYMPOSIUM «REGISTERS OF CARDIOVASCULAR AND COMORBID DISEASES: SIGNIFICANCE IN PRACTICE»

Chairpersons: **Yakushin S.** (Ryazan)

- **Tarlovskaya E.** (Nizhny Novgorod). KAMMA registry (clinical registry for studying the current population of therapeutic patients with identified multifocal atherosclerosis in the territory of the Russian Federation and Eurasian countries).
- **Shakhnovich R.** (Moscow). Features of reperfusion strategy in patients with myocardial infarction in the Russian Federation according to the “REGION-IM” registry.
- **Pereverzeva K., Pravkina E., Kozminsky A.** (Ryazan). Registry of cardiovascular diseases (RECVASA): results of a 10-year observation.
- **Lukyanov M.** (Moscow). Cardiovascular multimorbidity in clinical practice: key characteristics, treatment, and outcomes medical registries data.
- **Chesnikova A.** (Rostov-on-Don). Registry of real clinical practice detectability of albuminuria among patients with previously undiagnosed chronic kidney disease AURA.
- **Yakushin S.** (Ryazan). Results of the hospital registry of myocardial infarction in patients 75 years and older: significance for practical healthcare.

11:00–12:30

HALL №14 (A8-A9)

SCIENTIFIC SESSION

«CAD, LIPIDS AND ATHEROSCLEROSIS»

Chairpersons: Abdullaev A. (Makhachkala), **Shaposhnik I.** (Chelyabinsk)

- **Maltseva A., Kosinova A., Grinstein Yu., Shavrina E., Savchenko A., Levagina P., Subbotina T.** (Krasnoyarsk). Association of intercellular interaction with the level of the P-selectin gene in the development of resistance to acetylsalicylic acid in patients with coronary artery disease.
- **Gubina A., Chomakhidze P., Andreev D.** (Moscow). Diastolic stress test is the key to early diagnosis of coronary insufficiency.
- **Arutyunov G.** (Moscow), **Tarlovskaya E.** (Nizhny Novgorod), **Arutyunov A.** (Armenia), **Batluk T.** (Moscow), **Bashkinov R.** (Saint-Petersburg), **Fedorova Y.** (Moscow), **Melnikov E.** (Saint-Petersburg), **Trubnikova M.** (Sochi), **Gordeychuk E.** (Moscow). Features of the population of patients with multifocal atherosclerosis and obstructive coronary artery disease according to the international KAMMA registry.
- **Nalesnik E., Repin A.** (Tomsk). Acute periprocedural myocardial injury during planned percutaneous coronary interventions.
- **Bokovikov I., Protasov K.** (Irkutsk). Prognostic value of cellular indices of systemic inflammation in assessing the risk of hospital mortality in patients with myocardial infarction in combination with type 2 diabetes mellitus.
- **Zakovryashina I., Khaisheva L.** (Rostov-on-Don). Epicardial adipose tissue as a biomarker of cardiovascular death in patients who have undergone acute myocardial infarction and percutaneous coronary intervention.

11:00–12:30

ONLINE-HALL №1

SYMPOSIUM

«PERSONALIZED SELECTION OF PHYSICAL REHABILITATION REGIMEN FOR PATIENTS WITH CHRONIC HEART FAILURE. THE RESULTS OF BASIC RESEARCH AND CLINICAL PRACTICE»

Chairpersons: **Bubnova M.** (Moscow), **Poltavskaya M.** (Moscow)

- **Lelyavina T.** (Saint-Petersburg). Personalized calculation of the intensity of aerobic training for patients with chronic heart failure a scientific approach.
- **Begrambekova Yu.** (Moscow). Respiratory training in patients with CHF at home. The first results of a randomized clinical trial of AEROFIT-SPIRO.
- **Bubnova M.** (Moscow). From physiology and genetics to clinical aspects of cardiac rehabilitation.
- **Kolesnikova E.** (Moscow). Respiratory training in patients with CHF from general to personal.
- **Poltavskaya M.** (Moscow). The place of electromyostimulation in modern cardiac rehabilitation.

11:00–12:30

ONLINE-HALL №2

«SESSION OF YOUNG SCIENTISTS' WORKS. PART 1»

Chairpersons: **Belyalov F.** (Irkutsk), **Ivanov K.** (Yakutsk), **Evseyeva M.** (Stavropol)

- **Arablinsky N.** (Moscow). The results of the use of renal denervation in patients with resistant hypertension, diabetes mellitus and coronary heart disease after revascularization.
- **Manukyan M.** (Tomsk). Assessment of the activity of the sympathetic nervous system in refractory and uncontrolled resistant hypertension.
- **Hunkhinova S.** (Tomsk). Long-term efficacy of renal denervation in patients with resistant hypertension: results of 5 years of follow-up.
- **Georgieva K.** (Cheboksary). Analysis of the carriage of allelic variants of CYP2C19 and ABC1, and their association with the effectiveness of clopidogrel in individuals of the Chuvash population.

12:40–13:20

PLENARY HALL

PLENARY LECTURE

Simultaneous translation

Moderator: Khaisheva L. (Rostov-on-Don)

- **Ragi H. (Egypt).** Global trends in CHF therapy: A review of clinical recommendations.

12:40–13:20

ONLINE-HALL №1

LECTURE

- **Yakovlev A.** (Saint-Petersburg). Refractory angina pectoris: the search for modern solutions.

13:30–15:00

PLENARY HALL

PLENARY SESSION

«CLINICAL GUIDELINES. PART 1»

Simultaneous translation

Chairpersons: Irtyuga O. (Saint-Petersburg), **Barbarash O.** (Kemerovo)

- **Chazova I.** (Moscow). Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension.
- **Yavelov I.** (Moscow). Non-ST-elevation acute coronary syndrome.
- **Shakhnovich R.** (Moscow). Acute ST-elevation myocardial infarction.
- **Mikhailov E.** (Saint-Petersburg). Ventricular arrhythmias and sudden cardiac death.

13:30–15:00

HALL №1 (E7)

SATELLITE SYMPOSIUM

«10 YEARS OF THE PARADIGM-HF STUDY:
A ROAD OF LIFE CREATED FOR PATIENTS WITH CHF»
(supported by «Novartis Pharma», CME points are not accrued)

Chairperson: **Tereshchenko S.** (Moscow)

- **Bader F.** (UAE). International experience in clinical approaches to managing patients with CHF.
- **Uskach T.** (Moscow). Victories and achievements in the treatment of CHF in Russia.
- **Zhirov I.** (Moscow). Either I'll find a way or I'll make one: the roads we choose in clinical situations with CHF.

13:30–15:00

HALL №2 (E8–E9)

SATELLITE SYMPOSIUM

«BATTLE FOR THE HEART OF THE COUNTRY:
RESULTS OF NEW REAL CLINICAL PRACTICE RESEARCH»
(supported by «Nizhpharm», CME points are not accrued)

Chairperson: **Boitsov S.** (Moscow)

- **Karpov Yu.** (Moscow). The dilemma of choosing of antihypertensive therapy: the first study of real practice in the Russian Federation.
- **Kobalava Zh.** (Moscow). Unraveling the secrets of antiplatelet drugs with ischemic heart disease: data from a new Russian study.

13:30–15:00

HALL №3 (D1)

SATELLITE SYMPOSIUM

«MODERN APPROACHES IN THE TREATMENT OF A POLYMORBID PATIENT: THE TIME OF THE FIRST!»

(supported by «KRKA PHARMA LLC», CME points are not accrued)

Chairperson: Drapkina O. (Moscow)

- **Drapkina O.** (Moscow). Introduction.
- **Kobalava Zh.** (Moscow). The problem of polypharmacy in comorbid patients: challenges and strategies for optimizing hypertension therapy.
- **Konradi A.** (Saint-Petersburg). Prospects for the treatment of hypertension in frail patients: a vector for reducing the progression of cognitive impairment.
- **Nedoshivin A.** (Saint-Petersburg). Breakthrough in medicine: simplifying the selection of therapy for comorbid patients with hypertension and CKD.
- **Matskeplishvili S.** (Moscow). New opportunities in the treatment of dyslipidemia. Simple and effective.

13:30–15:00

HALL №4 (D2)

SATELLITE SYMPOSIUM

«OPPORTUNITIES FOR INTRODUCING EARLY CARDIOVASCULAR RISK STRATIFICATION»

(supported by «Abbott Laboratories», CME points are not accrued)

Chairperson: Pogosova N. (Moscow)

- **Vavilova T.** (Saint-Petersburg). Opportunities of laboratory diagnostics in the characteristics of lipid exposure parameters.
- **Drozdova L.** (Moscow). Opportunities of an early risk factors of ASCVD.
- **Alieva A.** (Saint-Petersburg). Non-HDL cholesterol in assessing cardiovascular risk: current status, prospects, difficult issues.
- **Ezhov M.** (Moscow). Opportunities of correcting hypertriglyceridemia in the prevention of cardiovascular complications.

13:30–15:00

HALL №5 (D3)

SYMPOSIUM

«NEW INSIGHTS INTO PERICARDITIS: MECHANISMS OF INJURY AND THERAPEUTIC TARGETS»

Chairpersons: Kosmachova E. (Krasnodar), Baranova E. (Saint-Petersburg)

- **Kruchinova S., Namitokov A.** (Krasnodar). Constrictive pericarditis: challenges of modern cardiology and strategies to overcome.
- **Ionin V.** (Saint-Petersburg). Recurrent pericarditis: what should a cardiologist know and can do?
- **Kozik V.** (Novosibirsk). Pericarditis after acute coronary syndrome: exception or rule?
- **Shvartz V.** (Moscow). Surgical treatment of pericarditis.

13:30–15:00

HALL №6 (D4)

SATELLITE SYMPOSIUM

«TARGET ORGANS: HOW TO TREAT AND HOW TO PROTECT? NEW HORIZONS»

(supported by «Akrikhin», CME points are not accrued)

Chairperson: Gurevich V. (Saint-Petersburg)

- **Gurevich V.** (Saint-Petersburg). New horizons of basic therapy of arterial hypertension.
- **Filippov A.** (Saint-Petersburg). Ideal protection of a patient with CHF to improve the prognosis.
- **Sergienko I.** (Moscow). Dyslipidemia. Where are we now?
- **Sitnikova M.** (Saint-Petersburg). Loop diuretics. To be or not to be? And what should I do?

13:30–15:00

HALL №7 (B1)

SATELLITE SYMPOSIUM

«HYPERURICEMIA: ACCENTS IN CARDIO-METABOLIC CONTROL»

(supported by «Egis», CME points are not accrued)

Chairpersons: Arutyunov G. (Moscow), **Nedogoda S.** (Volgograd),

- **Nedogoda S.** (Volgograd). Hyperuricemia and associated risks how to improve the prognosis.
- **Arutyunov G.** (Moscow). Current therapeutic algorithms for uric acid correction.
- **Tkacheva O.** (Moscow). Hyperuricemia: CV risk management strategy.
- **Meshkov A.** (Moscow). Cardiovascular safety of therapy in patients with gout.

13:30–15:00

HALL №8 (B2)

SATELLITE SYMPOSIUM

«IRON DEFICIENCY IN THE CARDIOLOGY PRACTICE IS NOT ABOUT ONLY HEART FAILURE»

(supported by «Vifor», CME points are not accrued)

Chairperson: Khasanov N. (Kazan)

- **Koziolova N.** (Perm). A patient with heart failure and iron deficiency is seeing a cardiologist.
- **Duplyakov D.** (Samara). A cardiologist's point of view on preoperative anemia in cardiac surgery patients.
- **Khasanov N.** (Kazan). Ferric carboxymaltose use in patients with myocardial infarction: interim results of the OPERA-MI trial.

13:30–15:00

HALL №9 (B3-B5)

MEETING

13:30–15:00

HALL №10 (B6–B8)

SYMPOSIUM

«PRACTICAL ASPECTS OF MANAGING PATIENTS WITH CARDIAC RESYNCHRONIZATION THERAPY»

Chairpersons: **Lebedeva V.** (Saint-Petersburg), **Neminuschiy N.** (Moscow)

- **Lebedev D.** (Kemerovo). Is there a place for cardiac resynchronization therapy without defibrillation?
- **Rimskaya E.** (Moscow). Effect of cardiac resynchronization therapy: criteria and methods of assessment.
- **Lyubimtseva T.** (Saint-Petersburg). Features of programming CPT devices taking into account automated algorithms.
- **Trofimova T.** (Moscow). Principles of management of patients with CRT in pediatric practice.
- **Kolunin G.** (Tomsk). When is cardiac resynchronization therapy not needed?

13:30–15:00

HALL №11 (F200)

SCIENTIFIC SESSION

«CLINICAL AND MORPHOLOGICAL PARALLELS OF THE COURSE OF SARCOIDOSIS OF THE RESPIRATORY ORGANS AND EXTRAPULMONARY LOCALIZATION IN THE PRACTICE OF A CARDIOLOGIST»

Chairpersons: **Karpov R.** (Tomsk), **PoPONINA T.** (Tomsk),

- **Denisova O., Kalacheva T., Chernyavskaya G.** (Tomsk). Pulmonary sarcoidosis: diagnostic and treatment possibilities in real clinical practice.
- **Petrova M.** (Krasnoyarsk). Clinical manifestations of extrapulmonary sarcoidosis: an interdisciplinary approach.
- **Trisvetova E.** (Belarus). Sarcoidosis of the heart: a modern view of the problem.
- **PoPONINA T., Ryabov V.** (Tomsk). Cardiac sarcoidosis: difficulties and possibilities of differential diagnosis for acute coronary syndrome with analysis of a clinical case.
- **Reznik I., Melyah S., Fedorova O.** (Yekaterinburg). Differential diagnosis of hypertrophic cardiomyopathy and cardiac sarcoidosis with analysis of a clinical case.

13:30–15:00

HALL №12 (A1–A3)

SYMPOSIUM

«MODERN TECHNOLOGIES FOR REMOTE MONITORING OF HEALTH INDICATORS IN PATIENTS WITH CARDIOVASCULAR DISEASES»

Chairpersons: Kontsevaya A. (Moscow), Kim Z. (Kazan)

- **Kim Z.** (Kazan). Information technologies in cardiology. The experience of the Republic of Tatarstan.
- **Kulikova M.** (Moscow). Remote control of behavioral risk factors: from theory to practice.
- **Korsunsky D.** (Moscow). Unresolved issues of a new technique for remote monitoring of blood pressure. The experience of large-scale technology implementation.
- **Kshnyakin P.** (Samara). Key aspects of the organizational model of remote monitoring in practical healthcare.
- **Matyushkina E., Petrichenko D.** (Tyumen). Experience of organizing a remote consultation center on the basis of the State Medical Institution «City Polyclinic 8».

13:30–15:00

HALL №13 (A4–A5)

«CARDIOCAP»

Moderators: Kruchinova S. (Krasnodar), Zaitsev V. (Saint-Petersburg), Magamadov I. (Saint-Petersburg)

Leading experts:

- **Kashtalap V.** (Kemerovo)
- **Chulkov V.** (Veliky Novgorod)
- **Dzhioeva O.** (Moscow)
- **Zagidullin N.** (Ufa)
- **Efremova E.** (Ulyanovsk)
- **Solovyova A.** (Saint-Petersburg)
- **Rodionov A.** (Moscow)
- **Derevyanchenko M.** (Volgograd)
- **Ilov N.** (Astrakhan)

13:30–15:00

HALL №14 (A8-A9)

SCIENTIFIC SESSION

«ARTERIAL HYPERTENSION, METABOLIC SYNDROME, DIABETES»

Chairpersons: **Gapon L.** (Tyumen), **Kulibaba E.** (Vladimir)

- **Falkovskaya A., Pekarsky S., Zyubanova I., Lichikaki V., Manukyan M., Solonskaya E., Popova A., Hunkhinova S., Skomkina I., Soltanakhmetova A., Gusakova A., Rudenko V., Mordovin V.** (Tomsk). Antihypertensive and nephroprotective effects of renal denervation in patients with resistant hypertension and type 2 diabetes mellitus.
- **Yakhontov D., Beksheneva E., Ostanina Y.** (Novosibirsk). Arterial hypertension in the postCOVID period: clinical features, cognitive status, biological age of patients.
- **Bezdenezhnykh N., Sumin A., Kuzmina A., Belik E., Noskov M., Barbarash O.** (Kemerovo). Diagnosis of carbohydrate metabolism disorders before coronary bypass surgery using an electronic expert program.
- **Gurevich A., Yemelyanov I., Ionov M., Rotar O., Boyarinova M., Moguchaya E., Kolesova E., Chernyavsky M., Konradi A.** (Saint-Petersburg). Dynamics of central and peripheral blood pressure in active orthostasis in hemodynamically significant carotid artery atherosclerosis in patients with arterial hypertension.
- **Safronova T., Volkov D., Mukhanova S., Podzolkov V.** (Moscow). Transforming growth factor- β 1 and CAVI and haStart indices in patients with arterial hypertension.
- **Klimova A., Ambatiello L., Smolyakova E., Zykov K., Chazova I.** (Moscow). Frequency of undiagnosed cases of chronic obstructive pulmonary disease and bronchial asthma in patients admitted to a specialized cardiology hospital.

13:30–15:00

ONLINE-HALL №1

SYMPOSIUM

«CURRENT ISSUES OF PALLIATIVE CARE IN CARDIOLOGY»

Chairpersons: **Lelyavina T.** (Saint-Petersburg), **Moskalev E.** (Saint-Petersburg)

- **Lelyavina T.** (Saint-Petersburg). Palliative care for patients with diseases of the cardiovascular system.
- **Moskalev E.** (Saint-Petersburg). Organization of palliative care in St. Petersburg. Topical aspects for the treatment of chronic pain syndrome.
- **Rashid M.** (Moscow). Palliative care for patients with chronic heart failure at different stages of patient management.
- **Larionova A.** (Saint-Petersburg). An algorithm for detecting unjustified polypragmasia in patients with CHF in need of palliative care. On the example of a clinical case.
- **Trukshina M.** (Saint-Petersburg). Indications for disabling the implanted cardioverter defibrillator in patients in the palliative stage.

13:30–15:00

ONLINE-HALL №2

«SESSION OF YOUNG SCIENTISTS' WORKS. PART 2»

Chairpersons: **Mikhin V.** (Kursk), **Salpagarova F.** (Cherkessk), **Ushakov A.** (Simferopol)

- **Kuzmichev K.** (Nizhny Novgorod). Clinical and genetic predictors of left ventricular remodeling in patients with ST-elevation myocardial infarction.
- **Kovalskaya A.** (Samara). Biomarkers of inflammation and matrix remodeling in patients with acute coronary syndrome and vulnerable atherosclerotic plaque.
- **Talibova S.** (Moscow). Levels of «new» biomarkers of systemic inflammation associated with atherosclerosis.
- **Portyannikova O.** (Chita). Some aspects of predicting coronary atherosclerosis in primary osteoarthritis.

15:30–17:00

PLENARY HALL

PLENARY SESSION

«CARDIOLOGY NEWS 2024. PART 2. ARTERIAL HYPERTENSION»

Simultaneous translation

Chairpersons: Chumakova G. (Barnaul), **Gapon L.** (Tyumen)

- **Kobalava Zh.** (Moscow). Hypertensive crises 2024 – resolved and unresolved issues.
- **Parati G.** (Italy). Nocturnal blood pressure monitoring: methodological aspects and clinical relevance.
- **Konradi A.** (Saint-Petersburg). Arterial hypertension 2024. Fundamental aspects.
- **Mirrakhimov E.** (Kyrgyzstan). The problem of diagnosis and control of arterial hypertension in Kyrgyzstan.

15:30–17:00

HALL №1 (E7)

SYMPOSIUM

«PLAQUE VS ISCHEMIA – WHAT IS RELEVANT TODAY?»

Chairpersons: Duplyakov D. (Samara), **Sumin I.** (Kemerovo)

- **Sumin A.** (Kemerovo). Diagnosis of patients with chronic coronary syndrome – is there an optimal algorithm?
- **Kuznetsova K., Shatskaia P.** (Samara). Coronary calcium – what we know about it?
- **Duplyakov D.** (Samara). Vulnerable plaque – real or fake?
- **Shcheglova A., Starovoitova A., Gorbunova E.** (Kemerovo). The state of diagnosis of obstructive ischemic heart disease in real clinical practice.
- **Bershtein L., Zbyshevskaya E., Gumerova V.** (Saint-Petersburg). From microvascular dysfunction to ISCHEMIA-EXTEND results: a paradigm shift in the diagnosis and treatment strategy of coronary artery disease.

15:30–17:00

HALL №2 (E8–E9)

SATELLITE SYMPOSIUM

**«CARDIORENAL METABOLIC SYNDROME —
BIRECTIONAL CONNECTION. FROM UNDERSTANDING —
TO PERSPECTIVES»**

(supported by «Berlin-Chemie/A.Menarini», CME points are not accrued)

Chairperson: Karpov Yu. (Moscow)

- **Karpov Yu.** (Moscow). Cardio renal metabolic syndrome: time for evidence.
- **Tarlovskaya E.** (Nizhny Novgorod). Cardiovascular disease in patients with DM2. Complex relationship.
- **Mkrtumyan A.** (Moscow). Metabolic domino. The role of early interference.

15:30–17:00

HALL №3 (D1)

SYMPOSIUM

**«PREGNANT WOMEN WITH CARDIOVASCULAR
DISEASES: HOW TO REDUCE THE RISK OF POSSIBLE
COMPLICATIONS»**

Chairpersons: Irtyuga O. (Saint-Petersburg), **Stryuk R.** (Moscow)

- **Stryuk R.** (Moscow). Pregnancy in women with Marfan syndrome: risks and their prevention.
- **Sefieva G., Chynybekova A., Irtyuga O.** (Saint-Petersburg). Strategy of anticoagulant therapy in pregnant patients with prosthetic heart valves.
- **Chesnikova A.** (Rostov-on-Don). Peripartur cardiomyopathy. Features of management in the prenatal and postpartum period.
- **Bergardt E., Treshkur T.** (Saint-Petersburg). Ventricular arrhythmias. To treat or not to treat during pregnancy.

15:30–17:00

HALL №4 (D2)

SATELLITE SYMPOSIUM

«SYNERGY OF INNOVATION AND TRADITION AS A NEW STANDARD OF LIPID-LOWERING THERAPY»

(supported by «Novartis Pharma», CME points are not accrued)

Chairperson: Shlyakhto E. (Saint-Petersburg)

- **Alieva A.** (Saint-Petersburg). Translational cycle in lipidology today: from innovation to implementation lowering therapy.
- **Nedogoda S.** (Volgograd). If statins are not enough, then what stops us from intensifying therapy? Key aspects of drug provision.
- **Kobalava Zh.** (Moscow). Inclisiran: why should innovation become part of routine lipid-lowering therapy today?

15:30–17:00

HALL №5 (D3)

SATELLITE SYMPOSIUM

«ANGINA IS UNDER CONTROL»

(supported by «Servier», CME points are not accrued)

Chairperson: Nedoshivin A. (Saint-Petersburg)

- **Nedoshivin A.** (Saint-Petersburg). Hypertension and CAD: to control the main risk factors.
- **Perepech N.** (Saint-Petersburg). Stable angina: how to prevent myocardial hypoxia.
- **Barbarash O.** (Kemerovo). Objective evidence for anti-ischemic therapy in patients with stable angina. Results of the study “METHOD.

15:30–17:00

HALL №6 (D4)

**JOINT SYMPOSIUM OF THE NATIONAL SOCIETY
OF PREVENTIVE CARDIOLOGY AND THE SOCIETY
OF HEART FAILURE SPECIALISTS
«CARDIAC REHABILITATION IN CHRONIC HEART FAILURE:
INDICATED OR CONTRAINDICATED?»**

Chairpersons: Pogosova N. (Moscow), Belenkov Yu. (Moscow)

- **Belenkov Yu.** (Moscow). The state of problems and key principals of rehabilitation for patients with heart failure
- **Ganaev K.** (Moscow). Features of introducing patients with severe heart failure with implanted left ventricular assist devise LVAD.
- **Barinova I.** (Moscow), **Terteryan T.**, **Ausheva A.** (Moscow). Cardiac rehabilitation algorithms in patients with implanted left ventricular assist devise LVAD.

15:30–17:00

HALL №7 (B1)

**SATELLITE SYMPOSIUM
«PULMONARY ARTERIAL HYPERTENSION:
ON THE WAY TO ACHIEVING STABLE DISEASE CONTROL»
(supported by «Johnson & Johnson, LLC» CME points are not accrued)**

Chairperson: Chazova I. (Moscow)

- **Chazova I.** (Moscow). A modern view of the PAH problem: data from international and Russian registers.
- **Avdeev S.** (Moscow). Risk assessment of annual mortality in PAH: the possibilities of non-invasive assessment methods under dynamic observation.
- **Martynyuk T.** (Moscow). Algorithms for managing patients with PAH: ways to optimize specific therapy.
- **Moiseeva O.** (Saint-Petersburg). Comorbid states in PAH: a new look at the problem and solutions.
- **Shmalts A.** (Moscow). Prostacyclin target: the role and place of prostacyclin pathway drugs in early combined treatment regimens for PAH.

15:30–17:00

HALL №8 (B2)

SATELLITE SYMPOSIUM

«THROMBOLYSIS IN PATIENTS WITH STEMI IN URBAN AGGLOMERATIONS: DO WE TAKE EVERYTHING INTO ACCOUNT IN THE RUSSIAN GUIDELINES?»

(supported by «SupraGen», CME points are not accrued)

Symposium is going on without broadcasting

Chairpersons: **Averkov O.** (Moscow), **Tereshchenko S.** (Moscow), **Zateyschikov D.** (Moscow)

- **Lebedeva A.** (Moscow). Prehospital thrombolysis in patients with STEMI in the first hours from the symptom's onset in conditions of rapid availability of a PCI center: counterarguments.
- **Rabinovich R.** (Moscow). Prehospital thrombolysis in patients with STEMI in the first hours from the symptom's onset: arguments for.
- **Shakhnovich R.** (Moscow). New evidence in thrombolytic therapy for acute myocardial infarction 2024.

15:30–17:00

HALL №9 (B3–B5)

SYMPOSIUM

«MULTIMODAL IMAGING OF VALVULAR REGURGITATION»

Chairpersons: **Bobrov A.** (Saint-Petersburg), **Alyokhin M.** (Moscow)

- **Alyokhin M.** (Moscow). Transthoracic echocardiography — the main way to detect regurgitation and assess its severity.
- **Karev E.** (Saint-Petersburg). The place of transesophageal echocardiography in the algorithm for assessing valvular insufficiency.
- **Bobrov A.** (Saint-Petersburg). The role of stress echocardiography in determining the valvular insufficiency severity and indications for surgical treatment.
- **Rud S.** (Saint-Petersburg). Methodological approaches to the assessment of regurgitation by MRI in heart valve insufficiency.

15:30–17:00

HALL №10 (B6–B8)

SATELLITE SYMPOSIUM

«WHEN DO YOU NEED TO GO BEYOND THE GUIDELINES TO SAVE A PATIENT?»

(Sponsored by «Implanta», CME points are not accrued)

Consecutive translation

Chairperson: Matskeplishvili S. (Moscow)

- **Vered Z.** (Israel). Revolutionary approach to management of heart failure.
- **Matskeplishvili S.** (Moscow). When do you need to go beyond the guidelines to save a patient?
- **Semitko S.** (Moscow). Optimization of heart failure therapy based on the results of non-invasive hemodynamic parameters determination based on impedanceometry.
- **Musikhina N.** (Tyumen). Hemodynamic profile of patients with ischemic heart disease in Far North conditions.

15:30–17:00

HALL №11 (F200)

DEBATE

«PREVENTIVE DEBATES»

Chairpersons: Shalnova S. (Moscow), **Boytsov S.** (Moscow)

- **Yakushin S.** (Ryazan). Is it possible to defeat arterial hypertension? Yes.
- **Kashtalap V.** (Kemerovo). Is it possible to defeat arterial hypertension? If not, what should we do?
- **Orlova Ya.** (Moscow). Obesity and diabetes are always together. Yes.
- **Koziolova N.** (Perm). Obesity and diabetes are always together No.

15:30–17:00

HALL №12 (A1-A3)

SYMPOSIUM

«HOT TOPICS OF PHARMACOTHERAPY OF CARDIOVASCULAR DISEASES IN OLDER ADULTS»

Chairperson: **Tkacheva O.** (Moscow)

- **Kotovskaya Yu.** (Moscow). Choice and deprescribing of antihypertensive drugs.
- **Zyryanov S.** (Moscow). Polypharmacy: how to manage it?
- **Villevalde S.** (Saint-Petersburg). Pharmacotherapy of heart failure in older and senile patients.
- **Khripoun A.** (Rostov-on-Don). Antithrombotic therapy in older adults.

15:30–17:00

HALL №13 (A4–A5)

«BATTLE OF THE SCHOLARS 2024. FINALE»

Moderators: **Kruchinova S.** (Krasnodar), **Zaitsev V.** (Saint-Petersburg), **Magamadov I.** (Saint-Petersburg)

Jury: **Kosmacheva E.** (Krasnodar), **Kontsevaya A.** (Moscow), **Zagidullin N.** (Ufa), **Schwartz V.** (Moscow), **Chukov V.** (Veliky Novgorod)

Finalists:

- «**Rhythm Drivers**» (MMA, Saint-Petersburg). **Varavin N.** (captain), **Novikov I.**, **Ismailov D.**, **Puzhalov I.**, **Sandakov A.**
- «**Classified**» (NMRC Chazova, Moscow). **Smirnov S.** (captain), **Merkulova I.**, **Krymukova M.**, **Ergasheva U.**, **Egorkina O.**
- «**Hearts of Kuzbass**» (Research Institute of CICD, Kemerovo). **Center I.** (captain), **Swarovskaya P.K.**, **Blinova A.V.**, **Karpova E.I.**, **Kareeva A.I.**
- «**Commotio Cordis Almazz**» (NMRC Almazova, Saint-Petersburg). **Suslov N.** (captain), **Shabutdinova O.**, **Filatova A.**, **Khatlamadzhyan V.**, **Sharapov S.**
- «**CardioTomsc**» (TNRMC RAS, Tomsk). **Hunkhinova S.A.** (captain), **Nesova A.K.**, **Dasheeva A.S.**, **Suslov I.V.**, **Gorokhovskiy A.A.**

15:30–17:00

HALL №14 (A8–A9)

SCIENTIFIC SESSION

«INTERDISCIPLINARY PROBLEMS IN CARDIOLOGY»

Chairpersons: Khaisheva L. (Rostov-on-Don), **Ratova L.** (Saint-Petersburg)

- **Keburia O., Achkasov E., Bondarev S.** (Moscow). The influence of sports at a young age on the prevention of cardiovascular pathology in middle-aged men of a sedentary lifestyle.
- **Shurakova V., Kulikov A., Lopatina E., Polushin A., Tsynchenko A., Zalyalov Yu.** (Saint-Petersburg). Cardiotoxicity of cyclophosphamide per se (analysis of data on the effects of high-dose chemotherapy in autologous table cell transplantation).
- **Swarovskaya A., Ogurkova O., Vendee A., Cheburanova V.** (Tomsk). Independent predictors of adverse outcomes in patients with stable coronary artery disease who underwent elective percutaneous coronary interventions.
- **Statsenko M., Guzenko D.** (Volgograd). Low-intensity inflammation and its effect on the state of the microcirculatory bed in patients with arterial hypertension and obliterating atherosclerosis of the arteries of the lower extremities.
- **Protasov K., Barakhtenko O.** (Irkutsk). Predictors of the development of acute myocardial injury after surgical treatment of lung cancer.
- **Kropacheva E., Zemlyanskaya O., Krivosheeva E., Panchenko E.** (Moscow). Chronic anemia increases the risk of thromboembolic complications in patients with atrial fibrillation receiving oral anticoagulants (according to prospective follow-up within the REGATA-2 registry).

15:30–17:00

ONLINE-HALL №1

SYMPOSIUM

«REPORTS OF THE WINNERS OF THE III RUSSIAN COMPETITION FOR THE BEST INNOVATIVE RESEARCH IN THE FIELD OF CARDIOLOGY»

Chairpersons: **Arutunov G.** (Moscow), **Grigoreva N.** (Nizhny Novgorod), **Garganeeva N.P.** (Tomsk)

- **Polanskaia E.** (Perm). Atrial fibrillation and cardiorenal syndrome: clinical-pathogenetic relationships and prognostic determinants.
- **Aliabieva P.** (Krasnoyarsk). Clinical and genetic predictors of the phenotype of arterial hypertension and tension headache.
- **Loginova A.** (Nizhny Novgorod). Features of clinical status, laboratory indicators and echocardiography data in patients with aortocoronary bypass graft in a history who have suffered a new coronavirus infection.
- **Vereshchak D.** (Moscow). Ways to optimize drug therapy of circular decompensation in patients with CHF, suffering type 2 DM and CKD.

15:30–17:00

ONLINE-HALL №2

«SESSION OF YOUNG SCIENTISTS' WORKS. PART 3»

Chairpersons: **Bogatyreva M.** (Vladikavkaz), **Zhanataeva L.** (Nalchik), **Cherevaty G.** (Kaluga)

- **Kofeynikova O.** (Saint-Petersburg). Clinical and genetic characteristics of pediatric patients with arrhythmogenic cardiomyopathy.
- **Moskovskikh T.** (Tomsk). Search for predictors of early and long-term efficacy of radiofrequency ablation of atrial fibrillation in patients with paroxysmal and persistent forms of atrial fibrillation.
- **Pischulov K.** (Saint-Petersburg). Development of a model for stratification of the risk of venous thromboembolic complications at the inpatient stage in patients with glial tumors of the central nervous system.
- **Ulanova N.** (Nizhny Novgorod). Predictors of venous thromboembolic complications in patients with ischemic stroke.

09:00–10:30

PLENARY HALL

PLENARY SESSION «ARTIFICIAL INTELLIGENCE»

Simultaneous translation

Chairpersons: Sychev D. (Moscow), Vasyuk Yu. (Moscow)

- **Vardas P.** (Belgium). The dawn of Metaclinical Medicine, the non human physician as an unavoidable fate.
- **Kopylov F.** (Moscow). Artificial intelligence in cardiology – why don't we use it every day?
- **Mirzoev U.** (Azerbaijan). Remote management of patients with chronic cardiovascular diseases.
- **Sinitsyn V.** (Moscow). Artificial intelligence for CT and MRI of the heart and blood vessels: achieved and desired.

09:00–10:30

HALL №1 (E7)

CLINICAL CASE DISCUSSION WITH THE EXPERTS «OPTIMAL ANTITHROMBOTIC THERAPY IN A PATIENT WITH PE, THROMBOSIS OF OTHER LOCALIZATION AND A HIGH RISK OF BLEEDING: BETWEEN SCYLLA AND CHARYBDIS, ANALYSIS OF THE CLINICAL CASE»

Chairperson: Panchenko E. (Moscow)

- **Komarov A.** (Moscow). Presentation of a clinical case of a patient with acute PE and thrombosis of other localization, multifocal atherosclerosis suffered by HIM, chronic heart failure with a decrease in the ejection fraction and a high risk of bleeding.
- **Yavelov I.** (Moscow). Causes of pulmonary embolism.
- **Pevsner D.** (Moscow). Treatment of PE in the acute period.
- **Vavilova T.** (Saint-Petersburg). The reasons for the decrease and the need for correction of antithrombin.
- **Kashtalap V.** (Kemerovo). The expediency of taking antiplatelet agents?
- **Panchenko E.** (Moscow). Which anticoagulants should I choose for long-term treatment?

09:00–10:30

HALL №2 (E8–E9)

SYMPOSIUM

«THE MULTIFACETED RELATIONSHIP BETWEEN CARDIOVASCULAR DISEASE AND DISORDERS OF CARBOHYDRATE METABOLISM»

Chairperson: **Mamedov M.** (Moscow)

- **Kanorskiy S.** (Krasnodar). Updated European recommendations for the treatment of cardiovascular diseases in diabetes mellitus 2023: opinion of Russian experts
- **Druk I.** (Omsk). Prediabetes — in modern clinical guidelines
- **Bondarenko I.** (Moscow). Antiplatelet agents and anticoagulants in patients with diabetes mellitus: evidence base
- **Arabidze G.** (Moscow). Secondary hypertriglyceridemia in type 2 diabetes mellitus

09:00–10:30

HALL №3 (D1)

SYMPOSIUM

«MICROVASCULAR ANGINA: YESTERDAY, TODAY, TOMORROW»

Chairpersons: **Boldueva S.** (Saint-Petersburg), **Soboleva G.** (Moscow)

- **Leonova I., Boldueva S.** (Saint-Petersburg). Microvascular angina: phenotypes, diagnostic criteria.
- **Kopieva K., Grakova E.** (Tomsk). Microvascular angina as a result of a subclinical inflammatory process.
- **Kochanov I., Burak T.** (Saint-Petersburg). Microvascular angina with complete revascularization of the myocardium: no-flow, slow-flow syndrome and others.
- **Karpov Yu., Soboleva G., Gaman S., Egorkina O.** (Moscow). Drug treatment of microvascular angina.

09:00–10:30

HALL №4 (D2)

SYMPOSIUM

«NEW CLINICAL GUIDELINES OF CPR: ADULTS»

Chairpersons: **Kusovlev A.** (Moscow), **Yusupov E.** (Saint-Petersburg)

- **Kusovlev A., Boeva E.** (Moscow). Presentation of the draft clinical guidelines of CPR (adult patients).
- **Alekseeva Y.** (Saint-Petersburg). Protocol of cardiac arrest in pulmonary embolism.
- **Kornelyuk R.** (Moscow). Causes of sudden cardiac arrest: CPR in cath-lab.

09:00–10:30

HALL №5 (D3)

SYMPOSIUM

**«NEW AND UPDATED TRIALS IN CARDIOLOGY.
UNAMBIGUITY AND CONTROVERSIES OF THE RESULTS.
VALUE FOR GUIDELINES»**

Chairpersons: **Barbarash O.** (Kemerovo), **Yakhontov D.** (Novosibirsk),

- **Konradi A.** (Saint-Petersburg). Real clinical practice data as a new era of evidence-based medicine.
- **Sergienko I.** (Moscow). Controversies in lipid-lowering therapy.
- **Krivoshapova K., Barbarash O.** (Kemerovo). Frailty in cardiac surgery of coronary artery disease. Inconsistencies in clinical research data.
- **Shpagina L.** (Novosibirsk). Biological therapy in cardiology — new trends.
- **Rubanenko O., Duplyakov D.** (Samara). Implementing adaptive design in clinical trials in cardiology.

09:00–10:30

HALL №6 (D4)

SYMPOSIUM

«“BLIND ZONES” OF THE EUROPEAN CLINICAL GUIDELINES ON CARDIO-ONCOLOGY 2022: WHAT PROBLEMS WERE REVEALED?»

Chairpersons: **Ilgisonis I.** (Moscow), **Belenkov Yu.** (Moscow)

- **Poltavskaya M.** (Moscow). Coronary toxicity of antitumor therapy: is there a “one size fits all” approach?
- **Tarlovskaya E., Badin Yu., Mishachkin I.** (Nizhny Novgorod). Risk stratification and prevention of cardiotoxicity in combined treatment of patients with lung cancer.
- **Ilgisonis I.** (Moscow). Features and difficulties of cardio-oncological care in oncohematology: what to be prepared for?
- **Duondoua D.** (Moscow). 2022 ESC Guidelines on Cardio-oncology: bright and gray zones of perioperative management for oncological patients.

09:00–10:30

HALL №7 (B1)

DISCUSSION

«METABOLIC SYNDROMIA AND POLYPILL — ARE EFFECTIVE SOLUTION GLOBAL PROBLEM»

Chairpersons: **Arutunov G.** (Moscow), **Lopatin Yu.** (Volgograd), **Nedogoda S.** (Volgograd)

- **Arutunov G.** (Moscow). Role of polypills in the management of patients with cardio-reno-metabolic syndrome.
- **Ratova L.** (Saint-Petersburg). Patient with arterial hypertension.
- **Lopatin Yu.** (Volgograd). Patient with hyperlipidemia.
- **Nedogoda S.** (Volgograd). Patient with type 2 diabetes and NAFLD.

09:00–10:30

HALL №8 (B2)**«PRESENTATIONS BY WINNERS OF THE YOUNG SCIENTIST'S AWARD»****Chairperson of the jury: Shlyakhto E.** (Saint-Petersburg)**Jury: Abdullaev A.** (Makhachkala), **Borovkova N.** (Nizhny Novgorod), **Villevalde S.** (Saint-Petersburg), **Grinstein Yu.** (Krasnoyarsk), **Duplyakov D.** (Samara), **Zateishchikov D.** (Moscow), **Kontsevaya A.** (Moscow), **Kosmacheva E.** (Krasnodar), **Mikhailov E.** (Saint-Petersburg), **Nikulina S.** (Krasnoyarsk), **Chumakova G.** (Barnaul), **Khaisheva L.** (Rostov-on-Don)

- **Mustafina I.** Role of epicardial adipose tissue and microRNA in the pathogenesis of heart failure after coronary bypass surgery.
- **Filatova A.** (Moscow). Clinical, hemodynamic and biological predictors of an unfavorable prognosis of heart failure with preserved ejection fraction.
- **Tolstokorova Yu.** (Krasnoyarsk). The associative role of the single nucleotide polymorphism of the *rs1061657 TBX3* gene on the development of WPW syndrome.
- **Kopyeva K.** (Tomsk). Comprehensive characterization and prognostic role of coronary microvascular dysfunction in patients with non-obstructive coronary artery disease.
- **Dil S.** (Tomsk). Efficacy and safety of intracoronary epinephrine administration in the refractory no-reflow phenomenon in patients with acute myocardial infarction.
- **Fetisova S.** (Saint-Petersburg). Features of the clinical course, genetic aspects, as well as the outcomes of hypertrophic cardiomyopathy in children with onset before 1 year.

09:00–10:30

HALL №9 (B3-B5)

«DISCUSSION OF RSC GUIDELINES ON STANDARDIZATION OF ECHOCARDIOGRAPHIC EXAMINATION AND STANDARD PROTOCOL DESIGN»

- **Matskeplishvili S.** (Moscow), **Saidova M.** (Moscow), **Mironenko M.** (Moscow), **Pavlyukova E.** (Novosibirsk), **Boschenko A.** (Tomsk), **Yaroslavskaya E.** (Tyumen), **Skidan V.** (Khabarovsk), **Akhunova S.** (Kazan), **Kozlenok A.** (Saint-Petersburg), **Fedorova D.** (Saint-Petersburg)

09:00–10:30

HALL №10 (B6-B8)

CLINICAL CASE DISCUSSION «ISCHEMIC HEART DISEASE»

Chairpersons: **Tsareva V.** (Smolensk), **Chernova A.** (Krasnoyarsk)

- **Bagmanova Z., Rudenko V., Musin T., Zagidullin N., Valeeva L., Blagodarov S., Sakhapov L.** (Ufa). ECG changes in the form of a J-wave in a patient with a myocardial infarction.
- **Vilizhinskaya K., Bogopolskaya O., Gens A., Charchyan E., Frolova Y.** (Moscow). Cardiac surgical treatment of radiation -induced coronary artery disease and aortic valve stenosis 34 years after radiation therapy of Hodgkin's lymphoma.
- **Tyurina T., Bublikova A., Zaslavskaya E., Kovtun D., Polyakova E.** (Saint-Petersburg). A case of late detection of alkaptonuria in a patient with severe ischemic heart disease.
- **Leonova I., Zakharova O., Boldueva S.** (Saint-Petersburg), **Goryainov A.** (Baltiysk). Vasospastic angina in combination with microvascular angina in a young woman.

09:00–10:30

HALL №11 (F200)

**TRAINING WORKSHOP
«ECHOCARDIOGRAPHIC IMAGING AT THE FOREFRONT
OF DIAGNOSTICS IN CARDIOLOGY»**

Chairpersons: **Dzhioeva O.** (Moscow), **Nikiforov V.** (Saint-Petersburg)

- **Nikiforov V.** (Saint-Petersburg). Emergency echocardiography in modern cardiology.
- **Bogdanova A.** (Moscow). Practical aspects of primary echocardiographic examination of a patient with acute decompensation of heart failure.
- **Dzhioeva O.** (Moscow). Echocardiography in obese patients. Important accents.
- **Sklyarova V.** (Saint-Petersburg). Diagnosis of infectious endocarditis of primary altered heart valves.
- **Surzhikov P.** (Saint-Petersburg). Ultrasound assisted examination in the practice of a cardiologist.

09:00–10:30

HALL №12 (A1–A3)

**DEBATE
«CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY
OR INVASIVE CORONARY ANGIOGRAPHY:
NOT ALWAYS AN OBVIOUS CHOICE»**

Chairpersons: **Zavadovsky K.** (Tomsk), **Ternovoy S.** (Moscow)

- **Zavadovsky K., Maltseva A.** (Tomsk). Is coronary computed tomography angiography already an alternative to invasive examination?
- **Menkov I.** (Saint-Petersburg). Coronary computed tomography angiography — what we see beyond stenosis.
- **Ardeev V.** (Vsevolozhsk). Planimetric measurements and determination of the morphology of the lesion of the coronary bed according to the IVUS.
- **Pekarsky S., Baev A.** (Tomsk). Advantages of invasive coronary artery imaging by optical coherence tomography.
- **Paleev P.** (Moscow). Invasive or non-invasive coronary angiography: what should a cardiologist choose?

09:00–10:30

HALL №13 (A4-A5)

SYMPOSIUM

«CLINICAL LIPIDOLOGY – A LIFE-LONG JOURNEY. IN MEMORY OF THE PROFESSOR N.V. PEROVA»

Chairpersons: Bubnova M. (Moscow), Gurevich V. (Saint-Petersburg)

- **Denisenko A.** (Saint-Petersburg). Lipoproteins and atherosclerosis.
- **Bubnova M., Aronov D.** (Moscow). Postprandial hyperlipidemia and atherogenesis.
- **Gurevich V.** (Saint-Petersburg). The role of lipids in determining cardiovascular risk.
- **Simonova G.** (Novosibirsk). Unconventional lipid parameters in the prevention of cardiometabolic disorders and diabetes.
- **Starodubova A.** (Moscow). Modern food models in the prevention of hyperlipidemia and atherosclerosis.
- **Ezhov M.** (Moscow). The future of clinical lipidology.

09:00–10:30

HALL №14 (A8-A9)

SCIENTIFIC SESSION

«URGENT CARDIOLOGY»

Chairpersons: Oleynikov V. (Penza), Khripun A. (Rostov-on-Don)

- **Belyaeva E., Koloskov A., Kournikova E.** (Saint-Petersburg). Dynamics of the von Willebrand factor level in patients of different age groups with acute coronary syndrome during the first 5 days.
- **Ladeishchikova A., Sherstobitov V., Shilko Y.** (Yekaterinburg). Urgent endovascular embolization in patients with acute coronary pathology.
- **Fomenko A., Zaigraev I., Krotenko N., Em Y., Dadaev V.** (Moscow). Nucleosomes in patients with STEMI. Associations with clinical and laboratory, instrumental indicators and hospital complications.
- **Panteleev O., Kercheva M., Ryabov V.** (Tomsk). Paraclinical predictors of delirium development in patients with myocardial infarction.
- **Popova O., Malyuk D., Pisaryuk A., Kazakhmedov E., Merai I., Watsik-Gorodetskaya M., Kobalava Zh., Petrikov S.** (Moscow). Prevalence, risk factors and prognostic significance of respiratory failure syndrome in patients with acute heart failure admitted to the intensive care unit.

- **Chashchin M., Strelkova A., Gorshkov A., Drapkina O., Kositsyna I., Golubev A.** (Moscow). Factors associated with death in the long-term period in patients with myocardial infarction who had previously suffered COVID-19.

09:00–10:30

ONLINE-HALL №1

SYMPOSIUM

«PERIPHERAL ARTERY DISEASES: ROLE AND POSITION OF SURGEONS OF REFERENCE CENTERS»

Chairpersons: **Alekyan B.** (Moscow), **Kavteladze Z.** (Moscow)

- **Alekyan B.** (Moscow). Current state of endovascular surgery of peripheral arteries in the Russian Federation.
- **Kavteladze Z.** (Moscow). Endovascular surgery of lesions of the arteries of the lower extremities.
- **Chernyavskiy M.** (Saint-Petersburg). Keeping up with the times — modern treatment of Leriche syndrome.
- **Karpenko A.** (Novosibirsk). Comparative assessment of carotid endarterectomy and stenting of the carotid arteries in real practice.
- **Kolegaev A.** (Moscow). The common femoral artery as a key segment when choosing the tactics of hybrid reconstructions in patients with cardiovascular pathology.
- **Vanyurkin A.** (Saint-Petersburg). Live case from hybrid operating room in Almazov National Medical Research Centre “Revascularization of the aorto-iliac segment using CERAB technique”.

11:00–12:30

PLENARY HALL

PLENARY SESSION

«CARDIOLOGY NEWS 2024. PART 3»

Simultaneous translation

Chairpersons: **Pogosova N.V.** (Moscow), **Yakushin S.S.** (Ryazan).

- **Averkov O.** (Moscow). Myocardial Infarction — 2024.
- **Zhirov I.** (Moscow). Acute heart failure — 2024.
- **Lebedev D.** (Saint-Petersburg). Sudden death.
- **Yavelov I.** (Moscow). Pulmonary embolism — 2024.

11:00–12:30

HALL №1 (E7)

SYMPOSIUM

«REMOTE MONITORING OF PATIENTS WITH CARDIOVASCULAR DISEASES: REALITIES AND PROSPECTS»

Chairpersons: **Boytsov S.** (Moscow), **Belenkov Yu.** (Moscow)

- **Paleev F., Rogoza A., Korsunsky D., Prosvirnin A., Kontsevaya A., Drapkina O., Boytsov S.** (Moscow). The possibilities of remote monitoring of blood pressure and pulse rate in patients with hypertension.
- **Kozhevnikova M., Belenkov Yu.** (Moscow). Ways to increase adherence to remote monitoring.
- **Laskova A., Lopatin Yu.** (Volgograd). The ability to self-help as the basis of a mobile application for patients with stable coronary artery disease.

11:00–12:30

HALL №2 (E8–E9)

SATELLITE SYMPOSIUM

«CHRONIC HEART FAILURE AND PNEUMONIA: HOW TO BREAK THE VICIOUS CIRCLE?»

(supported by «Pfizer», CME points are not accrued)

Chairperson: **Drozdova L.** (Moscow)

- **Drozdova L.** (Moscow). Introduction.
- **Polyakov D.** (Nizhny Novgorod). Chronic heart failure and pneumonia: a deadly duo.
- **Polibin R.** (Moscow). Pneumococcus: what does a cardiologist need to know?
- **Antonov V.** (Chelyabinsk). 10-year horizon of effectiveness of vaccination against pneumococcal infection in patients with coronary heart disease and combined pathology.
- **Drozdova L.** (Moscow). Contribution of vaccination against pneumococcal infection to the preservation of the health of a comorbid patient.
- **Drozdova L.** (Moscow). Discussion.
- **Drozdova L.** (Moscow). Closing.

11:00–12:30

HALL №3 (D1)

**SATELLITE SYMPOSIUM
«THROMBOLYTIC THERAPY 2024»**

(supported by «SupraGen», CME points are not accrued)

Chairpersons: Barbarash O. (Kemerovo), **Tereshchenko S.** (Moscow)

- **Duplykov D.** (Samara). Thrombolytic therapy for pulmonary embolism. Review 2024.
- **Oleinikov V.** (Penza). Different aspects of revascularization through the prism of successful implementation of pharmaco-invasive strategies in the region.
- **Pevzner D.** (Moscow). Hospital thrombolysis for STEMI: does it have a place in a PCI center?
- **Yakovlev A.** (Saint-Petersburg). Complications of thrombolytic therapy, risks minimization issues.

11:00–12:30

HALL №4 (D2)

**SYMPOSIUM
«EMBOLOGENIC MYOCARDIAL INFARCTION:
CASUISTRY OR MYOCARDIAL INFARCTION
OF THE FUTURE?»**

Chairpersons: Boldueva S. (Saint-Petersburg), **Kosmacheva E.** (Krasnodar)

- **Boldueva S., Solovieva M.** (Saint-Petersburg). Embologenic myocardial infarction: prevalence, causes, diagnostic criteria.
- **Kruchinova S., Kosnacheva E.** (Krasnodar). Sepsis as an independent risk factor for the development of cardioembolic myocardial infarction.
- **Barbarash O., Pecherina T.**, (Kemerovo). Type 2 myocardial infarction secondary to systemic embolism. Clinical case.
- **Tereshenko A.** (Moscow). Patent foramen ovale as a cause of embologenic myocardial infarction. Clinical case.
- **Novitsky N.** (Kaluga). Main aspects of treatment of embologenic myocardial infarction.

11:00–12:30

HALL №5 (D3)

SYMPOSIUM

«HEART AND BLOOD VESSELS AT RISK: HOW TO HELP?»

Chairpersons: **Obrezan A.** (Saint-Petersburg), **Sergienko I.** (Moscow)

- **Sergienko I.** (Moscow). Smoking is one of the three major risk factors for atherosclerotic cardiovascular disease.
- **Obrezan A.** (Saint-Petersburg). The concept of irreducible risk of atherosclerosis-associated cardiovascular disease
- **Panov A.** (Saint-Petersburg). The smoking patient with coronary heart disease. Risk reduction strategies.
- **Sitnikova M.** (Saint-Petersburg). Simple and complex steps in reducing the risk of developing chronic heart failure.

11:00–12:30

HALL №6 (D4)

SYMPOSIUM

«SOLVING TASKS WITH 3XS: CARDIOVASCULAR RISKS, COMORBIDITY, POLYPHARMACY»

Chairpersons: **Kotovskaya Yu.** (Moscow)

- **Kotovskaya Yu.** (Moscow). Vascular ageing: is arterial hypertension inevitable?
- **Villevalde S.** (Saint-Petersburg). Is heart failure with preserved ejection fraction a geriatric syndrome?
- **Efremova E.** (Ulyanovsk). Kidney and age: where is the line between CKD and normal aging?
- **Kashtalap V.** (Kemerovo). Three ages of dyslipidemia: myth or reality?

11:00–12:30

HALL №7 (B1)

SYMPOSIUM

«WORKING MEETING OF RSC'S EXPERTS WORKING GROUPS ON THE DEVELOPMENT OF CLINICAL GUIDELINES»

Chairperson: Shlyakhto E. (Saint-Petersburg)

- **Nedogoda S.** (Volgograd). Report on the work of the committee and working groups on the preparation of clinical guidelines and their implementation in the real clinical practice.
- **Lopatin Yu.** (Volgograd). Experience in developing clinical guidelines for chronic heart failure: problems and possible solutions.
- **Duplyakov D.** (Samara). Experience in developing clinical guidelines for acute coronary syndrome: problems and possible solutions.
- **Irtyuga O.** (Saint-Petersburg). Plans for the development and updating of clinical guidelines developed by RSC experts.
- **Discussion of the group leaders.**

11:00–12:30

HALL №8 (B2)

SYMPOSIUM

«RESTRICTIVE CARDIOMYOPATHY: CLINICAL FEATURES, GENETIC SPECTRUM AND NEW POSSIBILITIES FOR VISUALIZING TECHNIQUES»

Chairpersons: Kostareva A. (Saint-Petersburg), **Sinitsyn V.** (Moscow)

- **Blagova O., Lutihina Yu., Zaklyazminskaya E.** (Moscow). Restrictive cardiomyopathy in middle and old patients: features of phenotype and nosological diagnosis.
- **Muravyev A.** (Saint-Petersburg). Genetic spectrum of restrictive cardiomyopathy in different age groups.
- **Klimenko E.** (Saint-Petersburg). Different molecular mechanisms of filaminopathies associated with distinct molecular phenotypes.
- **Myasnikov R., Kulikova O.** (Moscow). Restrictive phenotype in patients with left ventricular noncompaction cardiomyopathy: prognosis and features of the clinical picture.

- **Mershina E., Ryzhkova E.** (Moscow). Cardiac MRI in differential diagnosis of restrictive cardiomyopathy.
- **Sdvigova N.** (Moscow). Clinical and genetic features of restrictive cardiomyopathy in children.

11:00–12:30

HALL №9 (B3-B5)

SYMPOSIUM

«PROBLEMS OF PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR RISK IN THE ERA OF POSTCOVID»

Chairpersons: **Mikhin V.** (Kursk), **Borovkova N.** (Nizhny Novgorod)

- **Mikhin V.** (Kursk), **Gindler A.** (Lipetsk). Features of the course of acute coronary pathology and secondary prevention of arterial damage in the post-hospital period in persons who have had COVID-19.
- **Borovkova N.** (Nizhny Novgorod). What do we know now about damage to the vascular wall, features of the development of cardiovascular pathology with COVID-19 in 2024.
- **Akhmedzhanov N.** (Moscow). Correction of dyslipidemia in patients with high vascular risk who have had COVID 19. What the cardiologist should consider?
- **Osipova O.** (Belgorod). Secondary prevention of cardiovascular risk: our capabilities in real clinical practice.

11:00–12:30

HALL №10 (B6-B8)

CLINICAL CASE DISCUSSION

«NON-CORONARY HEART DISEASES»

Chairpersons: **Moiseeva O.** (Saint-Petersburg), **Lipatova T.** (Saratov)

- **Afanasyev A., Bogachev-Prokofiev A., Zalesov A., Kirilova V., Chernyavsky A.** (Novosibirsk). Transapical myoectomy in patients with hypertrophic cardiomyopathy.
- **Vedernikov A., Mezhonov E., Shirokov N., Balina V., Reitblat O., Teffenberg D., Shalaev S.** (Tyumen). A case of early diagnosis of ATTR-amyloidosis during bone scintigraphy for a non-cardiological reason.

- **Skomkina I., Mordovin V., Falkovskaya A., Stepanov I., Ryumshina N., Triss S., Polyakova M., Hunkhinova S., Popova A., Zyubanova I., Lichikaki V., Manukyan M., Solonskaya E.** (Tomsk). Clinical case of diagnosis of isolated sarcoidosis of the heart.
- **Ryabova A., Galenko V., Fedotov P., Sitnikova M.** (Saint-Petersburg). Implantation of a long-term mechanical circulatory support device (LVAD) as a “bridge” to heart transplantation in a patient with viral hepatitis C: a clinical case.

11:00–12:30

HALL №11 (F200)

SATELLITE SYMPOSIUM

«STATIN THERAPY OF TODAY. EXPERT DISCUSSION»

(supported by «Teva LLC», CME points are not accrued)

Chairpersons: Tkacheva O. (Moscow)

- **Alieva A.** (Saint-Petersburg). Approaches to assessing cardiovascular risk: current status and prospects.
- **Glezer M.** (Moscow). Unlocking the possibilities of familiar therapy. Individual approach to each patient.
- **Zyryanov S.** (Moscow). How to achieve the goals of dyslipidemia therapy at the lowest cost? Figuring it out in practice.

11:00–12:30

HALL №12 (A1–A3)

DEBATE

«NON-INVASIVE AND INVASIVE ASSESSMENT OF CORONARY ARTERY FUNCTION: COLLABORATION OR BATTLE OF THE INDUSTRIES?»

Chairpersons: Boshchenko A. (Tomsk), **Matchin Yu.** (Moscow)

- **Boschenko A., Zhuravleva O.** (Tomsk). Diagnosis of myocardial ischemia hemodynamically significant coronary stenoses. The clinician’s view.
- **Matchin Yu.** (Moscow). Assessment of intracoronary physiology is a new standard for the diagnosis of ischemia and control of PCI results
- **Alyokhin M.** (Moscow). Stress echocardiography as a way to assess the functional significance of stenosing lesions of the coronary arteries.

- **Mochula A., Zavadovsky K.** (Tomsk). Myocardial perfusion imaging — the method with the greatest evidence base: the role in the era of anatomical techniques.
- **Pershina E.** (Moscow). MRI perfusion in the detection of epicardial and microvascular ischemia: current state of the issue

11:00–12:30

HALL №13 (A4-A5)

SATELLITE SYMPOSIUM

«I CAME TO YOU WITH A BOUQUET: PREVIOUS GOALS AND NEW APPROACHES TO TREATING MULTIMORBID PATIENTS»

(supported by «Grindex», CME points are not accrued)

Chairpersons: Nedoshivin A. (Saint-Petersburg)

- **Statsenko M.** (Volgograd). New treatment options for multimorbid patients: results of the INDIKOR study.
- **Mkrtumyan A.** (Moscow). The bouquet-candy period: or how to achieve the treatment goal for patients with type 2 diabetes and chronic heart failure. Clinical case from personal practice.
- **Ostroumova O.** (Moscow). Multimorbid patients: challenge or routine in a doctor's practice?

11:00–12:30

HALL №14 (A8-A9)

SCIENTIFIC SESSION

«ORGANIZATION OF CARDIAC CARE, INFORMATION TECHNOLOGY AND EDUCATION»

Chairpersons: Grinshtein Yu. (Krasnoyarsk), **Supryadkina T.** (Arkhangelsk)

- **Druzhilov M., Kuznetsova T.** (Petrozavodsk). Anticoagulant therapy for atrial fibrillation in selected subjects of the Russian Federation in 2016-2019: results of retrospective analysis of «big data».
- **Abdualimov T.** (Saint-Petersburg). Non-invasive predictive AI coronary angiography.
- **Sardakovskaya T., Makarov S., Alekseenko A.** (Kemerovo). Experience of work with the register of patients who have undergone cardiovascular events and are subject to preferential drug coverage.

- **Gorbunova E., Rozhnev V., Lyapina I., Barbarash O.** (Kemerovo). Role of internet technologies in conducting training programs after cardiac surgery.
- **Stryukov R., Makarov S.** (Kemerovo). Quality management system — a tool for implementation of patient-centered approach in medical organization.
- **Gazizova D., Sazykina L.** (Moscow), **Makoveev S.** (Tambov). Digital technology of diagnostics and treatment of acute heart failure.

11:00–12:30

ONLINE-HALL №1

SYMPOSIUM

«ARE RISK FACTORS IN CARDIOLOGY SO HARMFUL?»

Chairpersons: Shalnova S. (Moscow), **Filippov E.** (Ryazan)

- **Shalnova S.** (Moscow). Dynamics of behavioral risk factors in Russia — ESSE-RF research pool.
- **Runihina N.** (Moscow). The role of risk factors and health management strategies in older age.
- **Berezenko I.** (Ryazan). Metabolically healthy obesity does it happen?
- **Karamnova N.** (Moscow). High salt intake: does it only negatively affect the prognosis?!
- **Sinyaeva A., Filippov E.** (Ryazan). Galectin-3 a new risk factor?

12:40–13:20

PLENARY HALL

PLENARY LECTURES

Simultaneous translation

Moderator: Nikulina S. (Krasnoyarsk)

- **Galagudza M.** (Saint-Petersburg). Meta-inflammation: a new model of pathogenesis of cardiovascular diseases.
- **Parfenova E.** (Moscow). Angiogenesis 2024 — what's new?

13:30–15:00

PLENARY HALL

JOINT PLENARY SESSION WITH THE COMMISSION OF CIRCULATORY DISEASES OF THE RUSSIAN ACADEMY OF SCIENCES «INNOVATIONS IN CARDIOLOGY. ACHIEVEMENTS OF FUNDAMENTAL SCIENCE IN PRACTICE»

Simultaneous translation

Chairpersons: **Shlyakhto E.** (Saint-Petersburg), **Popov S.** (Tomsk)

- **Shlyakhto E.** (Saint-Petersburg). The PRIORITY— CHF key results and conclusions.
- **Catapano A.** (Italy). Novel biomarkers in assessing cardiovascular risk.
- **Rebrikov D.** (Moscow). Modern genetic technologies in cardiology.
- **Beleslin B.** (Serbia). Functional coronary physiology - third generation update.

13:30–15:00

HALL №1 (E7)

SATELLITE SYMPOSIUM «ETERNAL QUESTIONS AND NEW ANSWERS» (supported by «Akrikhin», CME points are not accrued)

Chairpersons: **Arutyunov G.** (Moscow), **Belenkov Yu.** (Moscow)

- **Arutyunov G.** (Moscow). Target BP for everyone. How to achieve it in the right time frame?
- **Belenkov Yu.** (Moscow). What is the meaning of life for a cardiologist and a patient with CHF?
- **Yezhov M.** (Moscow). Evolution of the patient: from 5.0 to 1.4.
- **Oleynikov V.** (Penza). Results of the study of CONTRAST-2: emphasis on organoprotection.

13:30–15:00

HALL №2 (E8–E9)

SYMPOSIUM

**«CARDIO-ONCOLOGY THE PATH OF THE PRESENT
TO THE FUTURE»**

Chairperson: Vasyuk Yu. (Moscow)

- **Vasyuk Yu.** (Moscow). Early diagnosis and drug prevention of cardiotoxic complications of antitumor therapy: do we have a chance to win?
- **Moiseeva O., Gavrilyuk N., Moiseenko F., Simakova M.** (Saint-Petersburg). Current understanding of the mechanisms of cardiotoxicity of immune checkpoint inhibitors.
- **Emelina E.** (Moscow). Anticoagulant therapy in cancer patients with Afib during antitumor treatment.
- **Poltavskaya M., Pavlova M., Novikova A.** (Moscow). Cardiovascular risks in patients undergoing radiation therapy for CNS tumors.
- **Gendlin G.** (Moscow). Anthracyclines more than half a century of research are there any questions left?

13:30–15:00

HALL №3 (D1)

SYMPOSIUM

**«ACUTE CORONARY SYNDROME:
BEYOND THE ORDINARY»**

Chairpersons: Barbarash O. (Kemerovo), **Yakushin S.** (Ryazan)

- **Barbarash O.** (Kemerovo). Acute coronary syndrome in aortic valve stenosis. clear answers to unclear questions.
- **Kosmacheva E., Kruchinova S.** (Krasnodar). Treatment of ACS with balloon valvuloplasty of the aortic valve in aortic stenosis.
- **Pereverzeva K.** (Ryazan). Embolic myocardial infarction.
- **Yakushin S.** (Ryazan). Exudative pericarditis in myocardial infarction: challenges in etiological diagnosis and treatment.

13:30–15:00

HALL №4 (D2)

SYMPOSIUM

«END-STAGE HEART FAILURE: A DEATH SENTENCE OR NOT?»

Chairpersons: **Sitnikova M.** (Saint-Petersburg), **Koloskova N.** (Moscow)

- **Sitnikova M.** (Saint-Petersburg). Criteria-based approach to diagnosing end-stage heart failure.
- **Utmanova I.** (Krasnoyarsk). Patients with heart failure: when is the time to refer to a specialized center?
- **Galenko V.** (Saint-Petersburg). Autonomic imbalance in patients with heart failure: options for correction. Place of exercise training.
- **Koloskova N., Kachanova Yu., Poptsov V.** (Moscow). Telemedicine technologies in the treatment of CHF: benefit or harm?

13:30–15:00

HALL №5 (D3)

SYMPOSIUM

«HEART FAILURE: LIFE AFTER DIAGNOSIS. VIEW OF YOUNG CARDIOLOGISTS»

Chairpersons: **Villevalde S.** (Saint-Petersburg), **Kuzheleva E.** (Tomsk)

- **Soloveva A.** (Saint-Petersburg). Organization of medical care for heart failure: «Where to go and what to do?».
- **Safronenko V.** (Rostov-on-Don). Optimal drug therapy for heart failure: «Which medications to take and for how long?».
- **Kuzheleva E.** (Tomsk). Adherence to treatment: «I dont feel the effect of medications, why take them?».
- **Baglikov A.** (Kaluga). Polypharmacy and taking non-recommended medications for CHF: «Why are there so many pills?».
- **Novitskii N.** (Kaluga). The impact of therapy on quality of life: «Is a full life possible with CHF?».
- **Shchendrygina A.** (Moscow). Prevention of sudden cardiac death in CHF: «Is there anything other than pills?».

13:30–15:00

HALL №6 (D4)

SYMPOSIUM

«STRATEGY AND TACTICS FOR MANAGEMENT OF PATIENTS WITH EDEMA IN CARDIAC PRACTICE»

Chairperson: Arutyunov G. (Moscow)

- **Tarlovskaya E., Vlasova T.** (Nizhny Novgorod). Edematous syndrome at liver cirrhosis.
- **Chesnikova A.** (Rostov-on-Don). Edema syndrome in chronic heart failure.
- **Malchikova S.** (Kirov). Edema syndrome in chronic kidney disease.
- **Koziołova N.** (Perm). “Special” forms of edema syndrome: Is diuretic therapy always required?

13:30–15:00

HALL №7 (B1)

SYMPOSIUM

«MANAGEMENT OF PATIENTS WITH CHF — WHY WE ARE MOVING TOWARDS A SEAMLESS MODEL OF MEDICAL CARE?»

Chairpersons: Provatorov S. (Moscow), **Filippov E.** (Ryazan)

- **Filippov E.** (Ryazan). Treatment of CHF what does the new classification give to an outpatient cardiologist?
- **Provatorov S.** (Moscow). The role of PCI in patients with CHF is it possible to increase survival?
- **Lysenko A.** (Moscow). Surgery for CHF when does a cardiac surgeon come into play? The effectiveness of cardiac surgery using the example of the RSC for Surgery named after Academician B.V. Petrovsky”
- **Borovkova N.** (Nizhny Novgorod). Aggressive therapy for AF in patients with coronary artery disease and heart failure — is it right? (from antiarrhythmic therapy to catheter ablation and pacemaker).

13:30–15:00

HALL №8 (B2)

DEBATE

«ROUNDTABLE WITH EXPERTS: DIAGNOSTIC CRITERIA AND CLASSIFICATION OF MYOCARDITIS»

Chairpersons: **Paleev F.** (Moscow), **Moiseeva O.** (Saint-Petersburg)

- **Paleev F.** (Moscow). Historical aspects of the classification of myocarditis. Is a new classification of myocarditis needed?
- **Moiseeva O.** (Saint-Petersburg). Challenges to real clinical practice and classification of myocarditis.
- **Blagova O.** (Moscow). New approaches to the diagnosis and treatment of myocarditis.
- **Zhirov I., Tereshchenko S., Stukalova O.** (Moscow). Discussion

13:30–15:00

HALL №9 (B3–B5)

SYMPOSIUM

«COVID-19 AND CARDIOVASCULAR DISEASES: THE RESULTS OF THE OWN RESEARCH OF YOUNG CARDIOLOGISTS»

Chairpersons: **Kashtalap V.** (Kemerovo), **Zagidullin N.** (Ufa)

- **Gubareva E.** (Samara). Echocardiographic predictors of adverse outcome and postcovid syndrome in hospital patients: data of 2 000 patients of the university hospital.
- **Verbilo S.** (Saint-Petersburg). Features of echocardiography and stress echocardiography in patients who have undergone COVID-19.
- **Sadovnikov A., Sadovnikova N.** (Kemerovo). Features of the course of myocardial infarction in patients with the new coronavirus infection.
- **Kozik V.** (Novosibirsk). Acute coronary syndrome in the postcovid period.
- **Gerasimenko O.** (Novosibirsk), **Tolmacheva A.** (Novosibirsk). Cardiovascular diseases and new coronavirus infection: treatment and rehabilitation.
- **Gareeva D.** (Ufa). Cardiovascular burden of the various waves of the COVID-19 pandemic.

13:30–15:00

HALL №10 (B6-B8)

**SCIENTIFIC SESSION
«EPIDEMIOLOGY, PREVENTION AND REHABILITATION»**

Chairpersons: Protasov K. (Irkutsk), **Nedbaykin A.** (Bryansk)

- **Zairova A., Rogoza A., Oshchepkova E., Shalnova S.** (Moscow), **Trubacheva I., Kaveshnikov V., Serebryakova V.** (Tomsk). Studying the effectiveness of the SCORE2 scale in the stratification of cardiovascular risk in a population sample of the adult population.
- **Ilyanova I., Rotar O., Tolkunova K., Boyarinoва M., Moguchaya E., Kolesova E., Vasilyeva E., Kvan V., Usoltsev D., Artemov N., Konradi A.** (Saint-Petersburg). The experience of using the new PREVENT cardiovascular risk scale in the Russian population.
- **Kolesova E., Kvan V., Rotar O., Boyarinoва M., Moguchaya E., Kibkalo S., Tolkunova K., Maslyansky A., Artemov N., Konradi A., Shlyakhto E.** (Saint-Petersburg). Assessment of the association of body indices with cardiovascular morbidity and mortality in participants of the ESSE-RF population study: the result of a 10-year follow-up.
- **Vorobyova N., Malyshkina N.** (Arkhangelsk). The role of genotyping in the diagnosis of hyperhomocysteinemia in athletes.
- **Kaveshnikov V., Trubacheva I., Serebryakova V.** (Tomsk). Frequency and predictors of the detection of carotid atherosclerotic plaques with uneven surfaces in the general population of working age.
- **Podpalov V., Surunovich Y.** (Belarus). Epigenetics and classical risk factors in the development of MACE in the Belarusian population.

13:30–15:00

HALL №11 (F200)

SYMPOSIUM

«MYOCARDIAL INFARCTION WITH NON-OBSTRUCTIVE CORONARY ARTERY»

Chairperson: Duplyakov D. (Samara)

- **Duplyakov D.** (Samara). Types of myocardial infarction and coronary syndromes.
- **Konstantinova E.** (Moscow). MINOCA — myocardial infarction with another etiology.
- **Kislukhin T.** (Samara). Functional coronary angiography in patients with non-obstructive coronary artery disease.
- **Sinitsyn V.** (Moscow). Challenges in diagnosis of MINOCA: how cardiac MRI can help?

13:30–15:00

HALL №12 (A1–A3)

SYMPOSIUM

«GENETIC PROBLEMS OF ROUTINE CARDIOLOGY»

Chairpersons: Minushkina L. (Moscow), Kostareva A. (Saint-Petersburg)

- **Petrova M.** (Krasnoyarsk), **Shnayder N.**, **Kidyayeva A.**, **Nasyrova R.** (Saint-Petersburg). Nongenetic and genetic predictors of antidepressant-induced QT prolongation.
- **Sleptcov A.**, **Nazarenko M.** (Tomsk). T-cell landscape in atherosclerosis.
- **Lifshits G.**, **Zelenskaya E.** (Novosibirsk), **Donirova O.** (Ulan-Ude). Pharmacogenetics of ticagrelor, ethnic aspects. Russians' vs buryats after ACS.
- **Kryuchkova N.**, **Chernova A.**, **Nicoulina S.** (Krasnoyarsk). New data on genetic predictors of pulmonary embolism.
- **Kaverina V.**, **Gandaeva L.**, **Basargina E.**, **Silnova I.**, **Pushkov A.**, **Davydova Y.**, **Savostyanov K.** (Moscow). Experience of a cardiologist in the management of children with RAS-pathies.

13:30–15:00

HALL №13 (A4–A5)

**RUSSIAN-KYRGYZ SYMPOSIUM
«DETECTION AND CONTROL OF CVD RISK FACTORS
IN KYRGYZSTAN AND RUSSIA: EXPERIENCE AND BEST
PRACTICES»**

Chairpersons: **Abilova S.** (Kyrgyzstan), **Yakovlev A.** (Saint-Petersburg).

- **Abilova S.** (Kyrgyzstan). Prevalence of CVD risk factors in the Kyrgyz Republic (according to the STEPS study). What has changed for 10 years?
- **Rotar O.** (Saint-Petersburg). Prevalence of CVD risk factors in the Russian Federation — data from three slices of the ESSE-RF study.
- **Duishenalieva M.** (Kyrgyzstan). Arterial hypertension: the situation in Kyrgyzstan.
- **Alieva A.** (Saint-Petersburg). Dyslipidemia in the Russian Federation: diagnosis and approaches to correction from the position of new clinical recommendations. The role of lipid centers.

13:30–15:00

HALL №14 (A8–A9)

**SCIENTIFIC SESSION
«HEART FAILURE/LEFT VENTRICULAR DYSFUNCTION»**

Chairpersons: **Libis R.** (Orenburg), **Tuaeva I.** (Vladikavkaz)

- **Berezikova E., Shilov S., Pankova I.** (Novosibirsk), **Tepliyakov A., Grakova E., Kopyeva K.** (Tomsk), **Mayanskaya S.** (Kazan). Relationship of the level of antibodies to cytomegalovirus with the course of chronic heart failure.
- **Gritsenko O., Chumakova G., Trubina E.** (Barnaul). Changes in parameters of left ventricular mechanics in epicardial obesity.
- **White S., Nemkov A., Khubulava G.** (Saint-Petersburg). Repeated cycles of intracoronary injection of autologous bone marrow cells to improve the effectiveness of treatment of patients with dilated cardiomyopathy.
- **Shilenko P., Tsoi M., Fomenko M., Pavlov A., Vygovsky A., Shneider Y.** (Kaliningrad). Predictors of possible increase of left ventricular ejection fraction in patients with atrial fibrillation and arrhythmogenic myopathy.

- **Safiullina A., Uskach T., Sapelnikov O., Akchurin R., Tereshchenko S.** (Moscow). Predictors of restored left ventricular ejection fraction 12 months after implantation of cardiac contractility modulation device in patients with chronic heart failure and atrial fibrillation.
- **Narusov O., Muxinova M., Sychev A., Sharf T., Masenko V., Tereshchenko S., Skvortsov A.** (Moscow). Benefits of outpatient biomarker-guided management of patients with decompensated CHF with reduced ejection fraction.

13:30–15:00

ONLINE-HALL №1

SYMPOSIUM

«METABOLIC SYNDROME. PROMISING DIRECTIONS OF DRUG AND NON-DRUG THERAPY»

Chairpersons: Babenko A. (Saint-Petersburg), Begrambekova Yu. (Moscow)

- **Khromova N.** (Saint-Petersburg). Browning and metabolic health.
- **Pavlova Z.** (Moscow). Metabolic syndrome and hormonal imbalance in men.
- **Babenko A.** (Saint-Petersburg). New targets for weight-loss therapy.
- **Lelyavina T.** (Saint-Petersburg). The effectiveness of personalized training in obese patients.
- **Begrambekova Yu.** (Moscow). Are doctors ready to correct metabolic and behavioral risk factors of patients?

15:30–17:00

PLENARY HALL

PLENARY SESSION

«CLINICAL RECOMMENDATIONS. PART 2»

Simultaneous translation

Chairpersons: Shlyakhto E. (Saint-Petersburg), Nedogoda S. (Volgograd)

- **Arutyunov G.** (Moscow). Myocarditis.
- **Sitnikova M.** (Saint-Petersburg). Dilated cardiomyopathy.
- **Kozioлова N.** (Perm). Hypertrophic cardiomyopathy.
- **The closing ceremony of the Congress.**
- **Awarding Ceremony: Young Scientists Awards**
- **Awarding of diplomas**

ABSTRACT SESSIONS

«Arrhythmology, stimulation, resynchronization»

1. Shnyukova T.V., Shavkuta G.V. (Rostov-on-Don), Shnyukov V.V. (Stavropol), Cherkashin A.A., Yakovleva N.V., Pakhomova V.M. (Rostov-on-Don). The detection of short episodes of atrial fibrillation using daily ECG monitoring at a separate medical center for a calendar year.
2. Garina I.A., Likhachev-Mishchenko O.V., Khaisheva L.A., Shlyk S.V. (Rostov-on-Don). To study the prevalence of cardiac arrhythmias in patients with chronic renal failure receiving programmed hemodialysis.
3. Enina T.N., Petelina T.I., Shirokov N.E., Repina I.A., Gapon L.I. (Tyumen). Arctic tension syndrome in male respondents of cardiac resynchronization therapy living in the Far North.
4. Loginova E.N., Nechaeva G.I., Potapov V.V. (Omsk). Echocardiographic assessment of myocardial strain in ventricular extrasystole on the background of undifferentiated connective tissue dysplasia.

«Arterial hypertension, metabolic syndrome, diabetes»

5. Mitina E.V., Kuznetsov V.I., Sturov N.V., Klimenko A.S., Prokofieva E.B. (Moscow). Analysis of the distribution of arterial hypertension in the family history and lipid profile of 5th and 6th year students of the RUDN Medical Institute.
6. Amanova A.A., Tlegenova Zh.Sh., Balmagambetova S.K., Zholdin B.K. (Kazakhstan). Arterial hypertension and antitumor therapy: trends in current data.
7. Avdeeva K.S., Petelina T.I., Bykova S.G., Sharoyan Yu.A. (Tyumen). The effect of rehabilitation measures on metabolic indices of body structure in postmenopausal women with arterial hypertension.
8. Talibov F.A., Zbyshevskaya E.V., Makeeva T.I., Butaev T.D., Bitakova F.I. (Saint-Petersburg). Hypercoagulation and thrombocytopenia after SARS-CoV-2 – pneumonia as predictors of an unfavorable prognosis in patients with arterial hypertension.
9. Shamkina A.R., Akhmetzyanova A.I., Gaziev A.R. (Kazan). Cardiovascular events among patients with cardiovascular diseases in combination with disproportionately high left ventricular myocardial mass.
10. Sharypova M.V., Mikhailova A.A., Chernikova A.T., Golovatyuk K.A., Karonova T.L. (Saint-Petersburg). Markers of metabolic disorders in patients after a new coronavirus infection.
11. Simanenkova A.V., Fuchs O.S., Timkina N.V., Fedotova A.D., Islamova A.I., Karonova T.L. (Saint-Petersburg). Mechanisms of the neuroprotective effect of arGPP-1 in experimental ischemic stroke.

12. Avdeeva I.V., Pavlenko K.I. (Penza). Evaluation of the side effects of lipid-lowering therapy in patients with hypertension and dyslipidemia who have suffered a new coronavirus infection.
13. Matveev G.A., Golikova T.I., Babenko A.Yu., Lyasnikova E.A. (Saint-Petersburg). Obese patients and cardiovascular risks: five-year follow-up experience.
14. Avdeeva K.S., Petelina T.I., Garanina V.D., Leonovich S.V., Kapustina A.A., Leonova E.S. (Tyumen). A prospective analysis of laboratory parameters in patients with arterial hypertension who suffered from COVID-19-associated pneumonia.
15. Yufereva Yu.M., Naumov Ya.A., Timofeev R.G., Grigoriev N.E., Shevchenko A.O. (Moscow). The relationship of clinical and outpatient blood pressure with coping strategy of confrontation in young people.
16. Yanevskaya L.G., Poghosyan K.A., Karonova T.L. (Saint-Petersburg). Echocardiographic parameters and osteoprotegerin levels in patients with primary hyperparathyroidism.

«Imaging in cardiology, ultrasound and tomography»

17. Oleynikov V.E., Golubeva A.V., Vershinina O.D. (Penza). The HFA-PEFF algorithm and noninvasive indicators of myocardial function in patients in the postinfarction period with preserved left ventricular ejection fraction.
18. Oleynikov V.E., Shcherbinina A.V., Galimskaya V.A., Donetskaya N.A. (Penza). The relationship of left ventricular contractility indices with components of ischemic myocardial injury according to magnetic resonance imaging.
19. Garipov A.S., Pateyuk I.V., Terekhov V.I. (Belarus). The relationship of longitudinal deformation and diastolic function of the left ventricular myocardium according to single-photon emission computed tomography in young patients with prolonged pacing.
20. Oleynikov V.E., Salamova L.I., Donetskaya N.A., Vdovkin A.V., Vershinina O.D. (Penza). Dynamics of indicators of ischemic injury in patients with moderately reduced and low left ventricular ejection fraction in the postinfarction period.
21. Oleynikov V.E., Salamova L.I., Donetskaya N.A., Vdovkin A.V. (Penza). The pattern of ischemic damage depending on reperfusion injury in patients with ST-segment elevation myocardial infarction.
22. Karasev A.A., Krylova N.S., Svanadze A.M., Poteshkina N.G., Maslova M.Yu. (Moscow). Predictors of the presence of hemodynamically significant coronary artery stenoses in coronary angiography: focus on stress testing.
23. Yaroslavskaya E.I., Shirokov N.E., Krinochkin D.V., Osokina N.A., Korovina I.O., Migacheva A.V. (Tyumen). Improvement of systolic and deterioration of diastolic function of the ventricles of the heart in patients with cardiovascular diseases within two years after COVID-19 pneumonia.

«CAD, lipids and atherosclerosis»

24. Nikitina A.O., Egorova I.S., Vesikova N.N., Malygin A.N. (Petrozavodsk). Lipid-lowering therapy and dyslipidemia in patients with acute coronary syndrome: 14-year follow-up.
25. Yaroslavskaia E.I., Gorbatenko E.A. (Tyumen). Ten-year dynamics of coronary lesions in residents of the Yamalo-Nenets Autonomous District in comparison with residents of the south of the Tyumen region.
26. Medvedeva E.A., Gelis L.G., Rusak T.V., Kuznetsova T.V., Kolyadko M.G., Melnik I.N. (Belarus). Dyslipidemia and features of correction of lipid metabolism in young patients with myocardial infarction.
27. Bagmanova Z.A., Rudenko V.G. (Ufa), Krokhaev A.N. (Nizhnekamsk), Zagidullin B.I. (Naberezhnye Chelny), Itkulov A.F., Sakaeva E.Z., Yakhina E.F. (Ufa). Multiple coronary-left ventricular fistulas and spongy myocardium in a patient with unstable angina pectoris.
28. Bezdenezhnykh N.A., Sumin A.N., Shcheglova A.V. (Kemerovo), Munir A.R. (India), Ankudinov A.S., Kalyagin A.N. (Irkutsk), Vijeyraghavan G. (India). Association of hypothyroidism with dyslipidemia and multivessel coronary artery disease in patients with coronary artery disease in the South Indian region.
29. Guskova E.S., Zagatina A.V., Kalinina E.S. (Saint-Petersburg). Severe coronary artery stenosis in asymptomatic patients, detected by transthoracic echocardiography.
30. Kolodina D.A., Belyaeva O.D., Berkovich O.A., Polyakova E.A., Ionova J.I., Zaraisky M.I., Karonova T.L. (Saint-Petersburg). The level of microRNA-21 expression in the myocardium and blood plasma in patients with coronary artery disease and obesity who underwent coronary bypass surgery.
31. Zakharyan E.A. (Simferopol). The level of endocan and endoglin in patients with coronary artery disease.

«Interdisciplinary problems in cardiology»

32. Okisheva E.A., Madoyan M.D., Fidanyan S.E., Krivova N.P., Kurnosova A.A., Mamaeva M.M., Redyanova E.A., Trushina O.Yu., Fomin V.V., Lychagin A.V. (Moscow). Analysis of the effectiveness of prevention of thrombotic complications after planned total arthroplasty of the joints of the lower extremities.
33. Karimov R.R., Salakheeva E.Yu., Antyufeeva O.N., Bochkarnikova O.V., Belenkov Yu.N., Ilgisonis I.S. (Moscow). The relationship of lactate dehydrogenase level with the parameters of the structural and functional state of blood vessels in patients with lymphoproliferative diseases on the background of polychemotherapy.

34. Deshko M.S., Snezhitsky V.A., Deshko T.A., Rudinskaya O.A., Vasilevskaya N.F., Uskova I.V., Osipova I.A., Bubeshko D.A. (Belarus). The importance of the parameters of the body's iron supply as predictors of the progression of heart failure in patients with preserved ejection fraction and atrial fibrillation.
35. Okisheva E.A., Zhazhieva A.A., Chasova I.D., Pyatigorets E.S., Kolomatskaya A.V., Sorokina S.A., Zotova D.A., Panferov A.S., Trushina O.Yu., Lychagin A.V., Fomin V.V. (Moscow). Investigation of the safety of prevention of thrombotic complications after planned total arthroplasty of the joints of the lower extremities.
36. Prom A.K. (Volgograd). The basic principles of a game application for cardiac patients.
37. Statsenko M.E., Turkina S.V., Kosivtsova M.A., Titarenko M.N., Tyshchenko I.A., Lopushkova Yu.E. (Volgograd). Assessment of the risk of predicting chronic liver disease in patients with chronic heart failure and non-alcoholic fatty liver disease.
38. Bikushova I.V., Smirnova E.A. (Ryazan). Portrait of a patient with atrial fibrillation who suffered a cardioembolic stroke.
39. Glova S.E., Khaisheva L.A., Shlyk S.V. (Rostov-on-Don). The use of artificial intelligence methods in predicting the course of coronary heart disease.
40. Glova S.E., Samakaev A.S., Khaisheva L.A., Shlyk S.V. (Rostov-on-Don). Prediction of adverse outcomes in patients with coronary artery disease and chronic kidney disease.
41. Yaroslavskaya E.I., Kharats V.E., Evlampieva L.G., Gorbatenko E.A., Guskova O.A. (Tyumen). A method for predicting long-term adherence to CPAP therapy in patients with a cardiological profile.
42. Anfinogenova N.D. (Tomsk). Factors associated with the development of sleep disorders during pharmacotherapy in persons with a cardiological profile, according to an online survey.
43. Berdysheva V.A., Ionin V.A., Vakulenko A.S., Baranova E.I. (Saint-Petersburg). Atrial fibrillation in patients with sleep respiratory disorders and metabolic syndrome.
44. Osmolovskaya Yu.F., Petrukhina A.A., Aksenova Yu.O., Zhirov I.V., Beniashvilia A.G., Morozova M.A., Tereshchenko S.N. (Moscow). The effectiveness of using a relaxation scenario in virtual reality technology to correct the symptoms of psychological distress in patients with chronic heart failure.

«Managing patients with non-coronary pathologies»

45. Rudenko V.G., Bagmanova Z.A., Plechev V.V., Zagidullin N.S. (Ufa), Mazur N.A. (Moscow), Kayumova L.M., Bakirova M.A. (Ufa). Clinical and electrocardiographic variants of stress-induced ischemia in patients with congenital muscular bridge of the coronary artery.

46. Klochkova I.V., Slivinsky D.V., Gulyaev N.I. (Krasnogorsk). Clinical observation of apical hypertrophic cardiomyopathy in a middle-aged patient.
47. Nikulin D.A., Zobova E.V., Lyzhenkova A.V., Danilova A.A., Dankovtseva E.N., Minushkina L.O., Zateishchikov D.A. (Moscow). The assessment of the dynamics of the severity parameters of idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension expands the possibilities of predicting their course.
48. Zlobina I.S., Goncharova N.S., Simakova M.A., Lapshin K.B., Marukyan N.V., Berezina A.V., Moiseeva O.M. (Saint-Petersburg). Comparative analysis of the features of the pathophysiological mechanisms determining the unfavorable prognosis in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
49. Makeeva T.I., Mayer M. V., Zbyshevskaya E.V., Butaev T.D., Bitakova F.I. (Saint-Petersburg). Risk factors for acute myocardial injury in patients with arterial hypertension with SARS-CoV-2 – pneumonia.
50. Lutokhina Yu.A., Blagova O.V., Nartov A.A., Nartova V.R., Zaklyazminskaya E.V., Dzemeshkevich S.L. (Moscow). The frequency and role of concomitant myocarditis in hypertrophic cardiomyopathy.

«Urgent cardiology»

51. Serdechnaya A.Yu., Sukmanova I.A. (Barnaul). The leading risk factors for recurrent cardiovascular events in patients with ST-segment elevation myocardial infarction and pharmacoinvasive management strategy.
52. Kvasova O.G., Salamova L.I., Tomashevskaya Yu.A. (Penza). The relationship between the parameters of the functional state of the kidneys and local arterial stiffness in patients with myocardial infarction with ST segment elevation.
53. Serdechnaya A.Yu., Sukmanova I.A. (Barnaul). The effect of hospital complications in patients with ST-segment elevation myocardial infarction on the risk of recurrent cardiovascular events during the 3-year follow-up period.
54. Erkinova D.E., Hastieva D.R., Tarasova N.A., Khasanov N.R. (Kazan). Changes in the systolic function of the left ventricle in patients with absolute and functional iron deficiency for 6 months.
55. Galenko A.S., Vasina N.O., Zelenin V.V. (Saint-Petersburg). Myocardial infarction of type 2 thromboembolic origin, complicated by the development of clinical death.
56. Medvedeva E.A., Gelis L.G., Polonetsky O.L., Russian I.I., Kolyadko M.G., Shibeko N.A., Rusak T.V. (Belarus). Comparative evaluation of the results of standard and personalized antithrombotic treatment of patients with unstable angina and coronary artery stenting.

57. Medvedeva E.A., Gelis L.G., Polonetsky O.L., Kolyadko M.G., Ostrovsky Yu.P. (Belarus). Comparative results of a seven-year follow-up of patients with unstable angina pectoris with endovascular and surgical treatment strategies.
58. Lobanova A.N., Petrova M.M., Kharkov E.I., Tsybul'skaya N.Yu. (Krasnoyarsk). Pharmacoepidemiological analysis of drug therapy for myocardial infarction with ST segment elevation on an electrocardiogram in the age aspect.
59. Lapina E.S., Nikulina N.N., Yakushin S.S., Antonenko A.O., Biryukov S.A. (Ryazan). ECG criteria for acute occlusion of the intermediate artery: the first results of the study.

«Organization of cardiac care, information technology and education»

60. Maksimova A.S., Shelkovnikova T.A., Ryumshina N.I., Chesalov N.P. (Tomsk), Usov V.Yu. (Novosibirsk), Anfinogenova N.D. (Tomsk). The experience and attitude of the unstructured population to diagnostic imaging methods during and after the COVID-19 pandemic: focus on cardiovascular pathology.

«Heart failure/left ventricular dysfunction»

61. Sedykh E.V., Smirnova E.A. (Ryazan). The effect of senile asthenia syndrome on functional activity, quality of life, approaches to therapy and prognosis of patients with acute decompensation of heart failure.
62. Wang Z. (China), Zbyshevskaya E.V., Butaev T.D., Makeeva T.I. (Saint-Petersburg). Long-term prognosis of heart failure with low ejection fraction in acute coronary syndrome in young and middle-aged patients with arterial hypertension.
63. Lebedeva N.B., Parfenov P.G., Egle A.P. (Kemerovo). The results of external validation of a model for predicting the risk of acute decompensation of heart failure with a low left ventricular ejection fraction.
64. Enina T.N., Shirokov N.E., Petelina T.I., Kosterin M.D., Gapon L.I. (Tyumen). The relationship of iron status indicators with the diastolic function of the left heart in patients with heart failure with preserved ejection fraction.
65. Tishkina I.E., Pereverzeva K.G., Yakushin S.S. (Ryazan). Systolic dysfunction of the left ventricle in patients with myocardial infarction with elevation of the ST segment of the electrocardiogram.
66. Ponomareva O.V., Smirnova E.A., Skiperskikh P.V., Proskurina E.V. (Ryazan). Phenotypic "portraits" of patients with chronic heart failure with preserved ejection fraction.

«Cardiovascular surgery and interventional cardiology»

67. Babakehian M.V., Sefieva G.G., Chynybekova A.N., Shadrina U.M., Irt'yuga O.B. (Saint-Petersburg). Thrombohemorrhagic events in patients with aortic stenosis who underwent aortic valve replacement.

«Fundamental research and personalized cardiology»

68. Kologrivova I.V., Dmitriukov A.A., Puryanskaya O.A., Kharitonova O.A., Narizhnaya N.V., Kravchenko E.S., Andreev S.L., Suslova T.E. (Tomsk). FoxP3+ T-regulatory lymphocytes of epicardial and thymus adipose tissue in ischemic heart disease and type 2 diabetes mellitus.
69. Komissarova S.M., Chakova N.N., Niyazova S.S., Rineyskaya N.M. (Belarus). Hypertrophic cardiomyopathy: clinical and genetic characteristics in a cohort of Belarusian patients.
70. Komissarova S.M., Rineyskaya N.M., Chakova N.N., Niyazova S.S. (Belarus). Clinical and genetic characteristics of phenotypes of hypertrophic cardiomyopathy in a cohort of Belarusian patients.
71. Khlyamov S.V., Mal G.S., Artyushkova E.B., Eliseeva R.S. (Kursk). Monotherapy of arterial hypertension induced by bevacizumab administration.
72. Enkhtayvan B., Yusupova A.O., Sipliv V.I., Safonova T.N., Kintyukhina N.P., Zhorzholadze N.V., Pakhtusov N.N., Slepova O.A., Krivova A.V., Belenkov Yu.N. (Moscow). Assessment of microcirculation disorders in conjunctival vessels in patients with cardiovascular diseases.
73. Ogibenina E.S., Bragina A.E., Rodionova Yu.N., Fomin A.S., Podzolkov V.I. (Moscow). The relationship of RAAS gene polymorphism with the severity of coronavirus infection in comorbid patients.
74. Kalinina M.I., Yusupova A.O., Pakhtusov N.N., Slepova O.A., Popova L.V., Belenkov Yu.N. (Moscow). Tumor necrosis factor alpha and vascular endothelial growth factor in patients with coronary artery disease and non-obstructive coronary artery disease.

«Epidemiology, prevention and rehabilitation»

75. Zakharevich A.L., Moroz-Vodolazhskaya N.N. (Belarus). Cardiopulmonary profiling: features of stress test parameters with gas analysis in athletes.
76. Zairova A.R., Rogoza A.N., Oshchepkova E.V., Shalnova S.A. (Moscow), Trubacheva I.A., Kaveshnikov V.S., Serebryakova V.N. (Tomsk). Assessment of arterial stiffness in volumetric sphygmography as an alternative to ultrasound examination of the carotid arteries in the stratification of cardiovascular risk.
77. Avdeev A.N., Shevchenko D.S., Tsurikova A.V. (Voronezh). Psychological assistance as a necessary component in the work of MDRK at the early stage of cardiac rehabilitation.
78. Medvedeva E.A., Shatova O.G., Kolyadko M.G., Pobivantseva N.F., Mankevich N.V., Mitkovskaya N.P. (Belarus). The results of laboratory screening of a number of major risk factors for cardiovascular diseases among the organized able-bodied population.

79. Rakovskaya Yu.S., Drozdova L.Yu. (Moscow). The results of the in-depth medical examination in 2022.
80. Anfinogenova N.D. (Tomsk). Factors associated with the profile of undesirable adverse reactions in patients with a cardiological profile, according to an online survey.

E-POSTER

«Arrhythmology, stimulation, resynchronization»

81. Fedoseenko A.V., Zenin S.A., Kononenko O.V., Pyataeva O.V., Zvonkova A.V. (Novosibirsk). Ablation catheters with an elongated active pole during ablation of the cava-tricuspid isthmus.
82. Belokurova A.V., Gizatulina T.P., Mamarina A.V. (Tyumen). Analysis of the effectiveness of anticoagulant therapy in patients with atrial fibrillation according to the thrombodynamics test.
83. Kononenko O.V., Zenin S.A., Pyataeva O.V., Fedoseenko A.V., Zvonkova A.V. (Novosibirsk). Antiarrhythmic effect of dapagliflazine in a patient with implanted EX and atrial fibrillation.
84. Rakhimova R.F., Zagidullin N.S., Badykova E.A., Gareeva D.F., Amineva A.M., Enikeeva A.M., Akhmetyanova G.R., Fatyhova R.R. (Ufa). The effect of defragmentation of the QRS complex on hospital mortality and mortality in the long-term period of myocardial infarction with ST segment elevation.
85. Zotova I.V., Kochkina M.S., Alkam D.M., Minushkina L.O., Zateishchikov D.A. (Moscow). The effect of anticoagulant therapy tactics on the probability of dissolution of a blood clot in the auricle of the left atrium in patients with atrial fibrillation.
86. Archakov E.A., Batalov R.E., Stepanov I.V., Afanasyev S.A., Popov S.V., Khlynin O.R., Eshmatov O.R. (Tomsk). The effect of chronic lymphocytic myocarditis on the effectiveness of atrial fibrillation ablation.
87. Ryngach E.A., Tatarinova A.A., Treshkur T.V. (Saint-Petersburg). The possibility of stratification of the risk of sudden cardiac death in patients with chronic coronary syndrome and ventricular arrhythmias based on the results of long-term prospective follow-up.
88. Khlynin M.S., Batalov R.E., Archakov E.A., Eshmatov O.R., Atabekov T.A. (Tomsk). Isolated atrial fibrillation, inflammation, and the effectiveness of radiofrequency ablation.
89. Rebrova T.Yu., Perevoznikova Yu.E., Muslimova E.F., Svintsova L.I., Afanasyev S.A., Jaffarova O.Yu. (Tomsk). The informative value of the adrenoreactivity index of erythrocyte membranes for assessing sympathetic hyperactivation of the body during radiofrequency correction of rhythm disturbances in adolescents.

90. Davydova V. G., Gudkova A. Ya., Yuricheva Yu.A., Dzaurova H.M., Belyaeva M.M., Mironov N.Yu. (Saint-Petersburg). Clinical and morphological characteristics of young patients with hypertrophic cardiomyopathy who have indications for implantation of a cardioverter defibrillator.
91. Yuricheva Yu.A., Dzaurova H.M., Belyaeva M.M., Mironov N.Yu., Sokolov S.F., Golitsyn S.P. (Moscow). Phase I clinical trials of the antiarrhythmic drug cavutilide, tablet form.
92. Pilant D.A., Kadochkin V.O. (Belarus). A clinical case of successful stimulation of the cardiac conduction system after radiofrequency ablation of the Maheim tract in a patient with atrioventricular block and arrhythmogenic cardiomyopathy.
93. Podzolkov V.I., Tarzimanova A.I., Kazantseva E.V., Ivannikov A.A. (Moscow). Pulmonary hypertension as a risk factor for atrial fibrillation in comorbid patients with arterial hypertension and chronic obstructive pulmonary disease.
94. Artemova E.A., Shekhovtsova L.V. (Stary Oskol). The experience of using cavutilide for drug-induced cardioversion in patients with persistent atrial fibrillation.
95. Kashtalap V.V., Sadovnikov A.V., Sadovnikova N.V., Zgurskaya T.D., Tupikova T.E., Zvereva T.N., Barbarash O.L. (Kemerovo). Features of the course of myocardial infarction in patients with COVID-19.
96. Khuziakhmetov R.D., Shishkina E.A., Khlynova O.V., Belov V.A., Azizov S.N., Kadyraliev B.K. (Perm). Long-term results of interventional treatment of atrial fibrillation in patients with chronic heart failure.
97. Ushakov R.Yu., Durmanov S.S., Glumskov A.B., Kozlov A.V., Makarova N.V., Bazylev V.V. (Penza). Later accumulation of gadolinium during magnetic resonance imaging of the heart increases the chance of justified responses in patients with ischemic cardiomyopathy and implanted cardioverter defibrillator.
98. Tarasik E.S., Bulgak A.G., Troyanova-Shchutskaya T.A., Tarasik M.S., Anasovich D.V. (Belarus). Predictors of the development of rhythm disturbances in patients with obstructive sleep apnea syndrome.
99. Malinkin I.A., Kovalev D.V., Chiaureli M.R., Danilov T.Yu., Samsonov V.B., Astrakhantsev T.O., Yanybaeva L.Ch., Minaev A.V., Dontsova V.I. (Moscow). Results of correction of mitral insufficiency in adult patients with CHD.
100. Pyataeva O.V., Zenin S.A. (Novosibirsk). A retrospective analysis of the use of the drug cavutilide.
101. Podzolkov V.I., Tarzimanova A.I., Kazantseva E.V., Ivannikov A.A. (Moscow). The role of hypoxia in the appearance of atrial fibrillation in comorbid patients with arterial hypertension and chronic obstructive pulmonary disease.

102. Atabekov T.A., Sazonova S.I., Khlynin M.S., Muslimova E.F., Krivolapov S.N., Kurlov I.O., Rebrova T.Yu., Afanasyev S.A., Batalov R.E., Popov S.V. (Tomsk). Stratification of the risk of sustained ventricular tachycardia using myocardial scintigraphy with ¹²³I-MIBG in patients with coronary heart disease and implantable cardioverter defibrillator.
103. Barashkova E.I., Ionin V.A., Kalmanson L.M., Berdysheva V.A., Ananyin A.M., Baranova E.I. (Saint-Petersburg). Risk factors for recurrence of arrhythmia in patients with atrial fibrillation and metabolic syndrome after performing electrical cardioversion.
104. Vaikhanskaya T.G., Koptuyukh T.M., Kozlov I.D., Frolov A.V. (Belarus). Electrocardiographic parameters of abnormal p-wave as noninvasive predictors of atrial fibrillation.

«Arterial hypertension, metabolic syndrome, diabetes»

105. Yakhontov D.A., Shriner K.A., Beksheneva E.M., Ostanina Yu.O. (Novosibirsk). Current aspects of pharmacotherapy of resistant hypertension.
106. Mukhtarova Sh.Sh., Nasyrova H.K., Trigulova R.H., Akhmedova D.T., Akhmedova S.S. (Uzbekistan). Analysis of hemodynamic parameters in comparison with the values of glycated hemoglobin in patients with coronary heart disease and type 2 diabetes mellitus.
107. Glenza A., Yakushin S.S., Dobrynina N.V. (Ryazan). Analysis of risk factors for hypertension in patients with detected arterial hypertension based on the materials of the epidemiological study ESSE-2 in the Ryazan region.
108. Elmi S. (Ryazan). Analysis of kidney function in persons with high normal blood pressure in the Ryazan region (according to the ESSAY-RF-2).
109. Kochetova O.V., Avzaletdinova D.Sh., Kochetova T.M., Korytina G.F., Morugova T.V. (Ufa). Analysis of the expression of a number of microRNA genes in patients with type 2 diabetes mellitus.
110. Stafeeva E.A., Arutyunov G.P., Sokolova A.V., Dragunov D.O., Lytkina K.A., Kulagina N.P. (Moscow). Asymmetric dimethylarginine as a new marker of the risk of resistant hypertension.
111. Vasilyeva I.N., Osadchuk M.A., Mitrokhina O.I., Kuzmina E.A., Bikmetova A.M. (Moscow). Associative relationship of neoplastic processes and arterial hypertension in the context of metabolic syndrome.
112. Vasilyeva I.N., Osadchuk M.A., Markin A.A. (Moscow). Associative links of arterial hypertension and systemic inflammation in obese patients.
113. Levkovich T.V., Pronko T.P., Babenko A.S., Gorchakova O.V., Borodavko O.N., Kardash I.A. (Belarus). Association of G915C polymorphism of the transforming growth factor beta 1 gene with the level of transforming growth factor beta 1 in male patients with arterial hypertension.

114. Andreeva G. F., Smirnova M. I., Gorbunov V. M., Kurekhyan A.S., Koshelyaevskaya Ya.N. (Moscow). The relationship of the severity of the white coat effect with lifestyle components in patients with arterial hypertension.
115. Vedenskaya S.S., Smolenskaya O.G., Grachev V.G., Klyachina E.S. (Yekaterinburg). The effect of antiplatelet therapy on hemostasis parameters and quality of life in patients with hypertension and multifocal atherosclerosis.
116. Starchenko A.D., Myasnikova A.A. (Orenburg), Liskova Yu.V. (Moscow). The effect of oxytocin on the molecular mechanisms of myocardial remodeling in experimental diabetic cardiomyopathy.
117. Shilov S.N., Berezikova E.N., Popova A.A. (Novosibirsk), Teplyakov A.T., Grakova E.V., Kopyeva K.V. (Tomsk). Endothelial dysfunction and features of the course of hypertension in the treatment of breast cancer with anthracyclines.
118. Mukhtarova Sh.Sh., Trigulova R.H., Nasyrova H.K., Akhmedova D.T., Alimova D.A. (Uzbekistan). The dependence of clinical and anamnestic parameters on the target values of glycated hemoglobin in patients with coronary heart disease and type 2 diabetes mellitus.
119. Kochuraeva U.S., Mikhailenko N.S., Yelsukova O.S., Naimushin D.A. (Kirov). To study the relationship between diastolic myocardial dysfunction and liver fibrosis in patients with type 2 diabetes mellitus.
120. Khaisheva L.A., Litvinova M.S., Shlyk S.V. (Rostov-on-Don). To study the relationship of calcification of the thoracic aorta with the features of the daily blood pressure profile in patients with resistant hypertension.
121. Zhmailova S.V., Weber V.R., Pavlova A.A., Pavlova V.A. (Veliky Novgorod). The use of a cold test to detect endothelial dysfunction in patients with hypertension.
122. Petrova V.B., Petrova A.B., Shumkov V.A., Petrova A.I. (Saint-Petersburg). A clinical case of hypertensive crisis complicated by transient global amnesia.
123. Barkovskaya M.K., Kushnir V.V., Martynyuk T.V. (Moscow). The clinical significance of ultrasound dopplerography of the portocaval hepatic blood flow in patients with chronic thromboembolic pulmonary hypertension on a clinical example.
124. Anikin V.V., Andreeva E.V. (Tver). Personal and pathopsychological paradoxes of patients with arterial hypertension and obesity.
125. Likhonosov N.P., Babenko A.Yu., Lyasnikova E.A. (Saint-Petersburg). Features of the molecular biomarker profile depending on the phenotype of diabetes mellitus: association with inflammation and cardiovascular complications.
126. Elmi S., Yakushin S.S., Dobrynina N.V. (Ryazan). Assessment of fatal and non-fatal cardiovascular events in individuals with high normal blood pressure.

127. Safronenko V.A., Chesnikova A.I., Skarzhinskaya N.S., Kolomatskaya O.E. (Rostov-on-Don). Evaluation of the effectiveness of antihypertensive therapy in patients with arterial hypertension and chronic heart failure, taking into account the presence of senile asthenia syndrome.
128. Korolev A.I., Fedorovich A.A., Gorshkov A.Yu., Chashchin M.G., Dadaeva V.A., Strelkova A.V., Mikhailova M.A., Drapkina O.M. (Moscow). Photoplethysmography indicators associated with the presence of undetected arterial hypertension in men with low and moderate cardiovascular risk.
129. Zyubanova I.V., Ryumshina N.I., Mordovin V.F., Vtorushina A.A., Lichikaki V.A., Manukyan M.A., Hunkhinova S.A., Skomkina I.A., Soltanakhmetova A.D., Falkovskaya A.Yu. (Tomsk). Sexual characteristics of abdominal fat depots and their clinical significance in patients with resistant hypertension.
130. Apukhtin A.F. (Nizhny Chir village, Surovikinsky municipal district, Volgogradskaya oblast). Kidney damage in patients with obesity and hypertension.
131. Minushkina L.O., Brazhnik V.A., Zateishchikov D.A. (Moscow), Khasanov N.R. (Kazan), Kosmacheva E.D. (Krasnodar), Chichkova M.A. (Astrakhan). Adherence to antihypertensive therapy for 1 year after acute coronary syndrome.
132. Popova (Vtorushina) A.A., Zyubanova I.V., Ryumshina N.I., Mordovin V.F., Lichikaki V.A., Manukyan M.A., Solonskaya E.I., Hunkhinova S.A., Skomkina I.A., Afanasyev S.A., Rebrova T.Yu., Gusakova A.M., Falkovskaya A.Yu. (Tomsk). A decrease in the functional state of the kidneys in patients with resistant arterial hypertension: the relationship with fat depots and pulse blood pressure.
133. Lyamina N.P., Lyamina S.V. (Moscow). Modern tactics of treatment of arterial hypertension is a multi—marker strategy.
134. Rebrova N.V., Falkovskaya A.Yu., Mordovin V.F., Chernyshova M.A., Schneider O.L. (Tomsk). Comparative assessment of vascular stiffness and endothelial function in patients with rheumatoid arthritis in combination with and without hypertension.
135. Ionov M.V., Kurapeev D.I., Zvartau N.E., Konradi A.O. (Saint-Petersburg). The degree of involvement and duration of active participation of patients with arterial hypertension in telemedicine monitoring.
136. Korolev A.I., Fedorovich A.A., Gorshkov A.Yu., Chashchin M.G., Dadaeva V.A., Drapkina O.M. (Moscow). The structural and functional state of various parts of the microcirculatory bed of the skin in men with isolated diastolic hypertension.
137. Spitsin A.P. (Kirov). Types of orthostatic hemodynamic reactions with normal and elevated blood pressure in young people.

138. Podzolkov V.I., Bragina A.E., Vasilyeva L.V., Bukina K.A., Khachatryan G.D., Tesovskaya A.D., Akvitskaya D.V. (Moscow). Morning hypertension and comorbidity.
139. Bragina A.E., Vasilyeva L.V., Khachatryan G.D., Bukina K.A., Tesovskaya A.D., Akvitskaya D.V., Podzolkov V.I. (Moscow). Morning arterial hypertension: is there a relationship with the properties of the left ventricle and arteries?
140. Makina O.V., Tuz V.V., Shchedrova E.V., Maslova E.Yu. (Yaroslavl). Risk factors for diabetic cardiomyopathy in children with type 1 diabetes mellitus.
141. Nistryanu D.N., Samoilova E.P., Kalugin A.V., Gapon L.I., Leonova E.S. (Tyumen). Formation of myocardial remodeling in patients with arterial hypertension in the Arctic region.
142. Bragina A.E., Rodionova Yu.N., Osadchy K.K., Vasilchenko M.K., Storozhenko D.D., Tarasova P.A., Shapovalova Yu.E., Podzolkov V.I. (Moscow). Ectopic adipose tissue: association of obesity phenotypes with integral metabolic indices of obesity.

«Imaging in cardiology, ultrasound and tomography»

143. Saushkin V.V., Varlamova Yu.V., Ryumshina N.I., Vrublevsky A.V., Panfilov D.S., Kozlov B.N., Sazonova S.I. (Tomsk). To study the possibilities of CT angiography in assessing the functional state of the aortic wall in patients with thoracic aortic aneurysm.
144. Kreneva E.L., Nelasov N.Yu., Sidorov R.V., Ovrulova M.M., Morgunov M.N., Doltmurzheva N.S. (Rostov-on-Don). Determination of left ventricular remodeling parameters by speckle-tracking stress echocardiography with adenosine triphosphate.
145. Zavadovsky K.V., Manukyan M.A., Mochula A.V., Gulya M.O., Mordovin V.F., Zyubanov I.V., Lichikaki V.A., Solonskaya E.I., Hunkhinova S.A., Popova A.A., Skomkina I.A., Pekarsky S.E., Dasheeva A.S., Ryumshina N.I., Falkovskaya A.Yu. (Tomsk). Epicardial adipose tissue density as a factor associated with the severity of myocardial ischemia (description of a series of cases).
146. Khamidova L.T., Rybalko N.V., Bashirova E.A., Ivannikov A.A., Ramazanov G.R. (Moscow). The role of determining left atrial myocardial deformity in the diagnosis of cardioembolic stroke.
147. Kirillova I.G., Korsakova Yu.O., Nikolaeva E.V., Kurmukov I.A., Alekseeva O.G., Yudkina N.N., Volkov A.V. (Moscow). Tricuspid regurgitation rate as a screening method for pulmonary hypertension in patients with systemic rheumatic diseases.
148. Zhuravleva O.A., Ryabova T.R., Svyazova N.N., Vrublevsky A.V., Boschenko A.A. (Tomsk). Standard stress echocardiography as a marker of prognosis in stable coronary heart disease.
149. Vishnyak D.A., Gadzhibekova N.G., Litovchenko O.G. (Surgut). The mystery of the three-atrial heart.

150. Usov V.Yu., Minin S.M. (Novosibirsk), Lishmanov Yu.B. (Tomsk), Anashbaev Zh.Zh., Vasilitseva O.Ya., Ivanovskaya E.A. (Novosibirsk), Bukhovets I.L. (Tomsk), Chernyavsky A.M. (Novosibirsk). Pharmacological test with nitroglycerin in combination with perfusion single-photon emission computed tomography combined with X-ray computed tomography with ^{99m}Tc-technetrit in assessing myocardial viability in patients who have suffered an acute heart attack.
151. Sidikov F.H., Tukhsanboev E.S., Filatova D.A., Pisaryuk A.S., Merai I.A., Kazakhmedov E.R., Kobalava J.D. (Moscow). The frequency and clinical and demographic associations of the patterns identified in the MRI examination of the heart in patients with myocardial infarction without coronary artery obstruction.
152. Mirzoev N.T. (Severomorsk), Shulenin K.S., Kutelev G.G., Cherkashin D.V., Ivanov V.V. (Saint-Petersburg). The effectiveness of two-dimensional speckle tracking echocardiography in identifying asymptomatic patients with myocardial “bridges”.

«CAD, lipids and atherosclerosis»

153. Kardashevskaya L.I., Mikhaylichenko E.S. (Donetsk). Symptomatic abnormality of the coronary arteries in a young woman.
154. Lomonosova A.A., Gognieva D.G., Abdullaev M.G., Nartova A.A., Silantyev A.S., Yeroshchenko N.N., Suvorov A.Yu., Novikova A.I., Komarov R.N., Dzunja A.N., Demura T.A., Kopylov F.Yu. (Moscow). Analysis of peripheral blood plasma overview lipidome in stable and unstable atherosclerosis of brachiocephalic arteries.
155. Sotskov A.Yu., Tatarinova A.A. (Saint-Petersburg). Arrhythmic mechanisms of circulatory arrest in patients with coronary heart disease at the hospital stage.
156. Maltseva A.N., Kopyeva K.V., Mochula A.V., Kravchenko E.S., Grakova E.V., Zavadovsky K.V. (Tomsk). The relationship of myocardial blood flow and reserve with the clinical and laboratory profile in patients with non-obstructive atherosclerotic coronary artery disease.
157. Gruzdeva O.V., Belik E.V., Dyleva Yu.A., Uchasova E.G. (Kemerovo). The relationship of the ceramide profile of adipose tissue with gender and age in patients with cardiovascular diseases.
158. Spasenkov G.N., Koryagin V.S., Khlynova O.V., Koryagina N.A. (Perm). The effect of telemedicine surveillance on the achievement of lipid metabolism targets.
159. Nedbayeva D.N., Kukharchik G.A. (Saint-Petersburg). The possibilities of predicting long-term outcomes of acute coronary syndrome without ST segment elevation of moderate and low risk.
160. Churashova I.A., Sokolov A.V., Kostevich V.A., Gorbunov N.P., Runova O.L., Firova E.M., Vasiliev V.B. (Saint-Petersburg). Diagnostic significance of myeloperoxidase activity and oxidative modification of high-density lipoproteins for chronic coronary heart disease.

161. Shcheglova A.V., Sumin A.N., Barbarash O.L. (Kemerovo). The dynamics of arterial stiffness as a possible pathophysiological factor of unfavorable long-term prognosis in patients after coronary artery bypass grafting.
162. Arutyunov G.P. (Moscow), Tarlovskaya E.I. (Nizhny Novgorod), Arutyunov A.G. (Armenia), Batluk T.I. (Moscow), Bashkinov R.A. (Saint-Petersburg), Fedorova Y.P. (Moscow), Melnikov E.S. (Saint-Petersburg), Trubnikova M.A. (Sochi), Gordeychuk E.D. (Moscow). The value of the level of highly sensitive C-reactive protein in patients with multifocal atherosclerosis according to the international CAMMA registry.
163. Korneva V.A., Kuznetsova T.Yu. (Petrozavodsk). The significance of classifications of the severity of familial hypercholesterolemia in predicting the development of coronary heart disease.
164. Korneva V.A. (Petrozavodsk), Zakharova F.M., Mandelstam M.Yu., Bogoslovskaya T.Yu. (Saint-Petersburg), Kuznetsova T.Yu. (Petrozavodsk), Vasiliev V.B. (Saint-Petersburg). Investigation of the molecular basis of familial hypercholesterolemia in the Northwestern region of Russia.
165. Yarmedova S.F., Yavelov I.S., Drapkina O.M. (Moscow). Myocardial ischemia and other causes of shortness of breath in patients with stable coronary artery disease.
166. Pirogova E.A., Tukhsanboev E.S., Kazakhmedov E.R., Pavlikov G.S., Pisaryuk A.S., Merai I.A., Kobalava J.D. (Moscow). Clinical and demographic characteristics of patients with coronary artery disease without obstructive atherosclerosis admitted to the intensive care unit.
167. Lutsik E.A., Skorodumova E.A., Kostenko V.A., Siverina A.V. (Saint-Petersburg). Clinical and genetic features of recurrent myocardial infarction in previously stented patients.
168. Lichikaki V.A., Mordovin V.F., Falkovskaya A.Yu., Zyubanova I.V., Manukyan M.A., Solonskaya E.I., Vtorushina A.A., Hunkhinova S.A., Skomkina I.A. (Tomsk). Lipocalin associated with neutrophil gelatinase in the prediction of coronary artery stenosis in patients with resistant hypertension.
169. Tymoshchenko O.V., Ivanoshchuk D.E., Semaev S.E., Orlov P.S., Zorina V.V., Shakhtschneider E.V. (Novosibirsk). Optimization of the diagnosis of familial hypercholesterolemia in patients under 18 years of age and at a young age.
170. Sidorov D.V. (Orel), Sukovytykh B.S., Bolomatov N.V. (Kursk), Sereditzky A.V., Karasev A. Yu. (Orel), Sletova A.M. (Kursk). Features of lipid-lowering therapy in patients with hereditary hypercholesterolemia after undergoing emergency percutaneous coronary intervention.
171. Neeshpapa A.G., Karetnikova V.N. (Kemerovo). Features of the musculoskeletal-fat status in patients with coronary artery disease.

172. Arutyunov G.P. (Moscow), Tarlovskaya E.I. (Nizhny Novgorod), Arutyunov A.G. (Armenia), Batluk T.I. (Moscow), Bashkinov R.A. (Saint-Petersburg), Melnikov E.S. (Saint-Petersburg), Trubnikova M.A. (Sochi), Gordeychuk E.D. (Moscow). Features of multifocal atherosclerosis and the diagnostic significance of the ankle-shoulder index in patients with coronary heart disease — data from the international CAMMA registry.
173. Kolomiets V.I., Odud A.M., Odud Y.S. (Lugansk). The peculiarity of the course of pain-free myocardial ischemia in diabetic patients who have suffered a coronavirus infection.
174. Uchasova E.G., Gruzdeva O.V., Dyleva Yu.A., Belik E.V., Slesareva T.A., Ponasenko A.V., Velikanova E.A. (Kemerovo). Evaluation of osteogenic potential by immunofluorescence staining in culture of mesenchymal stem cells isolated from epicardial adipose tissue in patients with coronary artery disease.
175. Gorbacheva N.S., Veselovskaya N.G., Nikolaeva M.G. (Barnaul). Assessment of the level of microvesicles of various origins in men under 45 years of age with type 2 myocardial infarction.
176. Krivoshapova K.E., Barbarash O.L., Bazdyrev E.D., Belik E.V. (Kemerovo). Assessment of serum myostatin levels in patients with senile asthenia syndrome and coronary heart disease.
177. Gruzdeva O.V., Uchasova E.G., Dyleva Yu.A., Belik E.V., Slesareva T.A., Ponasenko A.V., Velikanova E.A., Matveeva V.G. (Kemerovo). Assessment of the expression level of osteogenesis marker genes in mesenchymal stem cells of epicardial adipose tissue in patients with coronary heart disease.
178. Roitberg G.E., Sharkhun O.O., Davydova A.S. (Moscow). Pre-test probability of coronary artery disease: the role of additional factors in predicting obstructive coronary disease.
179. Kaveshnikov V.S., Trubacheva I.A., Kuzmichkina M.A. (Tomsk). Prevalence and predictors of carotid calcification in the general working age population.
180. Zykov M.V. (Kemerovo), Butsev V.V. (Sochi), Trubnikova O.A., Barbarash O.L. (Kemerovo). Comparison of the effectiveness of dual antiplatelet therapy and combination of aspirin with colchicine in patients with hemodynamically significant carotid artery atherosclerosis in the acute period of “minor” ischemic stroke. interim analysis of the research data.
181. Gruzdeva O.V., Belik E.V., Dyleva Yu.A., Uchasova E.G. (Kemerovo). The sphingomyelin spectrum of blood serum and adipose tissue of the heart of patients with cardiovascular diseases.
182. Dyleva Yu.A., Gruzdeva O.V., Belik E.V., Uchasova E.G., Ponasenko A.V., Barbarash O.L. (Kemerovo). The level of sphingolipids in the local fat depots of the heart in patients with coronary artery disease, depending on the degree of damage to the coronary bed.

183. Korneva V.A., Kuznetsova T.Yu. (Petrozavodsk). Risk factors for coronary heart disease in patients with familial hypercholesterolemia.
184. Yakhontov D.A., Ostanina Yu.O. (Novosibirsk). The frequency of early vascular aging syndrome in patients with various phenotypes of stable coronary artery disease with borderline coronary artery stenosis.
185. Ostanina Yu.O., Yakhontov D.A. (Novosibirsk). Epicardial adipose tissue as a marker of visceral obesity in patients with stable coronary artery disease with borderline coronary artery stenosis.
186. Krivosheeva E.N., Komarov A.L., Panchenko E.P., Khakimova M.B., Balakhonova T.V., Tripoten M.I. (Moscow). The effectiveness and safety of various modes of long-term multicomponent antithrombotic therapy in patients with stable coronary artery disease and multifocal atherosclerosis.

«Interdisciplinary problems in cardiology»

187. Kirichenko Yu.Yu., Chernichkina A.D., Palienco A.V., Ilgisonis I.S., Belenkov Yu.N. (Moscow). 4 years of experience in the scientific and practical cardiological center of Sechenov University.
188. Solovyova A.V., Uryasyev O.M., Panfilov Yu.A., Lunyakov V.A. (Ryazan). Obstetric and gynecological history in the assessment of cardiovascular risk.
189. Misharova A. P., Ametov A.S., Korotkova T.N. (Moscow). The relationship of the adiponectin/leptin ratio with the parameters of fat metabolism in patients with type 2 diabetes mellitus and obesity on empagliflozin therapy.
190. Popova A.A., Shilov S.N., Tretyakov S.V., Yakovleva N.F., Krylova V.B., Yakovleva I.V. (Novosibirsk). Types of postcovid syndrome, frequency of occurrence in patients who have suffered a new coronavirus infection.
191. Plinokosova L.A. (Barnaul). The effect of the inclusion of TNF- α inhibitors in therapy on remodeling in patients with axial spondyloarthritis.
192. Tukish O.V., Garganeeva A.A., Kondratiev M.Yu., Kuzheleva E.A. (Tomsk). Iron deficiency in chronic heart failure with preserved ejection fraction: relationship with functional status and quality of life.
193. Kournikova E.A., Belyaeva E.L., Shenderov S.V., Dyudin A.A., Dorofeev V.I., Sundukova Z.R. (Saint-Petersburg). Changes in the terminal part of the QRST complex in the acute period of hemorrhagic stroke.
194. Danilova A.V. (Saint-Petersburg), Garin Yu.Yu., Ardeev V.N. (Vsevolozhsk), Raskin G.A. (Saint-Petersburg), Zaitsev N.V. (Orenburg). A clinical case of metastasis of metaplastic breast cancer into the myocardium under the guise of an acute heart attack.

195. Kolomatskaya O.E., Chesnikova A.I., Lankina M.S., Pashchenko E.V., Zhachemukova E.S. (Rostov-on-Don). Pituitary macroadenoma as an “accidental” finding on the background of hemorrhagic stroke.
196. Sudzhaeva O.A., Karpova I.S., Koshlataya O.V., Kolyadko M.G. (Belarus). Disorders of the plasma and platelet components of hemostasis in people with chronic coronary heart disease after a coronavirus infection of varying severity.
197. Kournikova E.A., Belyaeva E.L., Dyudin A.A., Shenderov S.V., Sundukova Z.R., Dorofeev V.I. (Saint-Petersburg). Cardiac arrhythmias and conduction disorders in the acute period of hemorrhagic stroke.
198. Nonka T.G., Lebedeva E.V., Repin A.N. (Tomsk). Sleep disorders in patients with coronary heart disease in combination with depressive disorder.
199. Shakhmatova O.O., Komarov A.L., Khakimova M.B., Krivosheeva E.N., Titaeva E.V., Dobrovolsky A.B., Panchenko E.P. (Moscow). Initial albuminuria in assessing the risk of cardiovascular complications and bleeding in patients with coronary heart disease and peripheral atherosclerosis.
200. Sefieva G. G., Chynybekova A.N., Shadrina U.M., Bautin A.E., Vavilova T.V., Pozhidaeva A.M., Zolotova E.A., Zazerskaya I.E., Sirotkina O.V., Irtyuga O.B. (Saint-Petersburg). Features of hemostasis in patients of reproductive age with mechanical prosthetic heart valves.
201. Stefano E.A., Shchukina E.V., Kubai M.S., Grushko I.V. (Donetsk). Features of cardiac rhythm and conduction disorders in patients with chronic ischemic heart failure with a preserved ejection fraction in combination with chronic kidney disease of stages 1-3.
202. Fomina E.V., Kardovskaya S.A., Sokolova S.M., Kirichenko Yu.Yu., Belenkov Yu.N., Ilgisonis I.S. (Moscow). Features of the structural and functional parameters of the microcirculatory bed in patients with multiple myeloma before the start of antitumor therapy.
203. Shvyakova Yu.O., Fatyanova A.S., Novikova A.I., Poltavskaya M.G. (Moscow). Acute myocardial infarction as a consequence of coronary spasm against the background of the use of immune response checkpoint inhibitors.
204. Vorobyova N.A., Komissarova D.D. (Arkhangelsk). Adherence of patients with atrial fibrillation to therapy with direct oral anticoagulants.
205. Dragunova M.A., Sitkova E.S., Moiseeva E.S., Batalov R.E. (Tomsk). Development of a method for determining the concentration of rivaroxaban in whole blood using high-performance liquid chromatography.
206. Yakovenko A.A., Lavrishcheva Yu.V. (Saint-Petersburg). The prevalence of protein-energy deficiency in patients with chronic heart failure receiving treatment with programmed hemodialysis.

207. Gordeeva E.V., Timchenko L.V., Kosmacheva E.D. (Krasnodar). Symptoms of stroke as a manifestation of aortic dissection.
208. Demina V.A., Kotova D.P. (Moscow). The state of the coronary bed in patients with postoperative myocardial infarction.
209. Al Autairi A., Moiseeva A.Yu., Kotova E.O., Kobalava J.D. (Moscow). Comparative evaluation of scales for the diagnosis of senile asthenia syndrome in hospitalized senile patients with acute decompensation of heart failure.
210. Troshina A.A., Andreev M.A., Maksimenkov A.V., Botov A.V., Stoiko Y.M., Pavlevskaya D.O., Ibatov A.D., Volokhova T.V., Musailova V.R. (Moscow). Management tactics of a comorbid patient with coronary artery disease, left atrial myxoma and colorectal cancer: a description of the clinical case.
211. Botova S. N., Pochinka I. G., Tsvetkova D. I., Drozdova E. A. (Nizhny Novgorod). Risk factors and prognosis of young patients with ischemic stroke.
212. Popova A.A., Tretyakov S.V., Shilov S.N., Petrunin M.B., Yakovleva N.F. (Novosibirsk). The incidence and duration of postcovid syndrome in patients with diseases of the cardiovascular system.
213. Fashafsha Z.Z., Kuznetsova N.O., Kholstinina A.N., Chomakhidze P.Sh., Kopylov F.Yu., Sekacheva M.I. (Moscow). The effectiveness of remote monitoring of a single-channel ECG using machine learning methods for early detection of cardiotoxicity in polychemotherapy.

«Managing patients with non-coronary pathologies»

214. Kotova D.P., Klimenko A.A. (Moscow). Associated forms of pulmonary arterial hypertension — the importance of interdisciplinary dialogue.
215. Evdokimov D.S., Feoktistova V.S., Resnyanskaya E.D., Boldueva S.A. (Saint-Petersburg). Intrahospital complications in patients with primary and secondary takotsubo syndrome.
216. Bykova E.G., Leonova I.A. (Saint-Petersburg). Infarct-like course of myocarditis.
217. Mirolyubova O.A., Kokurina D.A., Semenova I.A., Antonov A.B. (Arkhangelsk), Ryabikov A.N. (Novosibirsk), Kudryavtsev A.V. (Arkhangelsk). Calcification of the aortic valve: the relationship with the severity of hyperlipoproteidemia (a).
218. Gabinsky Ya.L., Freidlin M.S., Zolotareva E.V. (Yekaterinburg). A clinical case of amyloid cardiomyopathy. the possibilities of modern diagnostics in real clinical practice.
219. P etukhova I.V., Shakirova R.M., Kamalov G.M., Urazaeva L.I., Akramova E.G. (Kazan). A clinical case of takotsubo syndrome in a patient with thyrotoxicosis.

220. Soldatova O.V., Goryanskaya I.Ya. (Simferopol). A clinical case of fatal coronavirus myocarditis on the background of non-compact left ventricular myocardium.
221. Nasonova S.N., Shoshina A.A., Tchaikovskiy O.Ya., Osmolovskaya Yu.F., Zhirov I.V., Tereshchenko S.N. (Moscow). Features of the clinical course of amyloid cardiomyopathy.
222. Ishmurzin G.P. (Kazan). Primary diagnosis of pulmonary arterial hypertension at the outpatient stage using a checklist.
223. Golovina G.A., Tatarintseva Z.G., Tochenaya A.S., Kosmacheva E.D. (Krasnodar). A family case of Noonan syndrome with multiple lentigos caused by a mutation of the PTPN11 gene.
224. Kirillova I.G., Korsakova Yu.O., Nikolaeva E.V., Kurmukov I.A., Alekseeva O.G., Yudkina N.N., Volkov A.V. (Moscow). Comparison of noninvasive and invasive assessment of hemodynamic parameters of the right ventricle and pulmonary artery in patients with systemic rheumatic diseases.
225. Devetyarova E.A., Chesnikova A.I., Dyuzhikov A.A., Dyuzhikova A.V., Chesheva (Vasilikhina) D.V. (Rostov-on-Don). Comparative characteristics of patients with pulmonary hypertension of various origins in the Rostov region.
226. Ionov M.V., Gurevich A.P., Yemelyanov I.V., Vanyurkin A.G., Belova Yu.K., Chernyavskiy M.A., Konradi A.O. (Saint-Petersburg). Central aortic pressure and vascular stiffness in patients with arterial hypertension and aortic aneurysm: a study with an active tilt test.

«Urgent cardiology»

227. Karpunina N.S. (Perm). Angiographic Y-phenomenon in myocardial infarction with ST segment elevation in young men: frequency of occurrence, clinical and laboratory characteristics.
228. Sokol E.V., Shekhovtsova L.V. (Stary Oskol). Temporary transvenous pacing in acute myocardial infarction as a method of relieving an electrical storm.
229. Spasenov G.N., Khlynova O.V., Prokhorov K.V., Koryagin V.S., Koryagina N.A., Pesterev E.A., Zagumenov A.S., Borodulin E.A. (Perm). Gender characteristics of myocardial infarction in the regional vascular center (GBUZ "Clinical Cardiological Dispensary").
230. Suspitsyna I.N., Sukmanova I.A. (Barnaul). Clinical characteristics and factors of unfavorable prognosis in patients with myocardial infarction with and without ST segment elevation.
231. Kuznetsova K.V., Nagornova V.V., Duplyakov D.V. (Samara). Computed tomography-coronary angiography for suspected acute coronary syndrome in patients with previously performed percutaneous coronary intervention or coronary artery bypass grafting.
232. Lebedeva O.K., Kukharchik G.A. (Saint-Petersburg). Monocytic response in patients with acute myocardial infarction and impaired renal function.

233. Lebedeva O.K., Kukharchik G.A. (Saint-Petersburg). Features of the course of the inflammatory reaction in patients with acute myocardial infarction and thrombectomy.
234. Troshina A.A., Kartasheva E.D., Musailova V.R., Kolesnikova I.A., Serov A.A., Marchak D.I., Melikyan S.K. (Moscow). Acute primary myocardial infarction with ST segment elevation without coronary artery obstruction in a young patient.
235. Dadova M.C., Kostenko V.A. (Saint-Petersburg). Long-term results of treatment of unstable angina pectoris in patients with complete and incomplete revascularization.
236. Zaitsev A.D., Korotaeva E.S., Koroleva L.Yu., Nosov V.P., Kovaleva G.V. (Nizhny Novgorod). Predictors of hospital mortality in patients with acute coronary syndrome.
237. Eshmakov S.V., Weber A.D., Savelyeva T.V. (Izhevsk). Adherence to the therapy of cardiac patients seeking emergency care.
238. Pronko T.P., Snezhitsky V.A. (Belarus). The relationship of platelet aggregation parameters with short-term prognosis in patients with acute coronary syndrome.
239. Malinova L.I., Yelebergenov V.N., Tolstov S.N., Dudakov V.A., Denisova T.P. (Saratov). Management strategy for patients with myocardial infarction with ST segment elevation complicated by acute heart failure: the clinical significance of the state of regulation of water metabolism.
240. Shchemeleva E.V., Skorodumova E.A., Kostenko V.A. (Saint-Petersburg). Pulmonary embolism in a multidisciplinary hospital.
241. Troshina A.A., Kartasheva E.D., Andreev M.A., Musailova V.R., Kolesnikova I.A., Pavlevskaya D.O. (Moscow). Thromboembolic complications in the outcome of coronavirus infection in an elderly patient.
242. Kournikova E.A., Shenderov S.V., Filippova O.I., Belyaeva E.L., Koloskov A.V., Dorofeev V.I. (Saint-Petersburg). Chronic anemia and acute coronary syndrome in elderly and long-lived patients: prognostic value.
243. Davydova A.V. (Moscow), Nikiforov V.S. (Saint-Petersburg). Epicardial fat in patients with varying severity of unstable angina pectoris.
244. Strelkova A.V., Chashchin M.G., Gorshkov A.Yu. (Moscow), Yurin A.V., Shabanov D.V., Permyakov S.V. (Odintsovo), Drapkina O.M. (Moscow). Echocardiographic features in patients with myocardial infarction without ST segment elevation and complicated damage to the infarct-responsible artery.

«Organization of cardiac care, information technology and education»

245. Atyunina I.V., Sorokin E.V., Dolgusheva Yu.A. (Moscow). Analysis of the quality of dispensary follow-up of adults after myocardial infarction in the subjects of the Russian Federation of the Central, Ural, Siberian and Far Eastern Federal Districts.

246. Rustamova M.M., Ratushnaya E.A., Kudryavtseva O.V., Astrakhantseva I.D., Tsugui V.S., Urvantseva I.A. (Surgut). “Red Dress” is a successful medical and social project of the district cardiology dispensary in Surgut.
247. Kim G.I., Blekanov I.S., Pyagai V.A., Shmatov D.V. (Saint-Petersburg). Artificial intelligence methods in cardiovascular surgery.
248. Artamonova G.V., Drushlyak I.A., Popsuiko A.N., Makarov S.A., Barbarash O.L., Samus I.V. (Kemerovo). Educational programs as an element of increasing the availability of medical care.
249. Kashapov L.R., Kashapova L.I. (Kazan). The successes and problems of big data technologies in the prevention and treatment of arrhythmias.

«Heart failure/left ventricular dysfunction»

250. Zhdanovich R.G., Kurlyanskaya E.K., Feoktistova N.V., Sevrukevich V.I., Popel O.N. (Belarus). ATTR-amyloidosis of the “wild type” as a rapidly progressive phenocopy of hypertrophic cardiomyopathy: a description of the clinical case.
251. Kolotse L.V., Sithara A.R., Seneviratne S.D.W. (Belarus). Correlations between left ventricular ejection fraction and electrocardiographic parameters in patients with heart failure.
252. Kolotse L.V., Aroosha I., Fernando E.S.C. (Belarus). Left atrial volume index is associated with left atrial appendage thrombus in patients with atrial fibrillation.
253. Galenko V.L., Lelyavina T.A., Ivanova T.E., Ryabova A.N., Sitnikova M.Yu. (Saint-Petersburg). Autonomous imbalance in patients with heart failure: possibilities of its correction and impact on survival.
254. Safiullina A.A., Tereshchenko S.N. (Moscow). Adjuvant therapy based on intravenous infusion of exogenous phosphocreatin in patients with chronic heart failure in the Russian observational study BYHEART.
255. Ovrulova M.M., Nelasov N.Yu., Nechaeva A.G., Kreneva E.L., Morgunov M.N., Eroshenko O.L. (Rostov-on-Don). Analysis of deformation by area measured during 4d stress echocardiography of the left ventricle with adenosine triphosphate to detect symptom-related coronary arteries in patients with signs of heart failure.
256. Korobkova E.O., Kozhevnikova M.V., Krivova A.V., Kuznetsov I.V., Appolonova S.A., Markin P.A., Shestakova K.M., Belenkov Yu.N. (Moscow). Analysis of the levels of metabolites of the choline catabolism pathway in patients with chronic heart failure, which complicated the course of hypertension.
257. Shevtsova V.I. (Voronezh). Association of clinical and nutritional status in patients with chronic heart failure.
258. Garganeeva A.A., Kuzheleva E.A., Tukish O.V., Witt K.N., Andreev S.L., Stepanov I.V., Syromyatnikova E.E., Soldatenko M.V. (Tomsk). Association of echocardiographic parameters with structural changes in mitochondria of cardiomyocytes in chronic heart failure.

259. Mikaelyan A.A., Liskova Yu.V., Starodubova A.V. (Moscow). The effect of hyperglycemia on the clinical and functional characteristics of patients with a phenotype of heart failure with a preserved ejection fraction associated with obesity.
260. Oktysyuk P.D., Konyaev V.V., Sveklina T.S., Shustov S.B. (Saint-Petersburg), Kozlov V.A. (Cheboksary). Inflammatory biomarkers in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction.
261. Klimova A.V., Sokolova A.V., Dragunov D.O., Gumerova E.R., Arutyunov G.P., Lytkina K.A., Kulagina N.P. (Moscow). High levels of hexanoic acid as an adverse risk factor for cardiovascular events in patients with chronic heart failure and sarcopenia.
262. Fedin M.A. (Moscow). Geriatric syndromes in patients 65 years and older with chronic heart failure.
264. Dragunova M.A., Sitkova E.S., Moskovskikh T.V., Batalov R.E. (Tomsk). Dynamics of parameters of noninvasive monitoring of cardiac hemodynamics and fluid content (NICAS) in patients with atrial fibrillation and chronic heart failure.
264. Hastieva D.R., Tarasova N.A., Khasanov N.R. (Kazan). Changes in systolic heart function within 12 months after myocardial infarction in patients with iron deficiency on the background of its correction.
265. Zhdankina N.V., Abasheva E.V., Makarova M.V. (Nizhny Novgorod). Clinical and pathogenetic phenotypes of chronic heart failure in patients with multifocal atherosclerosis.
266. Dragomiretskaya N.A., Tolmacheva A.V., Ivannikov A.A., Kosareva A.V. (Moscow). A multifactorial model for predicting annual mortality in patients with chronic heart failure with preserved and moderately reduced left ventricular ejection fraction.
267. Fedotov D.A., Karanadze N.A., Begrambekova Y.L. (Moscow). Respiratory disorders and exercise tolerance in patients with chronic heart failure.
268. Sambur D.B., Kilina D.A., Antonyuk E.V., Kalinina O.V., Korneva L.O., Sazonova Yu.V., Bortsova M.A., Fedotov P.A. (Saint-Petersburg). Determination of the level of freely circulating donor-specific DNA in patients early after heart transplantation.
269. Ibatov A.D. (Moscow). Features of heart rate variability in elderly patients with heart failure and reduced ejection fraction.
270. Silkina T.A., Baykina N.G., Ivanov K.M. (Orenburg). Features of the electrical activity of inspiratory muscles in chronic heart failure.
271. Sigareva A.A., Tsoi V.G., Shilenko P.A., Schneider Yu.A. (Kaliningrad). Assessment of the dynamics of NPPROBNP in patients with a long-term persistent form of atrial fibrillation with low, intermediate and preserved ejection fraction as a marker of the effectiveness of treatment of chronic heart failure.

272. Vasilyeva L.A., Simonenko M.A., Korneva L.O., Fedotov P.A. (Saint-Petersburg). Predictors of the development of infectious complications after heart transplantation.
273. Khazova E.V., Bulashova O.V., Malkova M.I. (Kazan). Prediction of the outcomes of heart failure in concomitant chronic kidney disease by the level of highly sensitive C-reactive protein.
274. Korneva L.O., Osipova M.A., Bortsova M.A., Musaeva B.B., Simonenko M.A., Akino A.D., Golovkin A.S., Sitnikova M.Yu., Fedotov P.A. (Saint-Petersburg). The level of some microvesicles in patients with heart transplant rejection.

«Cardiovascular surgery and interventional cardiology»

275. Uzhakhov I.R., Shloido E.A. (Saint-Petersburg). The use of fenestration techniques in the endovascular treatment of acute aortic syndrome.
276. Eshmatov O.R., Batalov R.E., Khlynin M.S., Archakov E.A., Popov S.V., Silivanova I.H. (Tomsk). Long-term results of anticoagulant therapy after catheter treatment data from the RPATIT registry.
277. Makhachev O.A., Abakarov A.M., Askadinov M.N., Akhmedova T.S., Hajiyev N.M., Almaskhanova N.S., Osmanov O.A., Dibiroya M.N., Aliyev G.N., Abusov G.M. (Makhachkala). Direct myocardial revascularization in elderly patients.
278. Zyubanov I.V., Mordovin V.F., Manukyan M.A., Lichikaki V.A., Hunkhinova S.A., Vtorushina A.A., Skomkina I.A., Pekarsky S.E., Gromovoy R.M., Rudenko V.V., Falkovskaya A.Yu. (Tomsk). The relationship of blood pressure parameters with the functional significance of coronary artery stenosis.
279. Maleva O.V., Ivanov S.V., Barbarash O.L. (Kemerovo). Methods of prevention of postoperative cognitive dysfunction during coronary bypass surgery and carotid endarterectomy.
280. Naumova N.A., Shishkina E.A., Khlynova O.V., Safarov E.N. (Perm). Risk factors for atrial fibrillation after coronary artery bypass grafting.
281. Bazylev V.V., Tungusov D.S., Mikulyak A.I., Senzhapov I.Ya., Abramova G.N. (Penza). Surgical options for the treatment of chronic heart failure: the feasibility of mitral valve reconstruction in patients with low left ventricular ejection fraction.
282. Kurnosov S.A., Azarov A.V., Kapranov M.S. (Moscow). Endovascular hemostasis of large arterial accesses in the treatment of cardiovascular diseases.

«Fundamental research and personalized cardiology»

283. Trubacheva O.A., Gusakova A.M., Schneider O. L., Chumakova S.P., Petrova I.V. (Tomsk). Platelet aggregation activity on the background of hydrogen sulfide relationship with biomarkers in patients with coronary heart disease.

284. Gusakova A.M., Suslova T.E., Syrkinina A.G., Ryabov V.V. (Tomsk). Association of adverse outcomes with dynamics of molecular biomarkers in patients over 80 years of age with acute myocardial infarction.
285. Dyleva Yu.A., Gruzdeva O.V., Belik E.V., Uchasova E.G. (Kemerovo). The relationship between the parameters of the lipidomic profile and morphomeric characteristics of local heart fat depots in patients with coronary heart disease.
286. Vaikhanskaya T.G., Levdansky O.D., Dubovik T.A., Danilenko N.G. (Belarus). The impact of magnetic resonance imaging of the heart and genetic screening on a personalized approach to the diagnosis and treatment of dilated cardiomyopathy.
287. Nalesnik E.O., Repin A.N. (Tomsk). The effect of T1565C polymorphism (rs5918) in the ITGB3 gene on the phenotypic characteristics of patients, acute complications and long-term outcomes of elective percutaneous coronary interventions.
288. Kashtanova D.A., Mamchur A.A., Dzhumaniyazova I.H., Ivanov M.V., Yerema V.V., Zelenova E.A., Bruttan M.V., Yakovchik A.Yu., Gusakova M.S., Rumyantseva A.M., Terekhov M.V., Matkava L.R., Hakobyan A.A., Strazhesco I.D., Yudin V.S., Isaev R.I., Kruglikova A.S., Maitesyan L.V., Tarasova I.V., Beloshevskaya O.A., Mkhitaryan E.A., Makarov V.V., Kraevoy S.A., Tkacheva O.N., Yudin S.M., Skvortsova V.I. (Moscow). The unity of the molecular genetic mechanisms of age-associated diseases.
289. Weber V.R., Zhmailova S.V., Shvetsov D.A. (Veliky Novgorod). Changes in collagen density in the myocardium of Wistar rats under the influence of adrenaline.
290. Dyakova M.L., Podoksenov Yu.K., Svirko Yu.S., Suslova T.E., Panfilov D.S., Kozlov B.N. (Tomsk). Changes in the level of markers of glyocalyx degradation in various variants of reconstructive operations on the aorta.
291. Shramko V. S., Ledovskikh S.R., Polonskaya Ya.V., Kashtanova E.V., Stakhneva E.M., Ragino Yu. I. (Novosibirsk). To study the effect of destruction factors on the formation of unstable atherosclerotic plaque.
292. Kercheva M.A., Stepanov I.V., Ryabov V.V. (Tomsk). An integrated approach to assessing the content of CD206+ cells in the tissues of the myocardium, spleen, kidneys and brain in patients with myocardial infarction.
293. Tashina E.I., Shakaryants G.A., Kaplunova V.Yu., Vysokykh A.V., Belenkov Yu.N., Privalova E.V. (Moscow). Evaluation of microRNA-21 expression in various clinical variants of hypertrophic cardiomyopathy.
294. Beloglazova I.B., Zubkova E.S., Dergilev K.V., Goltseva Y.D., Ratner E.I., Parfenova E.V. (Moscow). Efrin and NOTCH systems in the regulation of angiogenesis in a 2D model of HUVEC and MSC in vitro co-cultivation.

295. Ogurkova O.N., Suslova T.E., Dragunova M.A., Sitkova E.S., Batalov R.E. (Tomsk). The content of soluble thrombomodulin in the blood serum of men and women with atrial fibrillation of non-valvular origin.
296. Voronkina I.V., Evstigneeva P.E., Smagina L.V., Maltseva S.V., Pigarevsky P.V., Svetlikov A.V., Lukin S.V., Gurevich V.S., Uspensky V.E., Tanyansky D.A. (Saint-Petersburg). Comparative analysis of the components of the extracellular matrix and endothelial glycocalyx of the aorta and carotid arteries in atherosclerosis.
297. Polonskaya Ya.V., Ledovskikh S.R., Kashtanova E.V., Stakhneva E.M., Garbuzova E.V., Shramko V.S., Sadovsky E.V., Ragino Yu.I. (Novosibirsk). The level of tissue inhibitors of metalloproteinases and adipose tissue hormones in men with verified coronary atherosclerosis.
298. Solovey S.P., Zatoloka N.V., Denisevich T.L., Ogurtsova S.E. (Belarus). Endothelial progenitor cells in the assessment of endothelial function in individuals without clinical manifestations of atherosclerosis.

«Epidemiology, prevention and rehabilitation»

299. Dadaeva V.A., Rozanov V.B., Isaikina O.Yu., Kontsevaya A.V., Drapkina O.M. (Moscow). Association of obesity in adolescents with diabetes mellitus in adulthood. The results of a prospective cohort study.
300. Nikolaeva M.N., Glichuk A.I., Karamnova N.S., Goncharov M.V., Shvabskaya O.B., Izmailova O.V., Molchanova O.V., Ivanova E.I., Shalnova S.A., Drapkina O.M. (Moscow). Analysis of potassium consumption among medical facility workers.
301. Shabalin V.V., Grinstein Yu.I., Ruf R.R., Samsonov N.S. (Krasnoyarsk). The effect of hyperuricemia and its combination with arterial hypertension and dyslipidemia on cardiovascular outcomes in a large East Siberian region.
302. Dubovik A.Yu., Kazaeva N.A., Gubich T.S., Sukalo T.I., Krushevskaya T.V. (Belarus). The effect of interval physical training on the indicators of daily monitoring of the electrocardiogram and exercise tolerance in patients after coronary artery bypass grafting in conditions of artificial circulation.
303. Ivanchukova M.G., Lokhina T.V. (Penza). The effect of the patient's psychological status after coronary revascularization on exercise tolerance at the outpatient stage of rehabilitation.
304. Zemskov I.A., Gordeeva M.S., Popov S.V., Kirichkova M.M. (Saint-Petersburg). Identification of markers of electrical instability of the myocardium in young athletes with structural changes of the myocardium.

305. Omarova H.M., Makhachev O.A., Dibirova M.N., Askadinov M.N., Abusov G.M., Ibragimov R.G., Dibirova Z.G., Abdulaev K.I., Aliyev G.N. (Makhachkala). The hospital stage of rehabilitation after coronary bypass surgery: the first experience.
306. Serdechnaya A.Yu., Sukmanova I.A. (Barnaul). Overweight and obesity are the leading factors of recurrent cardiovascular events in patients with ST—segment elevation myocardial infarction.
307. Lyamina N.P., Orlova E.V., Skorobogatykh N.V. (Moscow). Individually dosed hypoxy-hyperoxytherapy in rehabilitation programs for patients with cardiovascular pathology with osteoarthritis.
308. Bondar S.A. (Saint-Petersburg), Salagai O.O. (Moscow), Konradi A.O. (Saint-Petersburg). The inertia of doctors towards smoking patients as a cause of poor management is an important risk factor.
309. Bulina P.A., Fedorova M.A., Leonova I.A. (Saint-Petersburg). Smoking of students in medical schools — the dynamics of observations for 2009, 2019, and 2024.
310. Bondar S.A., Kozhushko Yu.V., Petrova E.M., Konradi A.O. (Saint-Petersburg). Insufficient attention of doctors to smoking patients who want to quit smoking.
311. Matveeva I.F., Persiyanova-Dubrova A.L. (Moscow). Long-term results of the influence of a comprehensive cardiorehabilitation program on the quality of life, indicators of psychological status and motor activity of patients who underwent percutaneous coronary interventions against the background of acute myocardial infarction.
312. Khatalin N.E., Evseyeva M.E., Sergeeva O.V., Gorkovenko M.E., Kostina L.V., Shcherbakova L.E., Pisarev A.N., Marakhovskaya K.Yu., Kirichenko N.A., Nemykina A.S., Karakeshishyan S.L. (Stavropol). Assessment of the relationship between blood pressure and body weight in young girls by ROC analysis.
313. Gubich T.S., Kazaeva N.A., Dubovik A.Yu., Sukalo T.I., Zhushma N.E., Umanova N.Ya. (Belarus). Tolerability of the six-minute walk test in patients with chronic ischemic heart disease after myocardial revascularization using various cardiac rehabilitation programs.
314. Naumova E.A., Tyapaeva A.R., Semenova O.N. (Saratov). A prospective study of adherence to long-term therapy in patients with cardiovascular diseases after a coronavirus infection.
315. Dekhar V.V., Tankov S.V., Kalin D.A., Perepelitsa I.N., Osipova I.V. (Barnaul). Psychoemotional risk factors for noncommunicable diseases among students.
316. Shimkevich A.M., Molodtsova E.A., Martynenko A.A. (Yekaterinburg). The prevalence of cardiovascular risk factors among the middle-aged and elderly female population of Yekaterinburg.

317. Tonkikh N.A. (Donetsk). The state of the cardiovascular system in children involved in sports, according to cardioscreening data for 2022-2023.
318. Gilmutdinova L.T., Faizova E.R., Gilmutdinov B.R., Faizova D.E. (Ufa). The effectiveness of comprehensive programs of the third stage of rehabilitation after covid-associated myocarditis.

GENERAL PARTNERS



PRINCIPAL PARTNERS



ГЕДЕОН РИХТЕР

Здоровье — наша миссия

ПРИ ПОДДЕРЖКЕ
ООО «НОВАРТИС ФАРМА»



Р-ФАРМ

Иновационные
технологии
здоровья

TELERA  PHARMA

PARTNERS



CSL Vifor

Grindex

Johnson&Johnson



КАНОНФАРМА
продакшн

Cardiomedics

MERCK



mirpharm



teva



EXHIBITORS



ГЕМОТЕСТ | **ЦГИ** ЦЕНТР ГЕНЕТИЧЕСКИХ
ИССЛЕДОВАНИЙ



ЛЕОВИТ



PRO.MED.CS
Praha a.s.



INVITRO



Северная
ЗВЕЗДА
Нам доверяют!



GENERAL INFORMATION PARTNER



PRINCIPAL INFORMATION PARTNERS



INFORMATION PARTNERS



БРИЛИНТА® ДСТУПНА
БЕСПЛАТНО
НА 24 МЕСЯЦА

БРИЛИНТА®

ПРЕДТВРАТИЛА БОЛЬШЕ*
СЕРДЕЧНО-СОСУДИСТЫХ СОБЫТИЙ

У ПАЦИЕНТОВ

С ИБС

ВНЕ ЗАВИСИМОСТИ
ОТ НАЛИЧИЯ

ИМ
В АНАМНЕЗЕ^{1,2,4,7}



*Тикагрелор 90 мг в составе двойной антитромбоцитарной терапии (ДАТ) vs клопидогрел в составе ДАТ у пациентов с ОКС¹ или тикагрелор 60 мг в составе ДАТ vs монотерапия аспирином у пациентов со стабильной ИБС и высоким ишемическим риском^{4,5,6}

**СПАСАЕМ БОЛЬШЕ
СЕГОДНЯ И ЗАВТРА**

Брилинта®
Тикагрелор

1. Wallentin L et al. N Engl J Med. 2009;361:1045-1057. 2. Инструкция по медицинскому применению лекарственного препарата Брилинта® (таблетки, покрытые пленочной оболочкой, 60 мг). Регистрационное удостоверение ЛП-003779 от 12.08.2016 г. (переоформлено 24.02.2021). 3. Государственный реестр лекарственных средств. Электронный ресурс: <https://grls.rosminzdrav.ru/default.aspx> (дата обращения: 23.03.2021). 4. Bonaca MP, Bhatt DL, et al. N Engl J Med. 2015 May 7;372(19):1791-800. 5. Steg PG et al. N Engl J Med. 2019;381:1309-1320. 6. Bhatt DL, Steg PG, et al. Lancet. 2019 Sep 28;394(10204):1169-1180. 7. Инструкция по медицинскому применению лекарственного препарата Брилинта® (таблетки, покрытые пленочной оболочкой, 90 мг). Регистрационное удостоверение ЛП-001059 от 27.10.2011 г. (переоформлено 11.06.2020). 8. Приказ Минздрава России от 09.01.2020 N1ч "Об утверждении перечня лекарственных препаратов для медицинского применения для обеспечения в течение одного года в амбулаторных условиях лиц, которые перенесли острое нарушение мозгового кровообращения, инфаркт миокарда, а также которым были выполнены аортокоронарное шунтирование, ангиопластика коронарных артерий со стентированием и катетерная абляция по поводу сердечно-сосудистых заболеваний" (Зарегистрировано в Минюсте России 24.01.2020 N57272).

Инструкция Брилинта® 90 мг



Материал предназначен для специалистов здравоохранения.
Имеются противопоказания. Перед назначением ознакомьтесь, пожалуйста, с полной инструкцией
по медицинскому применению лекарственного препарата

ООО «АстраЗенека Фармасьютикалз»
Россия 123112 Москва, 1-й Красногвардейский проезд, дом 21, стр. 1.
Тел: +7 (495) 799 56 99, факс: +7 (495) 799 56 98 www.astrazeneca.ru
BRI RU-17606. Дата одобрения: 24.07.2023. Дата истечения: 24.07.2025

AstraZeneca

Инструкция Брилинта® 60 мг




Роксера® Плюс

розувастатин + эзетимиб

10 мг + 10 мг, 20 мг + 10 мг, 40 мг + 10 мг

таблетки, покрытые пленочной оболочкой



Терапия препаратом Роксера® Плюс стала еще доступнее²



Держит холестерин на поводке



Еще больше информации

- Два базовых компонента гиполипидемической^{3,4} терапии в одной таблетке
- Розувастатин 40 мг + эзетимиб 10 мг – возможность снижения ХС ЛНП при пероральном приеме до 70%⁵
- Доступная по цене ФК розувастатин + эзетимиб от компании КРКА⁶

ХС ЛНП - холестерин липопротеинов низкой плотности; ФК - фиксированная комбинация.

Список источников: 1. Новая форма выпуска Роксера®Плюс (розувастатин + эзетимиб): 10 мг + 10 мг №90, 20 мг + 10 мг №90; 2. Большие упаковки №90 доступнее по цене, чем другие упаковки Роксера®Плюс с учетом пересчета стоимости на 1 месяц терапии; 3. Инструкция по медицинскому применению лекарственного препарата Роксера®Плюс (розувастатин + эзетимиб); 4. Клинические рекомендации "Нарушение липидного обмена" 2023, РКО.

5. Ballantyne CM et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of CVD. Am J Cardiol 2007; 99(5): 673-80;

6. Согласно данным базы ООО «АЙКьюВИА Солюшнс» о средних розничных ценах в РФ за январь-июль 2024 г, Роксера®Плюс имеет доступную цену в сравнении с другими ФК РЗВ + ЭЗЕ в соответствующих дозировках.

У В Е Р Е Н Н О Е
превосходство*



ПРЕВОСХОДСТВО В СНИЖЕНИИ АД¹⁻⁶
над другими препаратами*



СТАБИЛЬНЫЙ КОНТРОЛЬ АД
в течение 24 часов^{7,8}

ИНСТРУКЦИЯ*



СТАНДАРТ ЛЕЧЕНИЯ АГ**
Минздрава РФ^{9,10}

Эдарби®

Эдарби® Кло



*Азилсартан медоксомил (Эдарби®) превосходит в снижении АД другие сартаны по результатам сетевого мета-анализа (валсартан, олесартан, лозартан, телмисартан, ирбесартан и кандесартан), а также некоторые ингибиторы ангиотензинпревращающего фермента (преимущественно рамиприл) по результатам регистрового исследования.¹ Азилсартан медоксомил + хлорталидон (Эдарби® Кло) превосходит в снижении АД другие препараты по результатам прямых сравнительных исследований (олмесартан медоксомил + гидрохлортиазид, ирбесартан + гидрохлортиазид, азилсартан медоксомил + гидрохлортиазид, периндоприла аргинин + индапамид).² **Азилсартан медоксомил и хлорталидон включены в Стандарты медицинской помощи взрослым при артериальной гипертензии, азилсартан медоксомил включен в Стандарты медицинской помощи взрослым при сахарном диабете 2 типа Минздрава РФ.⁹ АД – артериальное давление, АГ – артериальная гипертензия.

1. Wang J.C, et al. J Clin Hypertens (Greenwich). 2021 May;23(5):901-914. 2. Gitt A.K. BMC Cardiovascular Disorders (2016) 16:56. 3. Bakris G.L, et al. Am J Med. 2012 Dec;125(12):1229.e1-1229.e10. 4. Cushman WC, et al. Hypertension. 2012 Aug;60(2):310-8. 5. Драгунов Д. О., с соавт. Артериальная гипертензия. 2019;25(3):307-318. 6. Васюк Ю. А., с соавт. Российский кардиологический журнал. 2019;24(9):14–21. 7. Инструкция по медицинскому применению лекарственного препарата Эдарби® (азилсартан медоксомил). ЛП-002941 от 02.04.2015 (переоформлено 21.05.2023). 8. Инструкция по медицинскому применению лекарственного препарата Эдарби® Кло (азилсартан медоксомил + хлорталидон). ЛП-002941 от 02.04.2015 (переоформлено 21.05.2023). 9. Приказ Министерства здравоохранения РФ от 2 ноября 2020 г. N 1193н "Об утверждении стандартов медицинской помощи взрослым при артериальной гипертензии". 10. Приказ Министерства здравоохранения РФ от 1 октября 2020 г. N 1054н "Об утверждении стандартов медицинской помощи взрослым при сахарном диабете 2 типа".

ТРАНСТРЕТИНОВАЯ АМИЛОИДНАЯ КАРДИОМИОПАТИЯ (ATTR-КМП) —
ЖИЗНЕУГРОЖАЮЩЕЕ ЗАБОЛЕВАНИЕ, КОТОРОЕ ЧАСТО
ДИАГНОСТИРУЕТСЯ ПОЗДНО ИЛИ НЕВЕРНО¹

Виндамэкс[®]
(тафамидис)
капсулы 61 мг

**ПЕРВЫЙ И ЕДИНСТВЕННЫЙ
ПРЕПАРАТ В РОССИИ ДЛЯ ЛЕЧЕНИЯ
ATTR-КМП ДИКОГО ИЛИ НАСЛЕДСТВЕННОГО
ТИПОВ У ВЗРОСЛЫХ^{2,4}**

Исследование ATTR-АСТ показало^{2,3}:

-41%*

Смертность от всех причин³

-32%**

Частота госпитализаций, связанных
с сердечно-сосудистыми заболеваниями²

x1

Удобный прием 1 раз в сутки⁴



Частота нежелательных явлений сопоставима с плацебо³



**Отсканируйте QR-код, чтобы узнать больше
о диагностике и лечении ATTR-КМП**



Лица на изображении не являются реальными пациентами.
ССЗ — сердечно-сосудистые заболевания.

* снижение относительного риска ОР 0,59 (95% ДИ: 0,44–0,79); p < 0,001. ** снижение относительного риска ОР: 0,68 (95% ДИ: 0,56–0,81); p < 0,0001.

1. Maurer MS, et al. Circulation. 2017;135(14):1357-1370.

2. Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007-1016.

3. Elliott M, et al. Circ Heart Fail 2021; doi: 10.1161/CIRCHEARTFAILURE.120.008193

4. Инструкция по медицинскому применению препарата Виндамэкс ЛП-007319.



ООО «Пфайзер Инновации»
123112, Москва, Пресненская наб., д.10, БЦ
"Башня на Набережной" (Блок С)
Тел.: +7 495 287 50 00, Факс: +7 495 287 53 00
PP-VDM-RUS-0363 23.05.2024



Служба Медицинской Информации: MedInfo.Russia@Pfizer.com
Доступ к информации о рецептурных препаратах Pfizer
www.pfizermedinfo.ru



Инструкция по медицинскому
применению препарата
Виндамэкс ЛП-007319.

Превенар 13

Пневмококковая полисахаридная конъюгированная вакцина (13-валентная, адсорбированная)

Сочетание **ХСН*** и **пневмонии** повышает риск летального исхода¹



Вакцинация против пневмококковой инфекции **снижает риск смерти** у пациентов с ХСН^{2,3}

КРАТКАЯ ИНСТРУКЦИЯ по применению лекарственного препарата Превенар® 13

ОБЩЕЕ ОПИСАНИЕ: Вакцина для профилактики пневмококковой инфекции полисахаридная конъюгированная, адсорбированная.

ДЕКАРАТЕННАЯ ФОРМА: суспензия для внутримышечного введения.

Вакцина Превенар® 13 содержит 13 пневмококковых капсульных полисахаридов: 1, 3, 4, 5, 6В, 7F, 9В, 14, 18С, 19А, 19F и 23F, конъюгированных с белком-носителем CRM197 и адсорбированных на фосфате алюминия.

Вспомогательные вещества: натрий хлорид, янтарная кислота, полисорбат 80, вода для инъекций.

ОПИСАНИЕ: Гомогенная суспензия белого цвета.

ПОКАЗАНИЯ К ПРИМЕНЕНИЮ:

- активная иммунизация для профилактики пневмококковых инфекций, включая инвазивные (в том числе менингит, бактериемия, сепсис, тяжелые пневмонии) и неинвазивные (внебольничные пневмонии и средние отиты) формы заболеваний, вызываемые Эпидемиологическим серотипом 1, 3, 4, 5, 6В, 7F, 9В, 14, 18С, 19А, 19F и 23F от 6 недель жизни и далее без ограничения по возрасту;
- в рамках национального календаря профилактических прививок (если применимо);
- у лиц групп повышенного риска развития пневмококковой инфекции.

Вакцинация проводится в рамках национального календаря профилактических прививок (если применимо) согласно утвержденным срокам, а также лицам групп риска по развитию пневмококковой инфекции с иммунодефицитными состояниями, в т.ч. ВИЧ-инфекцией, онкологическими заболеваниями, получающим иммуносупрессивную терапию, с анатомической/функциональной асплезией, с установленными коллекарным имплантатом или планирующие на эту операцию; пациентам с подтвержденным спинномозговой жидкостью; с хроническими заболеваниями легких, сердечно-сосудистой системы, печени, почек, и сахарной диабетом; больным бронхиальной астмой; нервно-сенными детьми, находившимся в организованных коллективах (детские дома, интернаты, армейские коллективы); перенесшим острый средний отит, менингит, пневмонию, длительно и часто болеющим детьми, инфицированным микобактерией туберкулеза; всеми лицами старше 60 лет, табакокурщиками.

ПРОТИВОПОКАЗАНИЯ:

- гиперчувствительность к действующим веществам, любому из вспомогательных веществ или любому из компонентов анатоксина;
- применение препарата Превенар 13, как и других вакцин, следует отложить у лиц с острым тяжелой обильными заболеваниями. Однако наличие легкой инфекции, такой как простуда, не требует откладывания срока вакцинации.

СПОСОБ ПРИМЕНЕНИЯ И ДОЗИ

Способ применения

Вакцину вводят внутримышечно. Профилактическим местом вакцинации у младенцев является передне-задняя поверхность бедра (латеральная широкая мышца бедра), а детям и взрослым – дельтовидная мышца плеча. Рекомендуемый курс – 0,5 мл младенцам первого лет жизни, далее детям и взрослым. Вакцину Превенар 13 запрещено вводить внутривенно.

С учетом риска случаев анафилактических реакций, вводимых при применении любой вакцины, вакцинируемый пациент должен находиться под медицинским наблюдением в течение как минимум 30 мин после иммунизации.

Места проведения иммунизации должны быть обеспечены средствами противошоковой терапии. Если неата вакцинация Превенар 13, рекомендуется завершить ее также вакциной Превенар 13. При вынужденном увеличении интервала между инъекциями любого из приведенных выше курсов вакцинации введения дополнительных доз Превенар 13 не требуется. График иммунизации против пневмококковой инфекции определяется в соответствии с национальным календарем профилактических прививок (если применимо) и официальными рекомендациями.

Схема вакцинации

Возраст	Схема вакцинации	Интервалы и дозировка
от 6 нед. до 6 мес.	3+1 или 2+1	Индивидуальная иммунизация: 3 дозы с интервалом не менее 1 мес. между введениями. Первая доза препарата может быть введена уже в возрасте не менее шести недель. Ревакцинация однократно в 11–15 мес. Массовая иммунизация детей: 2 дозы с интервалом не менее 2 мес. между введениями. Ревакцинация однократно от 11–15 мес.
7–11 мес.	2+1	2 дозы с интервалом не менее 1 мес. между введениями. Ревакцинация однократно на втором году жизни.
12–23 мес.	1+1	2 дозы с интервалом не менее 2 мес. между введениями.
2 года и старше	1	Однократно

Взрослые в возрасте ≥ 18 лет и лица пожилого возраста

Рекомендуется введение одной дозы препарата. Необходимость в ревакцинации вакциной Превенар 13 не установлена. Если применены 23-валентная пневмококковая полисахаридная вакцина и/или конъюгированная, следует сначала вводить вакцину Превенар 13 независимо от статуса вакцинации другими пневмококковыми вакцинами.

Особые группы пациентов

У пациентов после трансплантации гемопозитивных клеток рекомендуется серия иммунизации, состоящая из 4 доз препарата Превенар 13 по 0,5 мл. Первую серию иммунизации состоят из введения трех доз препарата: первая доза вводится с третьим по шестой месяц после трансплантации. Интервал между введениями должен составлять 1 месяц. Ревакцинирующую дозу рекомендуется вводить через 6 месяцев после введения третьей дозы. Неродившимся младенцам (рожденные на < 37 неделе беременности) рекомендуется четырехкратная вакцинация. Первая серия иммунизации состоит из 3 доз. Первую дозу вводят в возрасте 2 месяцев. Интервал между дозами составляет не менее 1 месяца. Первую дозу вакцинации можно вводить

в возрасте не менее 6 недель. Введение четвертой (бустерной) дозы рекомендовано в возрасте от 11 до 15 месяцев.

Данные о применении препарата Превенар 13 у беременных женщин отсутствуют. В связи с этим следует избегать применения препарата Превенар 13 в течение беременности.

НЕЖЕЛАТЕЛЬНЫЕ РЕАКЦИИ (НР)

Очень часто (≥ 1/10): снижение аппетита, головная боль, сыпь, гипертермия, раздражительность, заторможенность или беспокойственность в месте введения; сонливость, нарушение качества сна, покраснение и/или припухлость в месте введения размером 2,5–7,0 см (розе реакции) и у детей старшего возраста (2–5 лет), ограничение двигательной активности (слабость – у взрослых лиц в возрасте от 18 до 39 лет, диарея, рвота (у взрослых в возрасте от 18 до 49 лет), артралгия, миалгия (у взрослых), тошнота, головокружение, головная боль, сыпь, крапивница или сыпь, не сопровождающаяся крапивницей (в возрасте от 6 до 17 лет), повышение температуры тела > 39 °С, ограничение двигательной активности в месте введения (в связи с возникновением боли), покраснение и/или припухлость в месте введения размером 2,5–7,0 см (розе курса вакцинации у детей и грудном возрасте).

См. полный перечень НР в ОКПД.

УСЛОВИЯ ХРАНЕНИЯ И ТРАНСПОРТИРОВАНИЯ: хранить в холодильнике (от 2 до 8 °С). Не замораживать.

Превенар 13 стабилен при хранении при температуре ниже 25 °С в течение 4 дней. По окончании указанного периода Превенар 13 необходимо использовать или утилизировать.

СРОК ГОДНОСТИ: 3 года.

ДЕЙТЕЛЬЕ РЕГИСТРАЦИОННОЕ УДОСТОВЕРЕНИЕ:

Превенар Инж., США, 60 Харрисон Бульвар, Ист-Нью-Йорк, штат Нью-Йорк 10001-2192, Тел.: +1 (212) 703-29-24

www.pfizer.com/contact/email

ПРЕДСТАВИТЕЛЬ ДЕПАРТАМЕНТА РЕГИСТРАЦИОННОГО УДОСТОВЕРЕНИЯ НА ТЕРРИТОРИИ СООБРАЗ: Препараты потребительского назначения по адресу: Российская Федерация (в также для Республики Армения и Кыргызской Республики)

ООО «Пфайзер Инновации» Адрес: 123112, г. Москва, Пресненская наб., д. 10, БЦ «Башня на набережной» (Блок С).

Тел.: +7 (495) 287-50-00; Факс: +7 (495) 287-53-00;

Эл. почта: Russia@pfizer.com



www.pfizermedinfo.ru
PP-PFV-RUS-0270 15.03.24

На правах рекламы

Материал предназначен для работников

систем здравоохранения

ООО «Пфайзер Инновации»
Россия, 123112, Москва, Пресненская наб., д. 10, БЦ «Башня на набережной» (Блок С)
Тел.: +7 (495) 287-5000; факс: +7 (495) 287-5300
www.pfizer.ru



* ХСН – хроническая сердечная недостаточность.

1. Руководство по клинической иммунологии в респираторной медицине / Под ред. М.П. Костинова, А.Г. Чулчина. 2-е изд., доп. М.: Группы МВБ, 2018. 304 с. 2. Клинические рекомендации МЗ РФ «Хроническая сердечная недостаточность», 2020. URL: https://clinicaldrav.org/recommend/156_1 (дата обращения – 06.05.2022). 3. Marques Antunes M. et al. Pneumococcal vaccination in adults at very high risk or with established cardiovascular disease: systematic review and meta-analysis // Eur Heart J Qual Care Clin Outcomes. 2021 Jan 25; 7(1): 97–106. doi: 10.1093/ehqcco/qaab030.

ЭЛИКВИС®

апиксабан

Единственный ПОАК, который приводил к снижению рисков по трем показателям у пациентов с НФП^{1*}



«Исследование ARISTOTLE – одно из 12 жизнеспасующих исследований, оказавших наиболее значимое влияние на клиническую практику за последние 19 лет»²

Д-р Дж. Дрезен, главный редактор «Медицинского журнала Новой Англии»

ARISTOTLE

10 ЛЕТ ЗАЩИЩАЕМ ПАЦИЕНТОВ С НФП

Эликвис® (апиксабан) – ОАК №1 в мире по количеству дней назначенного лечения пациентам** по показаниям НФП и ВТЗ***

Краткая инструкция по медицинскому применению препарата ЭЛИКВИС®. Торговое название: ЭЛИКВИС®. МНН: апиксабан. Лекарственная форма: таблетки, покрытые пленочной оболочкой. Состав: одна таблетка содержит 2,5 мг или 5 мг апиксабана. Показания к применению: профилактика венозной тромбозии у пациентов после планового эндопротезирования тазобедренного или коленного суставов; профилактика инсульта и системной тромбоэмболии у взрослых пациентов с неклапанной фибрилляцией предсердий, имеющих один или несколько факторов риска (таких, как инсульт или транзиторная ишемическая атака в анамнезе, возраст 75 лет и старше,atriальная фибрилляция, сахарный диабет, сопровождающаяся симптомами хронической сердечной недостаточности (функциональный класс II и выше по классификации NYHA). Исключение: составитель препарата с тяжелым и умеренно выраженным митральным стенозом или искусственными клапанами сердца; лечение тромбоз глубоких вен (ТГВ), тромбозии легочной артерии (ТЭЛА), а также профилактики рецидивов ТГВ и ТЭЛА. **Противопоказания:** повышенная чувствительность к апиксабану или любому другому компоненту препарата; активная хроническая почечная недостаточность; беременность (данные о применении препарата в системе свертывания крови и клинически значимом риске развития кровотечения). Заболевание или состояние, характеризующееся значимым риском большого кровотечения, существующее в настоящее время или недавнее обострение венозной болезни и/или артериального кровотечения, наличие злокачественного новообразования с высоким риском кровотечения; недавнее повреждение головного или спинного мозга; недавнее перенесенное оперативное вмешательство на головном или спинном мозге, а также на органе зрения; недавнее перенесенной геморрагической инсульт; установленное или подозреваемое варикозное расширение вен пищевода; артериовенозная мальформация; аневризма сосудов или выраженные внутримозговые или внутримозговые изменения сосудов. Нарушение функции почек (креатинин клиренс менее 15 мл/мин) в момент назначения пациентам, назначившимся к лечению. Возраст до 18 лет (данные о применении препарата отсутствуют). Беременность (данные о применении препарата отсутствуют). Период грудного вскармливания (данные о применении препарата отсутствуют). Одновременное применение с любыми другими антикоагулянтными препаратами, включая нефракционированный гепарин (НФГ), низкомолекулярные гепарины (НМГ) (кселоган, далаган и др.), производные гепарина (фондапаринум и др.), пероральные антикоагулянты (варфарин, ривароксабан, дабигатан и др.), за исключением тех ситуаций, когда пациент переводится на терапию или с терапии апиксабаном или если нефракционированный гепарин назначается в случае, необходимом для поддержания проходимости центрального венозного или артериального катетера. Врожденный дефицит лактазы, непереносимость лактозы, глюкозо-галактозная мальабсорбция. **Побочное действие:** частыми нежелательными реакциями были кровотечения различного генезиса (кожные, желудочно-кишечные, ректальные, кровотечения из десен, гематурия, кровоизлияния в ткани плазменного белка), кровотечения,

новосное кровоотечение и гематома, анемия, закрытая травма, тошнота. Перечень всех побочных эффектов представлен в полной версии инструкции по медицинскому применению. **Способ применения и дозы:** препарат Эликвис® принимают внутрь, независимо от приема пищи. Для пациентов, которые не могут проглотить таблетку целиком, ее можно измельчить и развести (в воде, водной дисперзии, яблочном соке или пиве) и немедленно принять внутрь. В качестве альтернативы, таблетку можно измельчить и развести в воде или 5% водном растворе дисперзии и немедленно ввести полученную суспензию через назалостральный зонд. Лекарственное вещество в измельченных таблетках сохраняет стабильность в воде, водной дисперзии, яблочном соке или пиве до 4 часов. У пациентов с фибрилляцией предсердий: по 5 мг два раза в сутки. У пациентов с фибрилляцией предсердий дозу препарата снижают до 2,5 мг два раза в сутки при наличии сочетания двух или более из следующих характеристик – возраст 80 лет и старше, масса тела 60 кг и менее или концентрация креатинина в плазме крови $\geq 1,5$ мг/дл (133 мкмоль/л). У пациентов с нарушением функции почек тяжелой степени (с креатинин креатинина 15-29 мл/мин) и фибрилляцией предсердий следует применять дозу апиксабана – 2,5 мг два раза в сутки. Не принимаясь ранее антикоагулянт пациент с фибрилляцией предсердий, которым требуется проведение кардиоверсии, для достижения антикоагулянтной возможности назначения, но крайней мере, 5 доз препарата по 5 мг 2 раза в сутки (2,5 мг в сутки, если пациент подходит под критерии снижения дозы) перед проведением процедуры. Если проведение кардиоверсии требуется до назначения 5 доз препарата Эликвис, возможное применение начальной дозы апиксабана 10 мг, но крайней мере, за 2 часа до проведения процедуры с последующим приемом 5 мг 2 раза в сутки (2,5 мг в сутки, если пациент подходит под критерии снижения дозы). У пациентов с фибрилляцией предсердий нет необходимости превышать терапию препаратом Эликвис® перед катетерной абляцией (у пациентов после планового эндопротезирования тазобедренного или коленного сустава: 2,5 мг 2 раза в сутки (первый прием через 12-24 ч после оперативного вмешательства). У пациентов, перенесших эндопротезирование тазобедренного сустава, рекомендуемая длительность терапии составляет от 32 до 38 дней, коленного сустава – от 10 до 14 дней. Лечение тромбоза глубоких вен, тромбозии легочной артерии (ТЭЛА): по 10 мг два раза в сутки в течение 7 дней, затем 5 мг 2 раза в сутки. Продолжительность лечения определяется индивидуально с учетом соотношения ожидаемой пользы и риска возникновения клинически значимых кровотечений. Профилактика рецидивов тромбоза глубоких вен, тромбозии легочной артерии (ТЭЛА): по 2,5 мг два раза в сутки после как минимум 6 месяцев лечения тромбоза глубоких вен или ТЭЛА. **Отсутствует по рецепту врача. Срок годности: 3 года. Регистрационное удостоверение:** ЛП-020007, ЛП-001475. **Побочная информация содержится в Инструкции по медицинскому применению лекарственного препарата, перед применением необходимо ознакомиться с полным текстом Инструкции по применению препарата Эликвис® 5 мг от 27.07.2023; Эликвис® 2,5 мг от 26.07.2023.**

* По сравнению с варфаринем. ** Дни назначенного лечения рассчитаны на основе данных аналитической платформы IQVIA MIDAS по реализации препаратов за 6 месяцев, в квартал 2020 года. Стандартные единицы рассчитаны по рекомендованной суточной дозе ПОАК (апиксабан 2 р/сут, дабигатан 2 р/сут, ривароксабан 1 р/сут). Дни назначенного лечения АВК основаны на стандартных единицах, рассчитанных на основе средней суточной дозы (IQVIA MIDAS). *** Показание учитывалось при назначении препарата стандартными единицами на основе данных медицинского журнала IQVIA и соответствующего кода МКБ-10.

1. Granger CB, et al. Apixaban versus warfarin in patients with atrial fibrillation // N Engl J Med. 2011 Sep 15; 365(11): 981-992. 2. Special Publication from New England Journal of Medicine. Edward L. Pratt. Reference URL: <https://pratt.blibrary.com/content/Special-publication-new-england-journal-medicine-data-obscuring--2012-2020>. 3. IQVIA MIDAS Sales Data Q3'20 Sell-In/Sell-Out data. 4. IQVIA MIDAS Summary and Detailed Medicine Data Q3'20. 5. NDA# Recomburly authorized until 24-hour period (apixaban BID, dabigatran BID, edoxaban QD, rivaroxaban QD).

ОАК – оральные антикоагулянты; НФП – неклапанная фибрилляция предсердий; ВТЗ – венозная тромбозия; ПОАК – прямой оральные антикоагулянты; АВК – антиагреганты витамина К.



Служба Медицинской Информации: MedInfo.Russia@Pfizer.com
 Доступ к информации о рецептурных препаратах Pfizer
 на интернет-сайте www.pfizermedinfo.ru



ООО «Файзер Инновации»
 Россия, 123112, Москва, Пресненская наб., д. 10, ЕЦ «Башня на набережной» (блок С)
 Тел: +7 495 287 5000, факс: +7 495 287 5300
www.pfizer.com

РР-ЕЛ-НУС-2592 от 02.04.2024

Регистрационный номер: РР-ЕЛ-НУС-2592 от 02.04.2024

«ДОКТОР,
ХОЧУ ДАВЛЕНИЕ
КАК У КОСМОНАВТА»

129/79
ММ РТ. СТ.
УЖЕ ЗА 4 НЕДЕЛИ
ТЕРАПИИ**²

ТРИПЛИКСАМ®



Russian
Pharma Awards

ЗА ДОСТИЖЕНИЙ В ОБЛАСТИ ФАРМАЦИИ

1-е место

в номинации «Комбинированное
решение для контроля АД»^{*,1}



SERVIER

АО «Сервье»: 125196, Москва, ул. Лесная, д.7, этаж 7/8/9.
Тел.: (495) 937 07 00, факс: (495) 937 07 01. www.servier.ru

* АД – артериальное давление
** группа пациентов до 50 лет (n=199)

1. <https://awards.doktorarabote.ru/winners2023> Дата обращения к ресурсу 14.08.24. 2. Карпов Ю. А., Логунова Н. А., Квасников Б. Б., Хомицкая Ю. В. Новые данные субанализа исследования ТРИКОЛОР: антигипертензивная эффективность тройной фиксированной комбинации амлодипина/индапамид/периндоприла и предикторы эффективности и контроля артериального давления у молодых пациентов. Российский кардиологический журнал. 2023; 28 (10): 5597.

МАТЕРИАЛ ПРЕДНАЗНАЧЕН ДЛЯ СПЕЦИАЛИСТОВ ЗДРАВООХРАНЕНИЯ.

Краткая справочная
информация по безопасности –
амлодипин/индапамид/периндоприл





Российское
кардиологическое
общество

РОССИЙСКИЙ НАЦИОНАЛЬНЫЙ КОНГРЕСС КАРДИОЛОГОВ

25–27 СЕНТЯБРЯ 2025 ГОДА | КАЗАНЬ



www.scardio.ru